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Abstract 
Martina Mason 
Sleep apnoea and cardiac surgery: Screening, prevalence and postoperative 
outcomes  
Introduction: An excess of postoperative complications have been reported in patients with 
Obstructive Sleep Apnoea (OSA) following surgical procedures, however, studies reporting 
outcomes in patients with OSA following cardiac surgery are sparse and of limited quality. 
The cause of worse surgical outcomes in the OSA population is unknown but deleterious 
effects of opiates/opioids, common pain relieve medication following surgery have previously 
been proposed. There is a move towards pre-operative screening for OSA prior to surgery 
but the best screening methodology has not yet been established and more importantly the 
effect of treatment, in particular Continuous Positive Airway Pressure (CPAP), on surgical 
outcomes in patients with OSA is unknown.  
Aim: This thesis examined the prevalence of sleep apnoea and its association with 
postoperative outcomes in patients undergoing major cardiac surgery. It also explored the 
usefulness of the STOP-Bang questionnaire, as a screening tool for OSA prior to cardiac 
surgery. In addition, current evidence regarding the effects of opiates/opioids and sedatives 
on patients with OSA was investigated and summarised in the Systematic Cochrane Review. 
The effect of morphine on severity of sleep apnoea in patients with moderate OSA was 
examined in a separate study. 
Methods: The prevalence and association of sleep apnoea with postoperative outcomes in 
patients undergoing cardiac surgery and the usefulness of the STOP-Bang questionnaire in 
identifying patients at risk of OSA prior surgery was examined in a prospective, 
observational cohort study. The Systematic Cochrane review included randomised controlled 
trials examining the effects of opioids and sedatives, compared to placebo on severity of 
OSA in patients with established diagnosis of OSA. The effect of intravenous morphine 
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sulphate on the severity of sleep apnoea was examined in a prospective, paired design trial 
which recruited patients with moderate OSA. 
Results: A high prevalence of sleep apnoea (47%) and a significant association between its 
severity and postoperative complications was found in 122 participants undergoing major 
cardiac surgery. The most significant risk factor for complications was found to be oxygen 
desaturations during the night reflecting the severity of sleep apnoea (OR=1.1 for each unit 
increase in oxygen desaturation index (ODI), 95% CI 1.02-1.17; p=0.014). It was found that 
the STOP-Bang scores between 0-2 would with high confidence exclude patients with at 
least moderate sleep apnoea prior surgery. The best diagnostic performance for diagnosis of 
at least moderate sleep apnoea was found at higher STOP-Bang scores of ≥6 which could 
identify those patients who might benefit from a sleep study before cardiac surgery. A 
systematic Cochrane review found that opiates/opioids, sedatives and hypnotics have no 
deleterious effect on the severity of OSA but most of the studies included in the review were 
of short duration, small size and with indiscernible methodological quality. The results of the 
Systematic Cochrane Review informed the development of my study, studying the effect of 
opiate, morphine sulphate, on patients with moderate OSA. This showed no change in 
Apnoea/Hypopnoea Index (AHI) where median difference (MD) was -12.95, IQR 9.45, 
p=0.173 but showed significant improvement in sleep apnoea indices including: obstructive 
apnoea index (MD -2.7, IQR 7.37, p=0.03), central apnoea index (MD – 0.35, IQR 0.83, 
p=0.04 ).However there was a fall in median nocturnal oxygen saturation. 
Conclusion: This thesis reports high prevalence of sleep apnoea which was also found to 
be a risk factor for postoperative complications in patients undergoing major cardiac surgery. 
In this population, STOP-Bang score ≥6 could identify patients in need of a sleep study to 
identify those who may be at increased risk of postoperative complications. To date there is 
no strong evidence supporting deleterious effects of opioids/opiates on patients with OSA 
but larger studies are needed to clarify its effect.   
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Overview 
This thesis examines OSA in a very specific population of surgical patients 
presenting for major cardiac surgery. In particular, it examines the prevalence of OSA and 
the risks that OSA poses on surgical outcomes in these patients. It also looks at safety 
concerns associated with administration of intravenous opioid analgesia not only after 
surgery, but also on the severity of sleep apnoea when given to patients with previously 
diagnosed OSA. The body of work consists of a prospective observational cohort study 
looking at the association of OSA, expressed as ODI from nocturnal oximetry with 
postoperative outcomes, as well as prospective paired design trial looking at the effect of 
acute administration of morphine sulphate on the severity of OSA in patients with moderate 
OSA. One Chapter is dedicated to secondary research in the form of a Systematic Cochrane 
review examining extant evidence of the effect of opioids and sedatives on patients with 
known OSA. 
OSA is common disease with complex and poorly understood pathophysiology. 
Chapter 1 sumarises current evidence regarding the pathophysiology, epidemiology, 
diagnosis and treatment of OSA. More particularly, it appraises current knowledge of OSA in 
people undergoing surgery, including epidemiology, screening, the effect of OSA on surgical 
outcomes and the evidence for CPAP treatment affecting postoperative outcomes.  
The first experimental study, a prospective observational cohort study (Sleep Apnoea 
in Cardiac Surgery), is described in Chapter 2 and Chapter 3 and investigates the 
prevalence of OSA in patients undergoing coronary revascularisation surgery. The null 
hypothesis tested was that there is no association between sleep apnoea and Intensive Care 
Unit lengths of stay, as an tangible impact of health care utilisation. The secondary 
outcomes included exploring for evidence of any association between OSA and 
postoperative complications in the Intensive Care Unit. As part of this study I have also 
explored the utility of the STOP-Bang questionnaire, a simple screening tool for sleep 
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apnoea, prior to surgery, and also looked for any association between the STOP-Bang 
scores and postoperative outcomes in the cardiac surgical population.  
The results of the SACS study informed the development of secondary research 
examining the effect of opioids and sedatives on the severity of OSA in patients with a 
known diagnosis of OSA. The results are summarised in the Cochrane Systematic review 
reported as a precis in Chapter 4. Based on the result of this review, in particular the lack of 
evidence regarding any effect of opiates on patients with OSA I developed a prospective, 
paired design study examining the effect of intravenous morphine sulphate on the severity of 
OSA in patients with known diagnosis of moderate OSA (Morphine In Moderate OSA). This 
study along with its outcomes is described in Chapter 5.  
Chapter 6 summarises findings of the thesis, considers the limitations of the 
research methodology, its usefulness and the possible impact of my results on clinical 
practice. Future directions of the research are also discussed. 
Experimental protocols,research approval and ethics  
All protocols involving new data acquisition in subjects received Papworth Hospital 
NHS Foundation Trust research approval and favourable ethical opinions from the local 
ethics committee with details in Appendix 3. Papworth Hospital NHS Foundation Trust 
sponsored the experimental protocols and funded the trials through the pump priming funds. 
Trials were conducted in keeping with recommendations for good clinical practice including 
the declaration of Helsinki. Written consent was obtained from all participants. All protocols 
were designed, ethical approval gained and funding secured by the author of this thesis. 
Ethical approval for the prospective observational cohort study (SACS) was granted 
by The National Research Ethics Service East Midlands Northampton Proportionate Review 
Sub-committee (12/WM/0433). The local research committee, NRES Committee East of 
England, Cambridgeshire and Hertfordshire, gave ethical approval for the prospective, 
paired design study examining the effect of intravenous morphine sulphate on the severity of 
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OSA in patients with a known diagnosis of moderate OSA (MIMOSA) with further information 
available in Appendix 3. 
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Chapter 1 
Obstructive Sleep Apnoea in the surgical population and its implications for the post-
operative care 
Introduction  
OSA, intermittent collapse of the upper airway in sleep, is very common in the adult 
population (Young et al. 1993; Duran et al. 2001) and it has been estimated that 80% of 
sufferers are undiagnosed (Young et al. 1997). It is inevitable that patients referred for 
surgery will include people with unrecognised and untreated OSA. There are conflicting data 
for the impact of undiagnosed OSA on the outcome of surgical procedures but at least some 
results suggest an association with poorer outcomes (Gupta et al. 2001; Hwang et al. 2008; 
Liao et al. 2009). Where an excess of postoperative complications has been associated with 
OSA it has been proposed that differences in sensitivity to the effects of opiates may be an 
explanation but the exact mechanism remains unknown (Catley et al. 1985; Esclamado et al. 
1989). There is a move towards pre-operative screening for OSA but the best screening 
methodology has not yet been established and currently the evidence does not support 
routine preoperative screening for OSA (Vasu et al. 2012; Lockhart et al. 2013) and perhaps 
more importantly there is no evidence that screening for OSA pre-operatively affects surgical 
outcomes. OSA and coronary artery disease share some of the same risk factors (Mooe et 
al. 1996) and a high incidence of undiagnosed OSA and other forms of sleep disordered 
breathing might be predicted in patients undergoing coronary artery bypass grafting (CABG). 
This thesis aims to inform our understanding of any excess risk associated with undiagnosed 
OSA in patients undergoing major cardiac surgery and will explore the safety of morphine, a 
common post-operative analgesia, in patients with OSA.  
 This Chapter reviews the evidence base for OSA including the epidemiology, 
pathophysiology, investigation as well as treatment of OSA. In addition, it will also 
summarise our knowledge of OSA in surgical populations, including the epidemiology of 
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OSA in this subset of patients and current evidence regarding the value of pre-operative 
screening, peri-operative care and postoperative outcomes in patients with OSA. 
Historical perspective of Obstructive Sleep Apnoea 
Although humans spend one third of their life sleeping the full  biological effects of 
sleep remain unknown. The perception of sleep has varied through history and many 
authors have portrayed sleep in their work. For example Macbeth in William Shakespeare’s 
play described sleep as “chief nourisher in life’s feast” (McNicholas et al. 2010). Some 
authors, however, including Tennyson, perceived sleep with fear and described it as “death’s 
twin brother”(McNicholas et al. 2010). This idea resonates with Greek mythology where 
Hypnos, personification of sleep, was twin brother of Thanatos, personification of death, and 
images of Hypnos were often shown close to the images of death. In the last two decades 
sleep has attracted large interest and the field of sleep medicine has rapidly expanded.  
OSA is one of the most prevalent sleep disorders and has, in the past, been 
described in classical literature including “The Tale of the Jack and the Beanstalk”, where 
the giant slept soundly and was famous for his loud snoring and most likely suffered with 
OSA syndrome. Charles Dickens in the “Posthumous Papers of the Pickwick Club” 
described the cardinal feature of OSA in a fat boy, Joe who snored heavily as if “the roaring 
of cannon were his ordinary lullaby”.  
A closer description of the breathing pattern of patients with OSA was reported in 
paper by Broadbent (Broadbent 1877) in the late nineteen century but OSA was described 
as a clinical entity only in the late 1950’s. In 1965 Gastaut et al. noted and described 
frequent apnoeas on polysomnographic assessment of obese, sleepy patients (Gastaut et 
al. 1965). The pathophysiology and clinical features of OSA were investigated and defined in 
the following decade. Early research focused on clinical and pathophysiological traits of OSA 
whereas the progress in understanding the OSA has lately been concentrating more on 
genetic and molecular aspects of OSA, association between OSA and other comorbid 
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conditions, including cardiovascular and metabolic, as well as on the effect of treatment on 
progress and prognosis of the conditions associated with OSA.  
Understanding the pathophysiology of OSA has helped to develop the treatments, 
and this along with progress in development of appropriate diagnostic tools has informed the 
current practice of sleep medicine. Treatment of OSA remains mainly mechanistic and 
concentrates on bypassing or reducing upper airway obstruction. The first treatment used to 
bypass the obstruction was placement of a tracheostomy tube, reported  in 1970 (Lugaresi 
et al. 1970). It was not until  the advent of CPAP, delivered non-invasively via a mask, 
developed by Sullivan in 1981 (Sullivan et al. 1981), that we experienced the revolution in 
management of sleep disordered breathing and even today CPAP represents the 
cornerstone of treatment of patients with OSA.  
Although our understanding of OSA has advanced considerably over the last few 
decades there is still much which remains unknown. This maintains research interest in 
OSA, comprising areas such as the basic mechanisms of OSA and its consequences, 
including after surgical procedures, genetic factors contributing to development of OSA as 
well as development of new innovative modalities of treatment.  
Pathophysiology of OSA 
Sleep Disordered Breathing is a term used to cover a range of breathing events, 
encountered during sleep and includes OSA, central sleep apnoea (CSA),  Cheyne–Stokes 
respiration (CSR) and respiratory effort related arousals (RERA’s). OSA is the most common 
form of SDB and when coupled with symptoms of excessive daytime sleepiness (EDS) it is 
described  as OSA syndrome (OSAS). OSA is caused by recurrent episodes of partial or 
complete upper airway collapse with ongoing ventilatory effort during sleep, leading to 
intermittent reduction (hypopnoea) or cessation (apnoea) of air flow through the upper 
airway. These cause transient hypoxia and hypercapnia and intermittent activation of 
sympathetic drive. These events are usually terminated by the patient’s arousal which 
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restores the airway patency and normalises the partial pressure of oxygen (PaO2) and 
carbon dioxide (PaCO2).  Occasional nocturnal obstructive apnoea and hypopnoea are 
normal  but when the frequency of these episodes increases to ≥5 per hour of sleep they can 
be associated with symptoms of excessive daytime sleepiness and un-refreshing sleep 
(Gottlieb et al. 1999) as well as adverse health outcomes including cardiovascular disease 
(Haas et al. 2005; Kuniyoshi et al. 2008), type 2 diabetes mellitus (Reichmuth et al. 2005)  
an increased risk of road traffic accidents  (George et al. 1987; Findley et al. 1988; Wu et al. 
1996) and mortality (Punjabi et al. 2009).  
The pathophysiology of OSA is complex and not fully understood. OSA is a 
heterogeneous disease and underlying pathophysiological mechanisms vary between 
individuals creating different phenotypes of OSA. Various pathophysiological mechanisms 
for the development of OSA have been proposed and include contributions from: upper 
airway anatomy, upper airway dilator muscles activity, ability to wake during an apnoeic 
episode (arousal threshold), ventilatory control stability (loop gain) and lung volumes.   
Upper airway anatomy  
The human upper airway (UA) is a complex structure involved in various functions 
including breathing, swallowing and speech.  It consists of four anatomical segments namely 
the  nasopharynx extending from nares to hard palate, velopharynx ranging from the margin 
of the hard palate to the margin of the soft palate, oropharynx from the soft palate to the 
edge of the epiglottis and hypopharynx  from epiglottis to vocal cords.  Human pharynx 
contains of more than 20 muscles creating three main functional groups including muscles 
controlling hyoid bone (geniohyoid, sternohyoid muscles), muscles of the tongue 
(genioglossus, the major upper airway dilator muscle) and palatal muscles 
(palatopharyngeus, tensor palatine, levator palatine muscles).  
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The majority of the UA is a collapsible structure extending from soft palate to the 
larynx and its patency and stability depend on the relationship between collapsing and 
expanding  forces. The forces supporting UA patency depend on  the size and the shape of 
the UA as well as the dilator muscle activity. Forces promoting UA collapse consist of 
negative intraluminal pressure created during the inspiration and the mass load placed on 
the UA by intraluminal surface forces and external soft tissues (Shneerson 2005).  
In patients with OSA, upper airway collapse and reinstatement of patency during 
sleep result from complex interactions (Berry et al. 1996; Mezzanotte et al. 1996; Wellman et 
al. 2004; Eckert et al. 2007). Generally, a narrow upper airway is more susceptible to 
collapse, compared to a larger one. Studies supporting this hypothesis, assessing cross-
sectional area of upper airway during wakefulness using computed tomography and 
magnetic resonance showed that, compared to normal subjects, patients with OSA have a 
smaller UA, as well as altered alignment of the soft tissue adjacent to the UA, leading to 
anatomical compromise and increased propensity to UA collapse (Schwab et al. 1995). 
Increased propensity to UA collapse was confirmed by Isono et al. who observed more 
collapsible airway in patients with OSA undergoing general anaesthesia and muscle 
paralysis as evidenced by increased closing pressure (pressure inside the airway at which 
the airway collapses as described in the next paragraph) in patients with OSA (Isono et al. 
1997).  
The severity of OSA, duration of apnoeas and degree of oxygen desaturations have 
been negatively affected by supine compared to lateral recumbent position (Oksenberg et al. 
2000). In some, this leads to positional OSA, defined as supine apnoea-hypopnoea index at 
least double of that in lateral position. One study reported  prevalence of positional OSA at 
50% of mild, 19% of moderate and 6.5% of severe OSA (Mador et al. 2005). This positional 
variability in OSA has been attributed to the effect of gravity on the shape of the UA, where 
the shape of UA changes from transverse elliptical in supine to circular in lateral position 
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potentially improving UA patency and reducing UA collapsibility in lateral position in patients 
with OSA (Gastaut 1965).  
As already elaborated, the oropharynx is a collapsible structure and the relationship 
between pressure and flow has been studied using a Starling-resistor model (Smith et al. 
1988), where the collapsible segment in the oropharynx has a critical closing pressure (Pcrit) 
defined as the pressure inside the airway at which the airway collapses, Pus is the 
atmospheric pressure at the nares and Pds is the tracheal pressure. When Pcrit exceeds 
Pus and Pds upper airway collapse follows. When Pcrit exceeds Pds but is less than Pus 
there is a flow limitation and when Pus and Pds are higher than Pcrit there is a free flow 
thorough the UA. Patients with normal breathing usually have  Pcrit of > -10cmH2O, snorers 
without apnoeas a Pcrit from -10 to -5 cmH2O and patients with obstructive hypopnoeas  
have Pcrit from -5 to 0 cmH2O, whereas patients with obstructive apnoea had Pcrit 
>0cmH2O (Schwartz et al. 1988; Smith et al. 1988; Gleadhill et al. 1991). Patients with 
obesity have more collapsible airways and weight loss has been shown to be associated 
with reduction in Pcrit and improvement in OSA severity, supporting the importance of 
weight loss in treatment of obese OSA patients (Schwartz et al. 1991).   
It has also been shown that UA anatomy and the severity of OSA can be affected by 
UA oedema reported to lead to narrowing of the UA lumen. Studies in healthy subjects have 
shown that displacement of fluid from legs to upper body leads to an increase in neck 
circumference (Chiu et al. 2006) and upper airway resistance and collapsibility (Su et al. 
2008). These changes correlate with the severity of OSA, defined as apnoea-apopnea index 
in OSA patients (Redolfi et al. 2009).  In another study diuresis of patients with severe OSA 
and diastolic heart failure led to a significant improvement in OSA, leading same support to 
the hypothesis of upper airway oedema influencing severity of OSA and diuresis as possible 
treatment option of OSA in patients who are fluid overloaded (Bucca et al. 2007). 
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Upper airway dilator muscles 
It appears that during wakefulness patients with OSA compensate for reduction in UA 
diameter by increased UA dilator muscle activity, however, this compensatory mechanism is 
lost at  sleep onset resulting in UA compromise. During wakefulness, the electromyogram 
(EMG) activity of genioglossus muscle, one of the most studied upper airway dilator 
muscles, is increased in patients with OSA, compared to healthy controls (Mezzanotte et al. 
1992) but reduction in EMG activity occurs at sleep onset and the reduction is larger in OSA 
patients, when compared to healthy controls. Healthy individuals may experience breathing 
instability at sleep onset but patients with OSA are particularly vulnerable and develop an 
increased  frequency of apnoeas and hypopnoeas during the transition from wakefulness to 
sleep (Trinder et al. 1992). As obstructive breathing events are terminated by arousals it is 
difficult for patients with OSA to enter deeper restorative slow wave sleep during which the 
upper airway dilator muscle activity is increased and it has been observed that the severity 
of OSA in this sleep stage improves (Basner et al. 1991).   
One of the major components promoting UA patency is locally mediated negative 
pressure reflex based on the mechanoreceptive response to surges of negative intraluminal 
UA pressure (Horner et al. 1991). There are both excitatory and inhibitory components to 
this reflex, where the excitatory component remains stable during the sleep but the inhibitory 
component is more pronounced and may be responsible for reduced negative pressure 
responsiveness during  sleep in healthy subjects (Eckert et al. 2007). This reflex has been 
less studied in OSA patients. 
Another mechanism proposed as a possible cause for an impaired response of UA 
dilator muscles to negative pharyngeal pressure in patients with OSA is UA sensory 
neuropathy due to the mechanical trauma of snoring and hypoxia related oxidative stress 
causing inflammation. Pathological changes consistent with a neuropathic process and 
muscle denervation have been found in UA muscle specimens of OSA patients (Bergeron et 
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al. 2005; Svanborg 2005). The degree of sensory neuropathy correlates with OSA severity 
(Nguyen et al. 2005) and the duration of OSA and may lead to worsening OSA severity. It 
has also been shown that cortical evoked potentials reflecting the sensory processing of 
respiratory afferent information are impaired in patients with OSA during sleep but not during 
wakefulness (Gora et al. 2002). Further research in this area is needed to confirm the role of 
UA sensory impairment in the pathophysiology of OSA as well as its role in modulating 
disease severity.  
Lung volumes 
Studies in animals and humans suggest that lung volumes may play a role in the 
pathophysiology of OSA. A reduction in lung volume has been associated with increased UA 
resistance (Hoffstein et al. 1984). The mechanism is not well understood but one explanation 
in animal models is loss of caudal traction on the UA (Kairaitis et al. 2007). Further studies 
are necessary to inform the exact mechanism on pathophysiology of OSA.  
Arousal from sleep 
Arousal from sleep at the termination of an apnoea or hypopnoea is a protective 
mechanism to restore UA patency during sleep. Arousal from sleep at the end of the 
breathing event is triggered by negative pleural pressure, generated by respiratory effort 
(Vincken et al. 1987) and leads to increased dilator muscle activity which restores airflow 
patency and normalised blood gas tensions (Jordan et al. 2003). Patients with OSA seem to 
have impaired arousal responses to breathing events compared to healthy subjects in that 
they either have a higher arousal threshold ( more difficult to wake up) or require a higher 
negative pressure to trigger the arousal (Berry et al. 1996).  It has been shown that CPAP in 
OSA patients lowers the arousal threshold which would suggest that other mechanisms 
associated with OSA  such as hypoxia, hypercapnia or frequent arousals may be 
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responsible for impaired arousal rather than an inherent defect in arousal threshold (Haba-
Rubio et al. 2015).   
It was believed that arousal from sleep is necessary for restoring upper airway 
patency but in the study by Younes et al. 22 % of patients with OSA exposed to transient 
reduction in CPAP pressure during sleep had increase in UA flow before the arousal 
occurred and 17% had the flow restored without an arousal (Younes 2004). To understand 
the mechanism of restoring UA flow without an arousal Jordan et al. found that up to five 
minutes of transient CPAP pressure reduction during  sleep leads to an increase in 
genioglossus muscle activity in both OSA as well as healthy individuals but patients with 
OSA were less able to restore flow without cortical arousal (Jordan et al. 2007). These 
findings may suggest that in a certain cohort of patients, with low arousal threshold, 
manipulating an arousal threshold may be beneficial, and would allow time to recruit UA 
dilator muscle and restore UA patency. This may also allow patients to consolidate sleep by 
entering deep, slow wave sleep during which the severity of OSA improves due to increased 
dilator muscle activity. 
Manipulation of arousal threshold may open new therapeutic strategies for a 
phenotype of patients with low arousal threshold but caution has to be exercised as this 
approach may be deleterious for patients with severe sleep disordered breathing and high 
arousal threshold as these individuals may experience prolong duration of breathing events 
and worsening in blood gas tension (Dyken et al. 2004). Manipulation of arousal threshold by 
hypnotics has been explored by Eckert et al. who showed that eszopiclone increases the 
arousal threshold and lowers the AHI in obstructive sleep apnoea patients that do not have 
marked overnight hypoxaemia (Eckert et al. 2011). More recently the effects of zopiclone, 
temazepam and zolpidem were compared in randomised, double blind, placebo controlled 
trial (Carberry et al. 2017). The arousal threshold increased with zolpidem and 
zopiclone compared to placebo but not with temazepam. These drugs did not reduce upper 
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airway muscle activity or alter airway collapsibility during sleep but rather, muscle activity 
increased during airway narrowing with zolpidem (Carberry et al. 2017). These results 
suggest that contrary to common beliefs hypnotics do not reduce UA dilator muscle activity 
and may bring about new possibilities of treatment for a particular phenotype of OSA 
patients. Larger and longer duration studies are needed to reproduce and confirm these 
findings.  
Ventilatory control stability 
Although, an arousal from sleep can be beneficial in restoring UA patency, optimising 
ventilation and normalising arterial blood gas tension, it can also destabilise ventilatory 
control and exacerbate sleep apnoea severity (Eckert et al. 2007). Ventilatory control refers 
to a system that assures stability of breathing and responsiveness to a disruption in 
breathing. Ventilatory control is mediated by feedback loops and loop gain (Khoo et al. 
1982), which in turn consist of controller gain and plant gain. Controller gain refers to 
ventilatory response to hypoxia and hypercapnia and plant gain is the ability of ventilation to 
excrete carbon dioxide (CO2).  
High loop gain refers to a system that overreacts to a respiratory stimulus and low 
loop gain to a system with a blunted response and under-reacts to the respiratory stimulus. 
Studies measuring loop gain such as proportional assist ventilation (PAV) techniques have 
demonstrated that some patients with OSA have elevated loop gain causing  ventilatory 
instability which  contributes to worsening of SDB (Wellman et al. 2004). An elevated loop 
gain may work through an elevated response to arousal, leading to reduction of PaCO2 
below the apnoeic threshold, causing obstructive or central apnoea, depending on the 
predominant mechanics of UA at the time. 
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Genetic factors  
 The different pathophysiological mechanisms for the development of OSA make OSA 
a  heterogeneous disease and the complex phenotypes of OSA render establishment of a 
single genetic link for OSA most unlikely.  
Different genetic approaches have been used to seek  genetic predisposition to OSA, 
including linkage studies, case-control studies and genome wide association studies. 
Linkage studies are used for single gene disorders and usually use extended families. In 
these studies, a genetic marker may be identified, but this marker is not necessarily linked to 
phenotypic effect. Complex statistical methods expressed as a logarithm of odds (LOD) 
score is used to describe the association between genetic locus and phenotypic marker. A 
LOD score of 3 indicates significant association, where the genetic and phenotypic marker 
have a chance of <1/1000 not to be linked. Scores of <2 are not suggestive of linkage 
(Lander et al. 1995). There are 3 large genome wide association studies including 
European-American pedigrees and African-American pedigrees, where OSA was 
phenotyped on AHI alone, diagnosed on multichannel home polyghraphy.  In all of these 
studies when AHI was adjusted for BMI there was no significant association between genetic 
markers and OSA (Palmer et al. 2003; Palmer et al. 2004).   
Candidate gene association studies identify a gene of interest which is then 
sequenced in cases with disease in question and unrelated, disease free controls. In these 
studies common and variant genes can be detected. Several studies have been published  
with various genes of interest but a  meta-analysis of 8 studies examining the apolipoprotein 
E gene epsilon 4 (APOE4), considered to be a precursor of atherosclerosis, reported ods 
ratio (OR) of 1.13 (95%CI 0.86-1.47) with significant heterogeneity in included studies and 
concluded that there was no significant association between this gene and OSA (Thakre et 
al. 2009). Studies examining various other genes have not been replicated, not properly 
controlled and variable phenotypes of OSA were used.  
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There is some evidence  for a heritable component to OSA taking into account 
familial predisposition to obesity (Pillar et al. 1995; Redline et al. 1995) but anatomic traits 
including UA soft tissue size, ventilator control and response to UA resistance during the 
sleep also appear to share a genetic predisposition (Pillar et al. 1997; Bhama et al. 2006). It 
appears that genetic traits may also be responsible for OSA in different racial groups such 
as Asians who have shorter maxillae and mandibles and lower BMI compared to Caucasians 
for a given degree of OSA severity (Redline et al. 1997) and African-Americans who have an 
increase in soft tissue load on the UA compared to Caucasians (Cakirer et al. 2001).  It is 
likely that further meaningful genotyping of OSA will depend on more accurate phenotyping 
of OSA cohorts.  
The consequences of OSA are in part mediated by chronic intermittent hypoxia, 
sympathetic activation, oxidative stress and inflammation. Assessing molecular signatures of 
the disease described as “pattern of gene or protein expression in cells or tissue related to 
the disease state” could assist with diagnosis and advice regarding the prognosis of OSA 
related comorbidities or development of new therapies (Arnardottir et al. 2009) and studies 
assessing gene expression in blood cells during  sleep may provide important information 
regarding gene expression during the sleep and molecules affected by OSA. In this regard, 
there is one published study in adult OSA involving only 4 patients and 4 controls showing 
overnight upregulation of expression of oxidative stress responsive genes such as the 
antioxidant enzyme superoxidase dismutase 2 (SOD2) and over-regulation of 
superperoxidase desmutase 1 (SOD1), compared to controls (Hoffmann et al. 2007). 
The main issue in identifying molecular signatures and biomarkers of OSA lies in 
separating the consequence of OSA and obesity which is an independent risk factors for 
many comorbidities associated with OSA and seems to activate the same molecular 
pathways (Arnardottir et al. 2009). One proposed strategy is to evaluate relevant molecular 
pathways during sleep and at the transition from wake to sleep as such changes may, at 
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least partly, be related to chronic hypoxia and sympathetic surges occurring in OSA patients 
during the sleep.  
Another expanding area looking at the molecular signature of OSA is proteomics 
providing information on true molecular phenotype of a disease as knowledge of gene 
variants and gene expression may not translate into actual changes in proteins. Proteomics 
is more complicated than genomics and the technology is not yet as developed as 
microarrays, the platform that allows automated analysis of high volume DNA at once. Two 
studies have been published assessing proteomic pattern in children (Krishna et al. 2006; 
Shah et al. 2006). One study reported increased expression of three proteins in children with 
OSA compared to simple snorers. One of the proteins was osteocalcin a precursor of 
gamma-carboxyglutamic acid containing protein, used as a biomarker as growth retardation 
(Shah et al. 2006). This exciting strategy may provide important details of the  molecular 
signature of OSA and may lead to new diagnostic techniques using OSA biomarkers.  
Risk factors for OSA 
Various risk factors have been proposed in the development of OSA including: the 
male sex, age and obesity (Eckert et al. 2008).  
Obesity 
The link of obesity to OSA is supported by finding that modest reduction in weight 
results in improvement of OSA severity (Peppard et al. 2000). Proposed physiological 
mechanisms for the effect of obesity on the development of OSA include:  deposition of fat 
around pharyngeal airways, reduction of functional residual capacity as well as low lung 
volumes leading to decreased oxygen reservoir and ventilatory control instability (Eckert et 
al. 2008). In one longitudinal study of 690 subjects assessed at 4 years intervals, Peppard et 
al. reported that 10% weight gain led to 32% increase in AHI (95% CI 20-45%) and a 6 folds 
increase in odds of developing moderate to severe OSA (AHI>15 events/hr) but 10 % weight 
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loss led to 26%(95% CI 18-34%) reduction of AHI (Peppard et al. 2000). This stresses the 
importance of implementation of weight reduction programmes in the management of OSA 
but also in the prevention of OSA. Although the relation to obesity has been demonstrated 
from these studies, it is not a sole risk factor in development of OSA as 1/3 of OSA patients 
are not obese and not all obese patients with large neck circumference suffer with OSA 
(Lecube et al. 2010).  
Sex 
Studies have confirmed that OSA is more common in males compared to females 
with male-female ration of 2:1 and a similar finding has been observed in simple snoring. 
The reason for male predominance is not clear but some  mechanisms have been proposed. 
A longer pharyngeal airway in males and increased fat deposition around the UA could 
increase pharyngeal collapsibility (Whittle et al. 1999; Malhotra et al. 2002). In addition, 
hormonal differences between sexes, especially of testosterone, may be implicated, as the 
prevalence of OSA is higher in post-menopausal females. The role of hormones is not fully 
understood. Despite higher prevalence of OSA in postmenopausal women, it was shown 
that in the elderly population over 65 years, the same ratio of male to female distribution 
persists (Hader et al. 2005) and therefore clear mechanism remains unknown and more 
research is needed to provide further understanding. 
Age 
Most studies examining the prevalence of OSA have included populations up to 60 
years old but studies which included older patients show continuous increase in prevalence 
which seems to plateau after 65 years (Young et al. 2002). Proposed mechanisms for 
developing OSA in the elderly include:  increased pharyngeal fat deposition and reduced 
genioglossus negative pressure reflex with aging (Eckert et al. 2008). Ancoli-Israel et al. 
studied a sample of 427 elderly men and women, 65-95 years old, and found OSA (AHI>10) 
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in 70% of men and 56% of women, which is much higher than the prevalence found in 
middle age (Ancoli-Israel et al. 1991). Similar findings were reported in Sleep Heart Health 
study, where OSA (AHI>15) was 1.7 fold higher in older patients (60-99), compared to 
younger participants (40-60) (Young et al. 2002). In both studies the prevalence plateaus 
after the age of 65 years which may imply either increased mortality rate in people with OSA 
in this age group or remission of OSA with aging.  
There has been a suggestion that OSA represents a different entity in the older age 
group as several studies have reported little or no association of OSA with sleepiness, 
hypertension or cognitive function impairment compared to patients in the middle age 
(Young et al. 2002). In one study, OSA syndrome defined as AHI≥10/hr and associated 
hypertension or sleepiness, was reported in 1.75% in those over 65 years and 4.7% in 45-64 
years adults (Bixler et al. 2001). In an 18 years follow up study of older participants there 
was weak association of BMI and AHI (Ancoli-Israel et al. 2001) and similarly, the 
association of obesity and AHI was weaker in older compared to younger participants in the 
Sleep Heart Health study (Young et al. 2002). It has also been noted that self-reported 
snoring decreases past middle age (Bliwise et al. 1988; Wetter et al. 1994; Bixler et al. 1998) 
with possible explanations being that their bed partners are no longer alive to witness 
snoring in the elderly or they may suffer with central sleep apnoea not associated with 
snoring, reported to occur at 5 % in over 65 years old (Bixler et al. 1998). Although OSA 
syndrome may not be as prevalent as in middle aged patients those who are symptomatic 
benefit from CPAP similarly to younger adults (Launois et al. 2007; McMillan et al. 2014). 
With increasing longevity further studies are needed to investigate the nature and 
consequences of OSA in the elderly to inform the appropriate clinical management of the 
older patients. 
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Smoking and alcohol 
Several studies report an association between cigarette smoking and snoring or OSA 
with one possible underlying mechanisms being upper airway inflammation. In a Swedish 
ten year longitudinal study smoking was a predictor of snoring in males below 60 years but 
not older males (Lindberg et al. 1998). Another study found a dose response relationship 
between smoking and AHI and current smokers (but not ex-smokers) were three times more 
likely to have OSA than never smokers [95% CI 1.4-6.4] (Wetter et al. 1994). However, the 
role of smoking as a risk factor for OSA is not clear as the Sleep Heart Health Study 
reported an inverse association of smoking and OSA in that that smokers less frequently had 
sleep apnoea compared to non-smokers (Newman et al. 2001). As such, although a 
plausible hypothesis exists for the effect of smoking on the development of OSA the role of 
smoking as a risk factor for OSA remains unknown and needs to be established.  
 Alcohol reduces UA dilator muscle activity leading to hypotonia and predisposition to 
UA collapse and therefore could potentially worsen OSA severity (Krol et al. 1984). Studies 
examining alcohol effect looked at acute administration of alcohol in relation to respiratory 
disturbance index and epidemiological studies have looked at the correlation between self-
reported alcohol intake and OSA. Most, but not all studies where alcohol was administered 
to healthy subjects or patients with OSA before bedtime showed an increase in AHI 
(apnoea/hypopnoea index) and duration of apnoeas during the night (Young et al. 2002). 
Two CPAP titration studies examining the pressure needed to abolish apnoeas and 
hyponoeas during the night in patients who ingested a moderate amount of alcohol before 
bed time showed conflicting results (Mitler et al. 1988; Teschler et al. 1996). The association 
between chronic alcohol consumption and OSA severity was examined in longitudinal 
studies and again showed contradicting outcomes (Young et al. 2002).
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Epidemiology of OSA  
Understanding the disease prevalence, proportion of population with the condition in 
question, is paramount in planning health care needs and allocating healthcare resources. 
When comparing prevalence of disease by demographic factors, important hints regarding 
etiological factors or populations at risk may arise. It has to be remembered, however, that 
estimates of prevalence are vulnerable to many methodological concerns including: sleep 
diagnostics used, definition of OSA (which has changed over the years), sample size, 
participation bias and loss to  follow up. For example, choosing a sample population from a 
sleep clinic with referrals directly from cardiac clinics would likely overestimate the 
association of OSA and cardiovascular disease. It is also important to note that even when 
recognised diagnostic methods such as polysomnography or respiratory polygraphy are 
used it is difficult to distinguish between central and obstructive hypopnoea. In addition, 
there is a lack of standardisation in quantifying airflow where methods such thermistry, and 
nasal cannula pressure transducer provide different levels of sensitivity to airflow. 
Some reviews have addressed this issue by adjusting for differences in definition and 
comparing the results of studies with similar study designs. One study that analysed 12 
studies of OSA prevalence in Western populations estimated that 1-5% of adults suffer 
OSAS (Davies et al. 1996). Lindberg and Gislason estimated the prevalence of OSA from 
nine studies using a two- stage sampling procedure (Lindberg et al. 2000). In this method 
sleep studies are undertaken on a sample of a population drawn from  large surveys using 
questionnaires of symptoms such snoring to identify patients at risk for OSA and therefore 
these studies are vulnerable to selection bias and may overestimate the prevalence of OSA. 
The prevalence of OSAS in the studies ranged from 0.3% to 5%. Based on these results, it 
appears that up to 5% of Western, middle aged population suffers with OSAS and may be 
candidates for treatment with CPAP.  
OSA without symptoms appears to be much more prevalent, and is not included in 
these estimates. More importantly, its clinical and public health significance remain 
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unknown. Taking into account large population based studies using in-laboratory 
polysomnography with a similar definition of OSA, and using cohorts from Wisconsin, 
Pennsylvania and Spain, prevalence of mild OSA in men ranges between 17-26% and 
women 9-28%, whereas moderate OSA has been described in 9-14% of men and 2-7% of 
women (Young et al. 1993; Bixler et al. 1998; Bixler et al. 2001; Duran et al. 2001). As 
reported by Peppard et al. this prevalence has risen in the last two decades (1993-2013) 
with relative increases of between 14% and 55%, depending on the subgroup, but moderate 
to severe OSA (AHI≥15) was present in 34% in men and 17 % in women aged 30-70 years 
(Peppard et al. 2013). The latest population based study (HypnoLaus study) in Switzerland 
showed that at least mild OSA (apnoea-hypopnoea index ≥5) was present in 84% of men 
and 61% of women and at least moderate disease (apnoea-hypopnoea index ≥15) was 
present in 50% of men and 23 % of women (Heinzer et al. 2015). The strength of this cohort 
is that the population was selected from the general population and not based on the result 
of sleep questionnaires, minimising selection bias. The high prevalence in this study, 
compared to earlier work, may be due to the more sensitive polysomnographic techniques 
developed over the years and a change in apnoea-hypopnoea definition. The 2012 
American Academy of Sleep Medicine (AASM) guidelines defined hypopnoeas as a ⩾30% 
decrease in nasal flow with ⩾3% desaturation of arterial oxygen measured by pulse oximetry 
or electroencephalography (EEG) arousal (Berry et al. 2012). Duce et al. looked at the 
impact of applying this new definition on OSA prevalence in a retrospective set of 112 
polysomnography (PSG) studies, where he compared prevalence with more stringent AASM 
2007 criteria and not surprisingly found that the more liberal AASM 2012 criteria resulted in a 
markedly higher prevalence of OSA (Duce et al. 2015).  
Given the fact that mechanisms by which OSA affect health consequences are still 
poorly understood, the most meaningful definition of OSA is unknown and the AHI does not 
distinguish between different aspects of OSA such as hypoxia or sleep fragmentation which 
may have distinctive consequences for the patient (Thomas et al. 2014). Although a higher 
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prevalence of OSA was reported in the HypnoLaus study, the prevalence of OSAS in this 
study seems to be in line with previous reports ranging from 0.07% to around 6.2 % across 
the severity of OSA spectrum from severe to mild OSA. Moreover, after variable 
adjustments, this study also reported that more severe OSA, with an AHI of over 20·6 
events/hr, was independently associated with the presence of hypertension (OR1·60, 95% 
CI 1·14–2·26; p=0·0292), diabetes (OR 2·00, 95%CI1·05–3·99; p=0·0467), metabolic 
syndrome (OR 2·80, 95%CI1·86–4·29; p<0·0001) as well as depression (OR1·92, 
95%CI1·01–3·64; p=0·0292).  
The prevalence of OSA has been reported in only a few non Western populations 
and  racial and ethnic prevalence patterns are poorly understood. Geographical distribution 
of the disease could generate important clues regarding the aetiology of OSA but it is difficult 
to distinguish between environmental and cultural influences such as diet from genetic 
factors. A few studies suggest that OSA prevalence is higher in African – Americans, 
compared with Caucasians (Ancoli-Israel et al. 1995; Redline et al. 1997), but data from over 
6,000 participants in the Sleep Heart Health study did not confirmed this when adjusted for 
age, sex and BMI (Young et al. 2002). Only a few studies from Asian populations are 
available. In Hong-Kong, men, aged 30-60 years had a prevalence of OSA (AHI≥15) of 5% 
and OSA syndrome (AHI≥5 and excessive daytime sleepiness) of 4% (Ip et al. 2001). The 
prevalence of OSAS in Chinese women in Hong Kong was found to be 2% (Ip et al. 2004). 
Although the prevalence appears to be similar to  that in the Western population, correlation 
of BMI and weight with OSA was weaker. It was therefore hypothesized that other risk 
factors such as craniopharyngeal features may be more influential in this population and this 
hypothesis was supported by other observational studies of Asian patients. Because genetic 
and environmental risk factors may vary between African, Asian and Western populations 
more studies on native population as well as migrants and their offsprings may offer more 
understanding.  
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There is considerable evidence about prevalence of OSA from Western populations 
but little is known about the incidence, defined as occurrence of new cases over time interval 
or progression or worsening over the time. Identifying the incidence comes with all the 
issues related to prevalence but moreover it is difficult to identify a disease free cohort. This 
can be further influenced by night to night variability in AHI, hence validity of an OSA free 
cohort. Only a few reports are available on the progression of OSA. Eight years follow up of 
282 participants from the Wisconsin cohort showed an overall increase in mean AHI by 2.6 
events/hr from baseline 2.5 to 5.1 and the progression was greater in obese, older and 
habitual snorers (Young et al. 2002). Similar findings were reported in a preliminary report 
from the Cleveland family study with an increase in AHI from a mean baseline of 2 (±1.4) to 
6.2 (±7.9) at 5 years follow up with significant predictors of progression being BMI, central 
obesity, cardiovascular disease and diabetes (Tishler et al. 2003).  
These results suggest that significant progression can occur within a relatively short 
period of time with obesity being the main risk factor. As the “obesity epidemic” increases it 
is likely that there will be a rise in incidence and prevalence of OSA and the public health 
effort should be aimed at weight reduction programmes to mitigate the risk on already over-
streched healthcare systems. 
Sleepiness 
Sleepiness is the main symptom of  OSAS but as recognised from clinical practice 
there is significant interpersonal variability in terms of sleepiness in patients with OSA 
regardless of severity of OSA. There is evidence that effective treatment of selected patients 
with OSAS with CPAP, compared to sham CPAP improves sleepiness (Engleman et al. 
1994; Patel et al. 2003; Giles et al. 2006). In addition, large cross-sectional studies in the 
general population show evidence that snoring as well as OSA is associated with 
sleepiness.  
For example, in the Wisconsin Sleep Cohort study 35% of women and 23% of men 
with AHI>5 reported excessive sleepiness compared to 29% of women and 24% of men who 
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snored with AHI<5 and 19% women and 6% men with AHI<5 who did not snore (Young et 
al. 1993). In another study of 850 randomly selected males snoring was associated with a 5 
fold increase in the odds of excessive sleepiness adjusting for severity of OSA (Stradling et 
al. 1991). Young et al. reported that snorers with AHI of < 5/hr reported hyper somnolence 
more frequently than non-snoring controls (Young et al. 1993) and she also showed that 
habitual snores with AHI<5 had a 3 fold increased odds of experiencing road traffic collisions 
during a 5 year period, compared with subjects without habitual snoring (Young et al. 1997). 
In the Sleep Heart Health study there was a significant increase in excessive sleepiness 
assessed by Epworth Sleepiness Scale (ESS) score (Johns 1991) in patients with AHI<5 
(ESS 7) to ESS of 9 in participants with AHI>15, independent of sex , age and BMI (Gottlieb 
et al. 1999).  
However, the cause of sleepiness in patients with OSA is not fully understood. It was 
believed that arousals leading to sleep fragmentation may be responsible for this symptom  
but studies have failed to confirm this hypothesis (Stradling et al. 2000; Kapur et al. 2005). A 
multi-center cohort study published in 2008 suggested that apnoeas and sleep disruption 
were not the primary determinants of excessive sleepiness and patients with excessive 
sleepiness had longer sleep duration, increased slow wave sleep and more sleep 
fragmentation (Roure et al. 2008). 
These studies suggest that snoring, independent of OSA is associated with 
excessive daytime sleepiness. The mechanism of this is not clear and validation of self-
reported snoring is challenging. Although, there is night to night variability in measured AHI it 
is possible that one night assessment of patients diagnosed with simple snoring may miss 
the diagnosis of OSA. One possible mechanism for snoring related sleepiness is mechanical 
trauma to the pharynx, leading to an inflammation cascade and release of cytokines such as 
tumour necrosis factor α  and interleukin-6. These are elevated in patients with OSA and 
associated with sleepiness, independently of obesity (Vgontzas et al. 2000). In a placebo 
controlled, double blind study treatment with tumour necrosis factor α antibody significantly 
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reduced day time sleepiness and AHI (Vgontzas et al. 2004). These data have to be 
interpreted with caution, but if this hypothesis of snoring related hyper somnolence is correct 
the burden of snoring related sleepiness on public health may well exceed that of OSA.  
Diagnosis of OSA  
When considering a diagnosis of OSA or OSAS it is important to establish a detailed 
clinical history and obtain objective evidence of respiratory disturbances during the night. 
The majority of the clinical evidence to date has focus  on middle-aged, overweight men with 
the female phenotype of OSAS less clearly defined. Female OSAS patients may present 
differently with headache, insomnia and mood disturbances (Ye et al. 2009). Age at 
presentation may also determine clinical symptoms where for example in the elderly, co-
morbidities and lifestyle adjustments such as diurnal napping could cloud symptomatology 
(McMillan et al. 2014). 
Polysomnography 
Clinical history is extremely important in raising the possibility of the diagnosis but 
confirming OSA requires objective clarification through overnight studies. The method 
considered by some as the gold standard, despite limited evidence, is overnight PSG which 
simultaneously monitors sleep architecture, nocturnal oxygen saturations, air flow, cardiac 
rhythm and thoraco-abdominal movements. The routine components of polysomnography 
include: EEG which differentiates sleep from wakefulness and sleep stages as well as 
establishes arousals from sleep, electro-oculography (EOG) which is necessary for scoring 
REM sleep and electromyography, another component of sleep staging, in particular for 
REM sleep.   
Assessment of respiratory function is via the respiratory channels which include 
assessment of airflow, thoracic and abdominal effort and oxygenation with pulse oximetry. 
These measures are used to quantify apnoeas and hypopnoeas. An obstructive apnoea is 
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defined as a cessation or reduction by >90% of airflow with continued effort for at least 10 
seconds. The hyponoea definition has changed over the years. It was defined previously as 
reduction in flow of 50% to 90% lasting ≥10 seconds accompanied by ≥3% decrease in 
oxyhaemoglobin saturation (SpO2) or terminated by arousal from sleep [American Academy 
of Sleep Medicine Task Force (1999)]. The 2012 AASM guidelines defined hypopnoeas as a 
⩾30% decrease in nasal flow with ⩾3% desaturation of arterial oxygen measured by pulse 
oximetry or EEG arousal. (Berry et al. 2012). OSA is defined as the presence of ≥5 episodes 
of apnoea and hypopnea per hour of sleep. An AHI cut off has been used to define the 
severity of OSA, defined as mild (AHI 5-15 events /hour), moderate (AHI 15-29 events/hour) 
and severe (AHI ≥ 30 events /hour). OSAS comprises of AHI≥5 episodes/hour and 
excessive daytime somnolence or at least two of the following: choking or gasping during 
sleep, recurrent awaking, unrefreshing sleep, daytime fatigue or impaired concentration or 
memory (1999). This constitutes a definition of the disorder with reasonable utility. It is 
important to note, that there are very few normative data for the general population, let alone 
more specific populations such as, the elderly or people with intellectual disability (Eckert et 
al. 2008). 
Portable monitoring devices 
As overnight in-laboratory PSG is labour and resource intensive other diagnostic 
tools have been developed and validated for  home screening and diagnosis of OSA. These 
include home unattended PSG with portable devices which according to the Standards of 
Practice Committee of the American Sleep Disorders Association, are classified into several 
types (Collop et al. 2007). 
 “Comprehensive portable PSG: minimum of seven channels monitored, including EEG, 
EOG, chin EMG, ECG or heart rate, airflow, respiratory effort and oxygen saturation” 
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 “Modified portable sleep apnoea testing: minimum of four channels, including ventilation or 
airflow with at least two channels of respiratory movement, or respiratory movement and 
airflow; heart rate or ECG; and oxygen saturation” 
 “Continuous single or dual bioparameters: one or two channels, typically including oxygen 
saturation or airflow” 
As a minimum requirement it is recommended that portable home monitoring should 
comprise airflow, respiratory effort and blood oxygenation. Respiratory polygraphy (rPG) has 
become a useful and reliable method for the diagnosis of OSAS. PSG is frequently replaced 
by portable monitors a move driven by costs which was quantified in an economic analysis 
by Kim et al (Kim et al. 2015). Three hundred and seventy three patients with a high pre-test 
probability of OSA were randomly allocated to an in-laboratory PSG followed by CPAP 
titration or a portable assessment at home, followed by auto-titrating CPAP. From a payer 
perspective, the in-laboratory pathway was about 17% more expensive, compared to the 
home-based pathway. For providers, the costs of both pathways were comparable. A 
concern was raised that patient care may suffer if economics become the primary driver of 
OSA diagnostic pathways.  
In terms of the diagnostic comparability, data are becoming more widely available. A 
multi-centre European cohort included over 11,000 subjects, of whom, approximately half 
underwent PSG and o half rPG (⩾4 channels of data, no electroencephalography). The AHI 
was lower by 30% in those who underwent rPG which may be explained, at least in part, by 
an overestimate of sleep time if  EEG data are not available and inability of scoring 
respiratory events associated with arousals. The report of the Swiss respiratory polygraphy 
registry was based on 11, 485 rPG’s. In patients with clinical symptoms of OSAS (snoring, 
witnessed apnoea and hypersomnia, 4180 patients), 80% of rPG’s confirmed OSAS, and 
only 3.5% were inconclusive and required PSG. According to the practice in Switzerland, 
PSG is  rarely required in the diagnosis of OSA (Thurnheer et al. 2007).
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Nocturnal oximetry 
Ambulatory oximetry has been developed as a simple and inexpensive tool to screen 
for OSA. It works on the basis of diodes producing light in red and infrared regions and a 
photodetector which measures the amount of transmitted light through a body part, usually  
the fingertip. Pulse oximetry estimates the blood oxygen haemoglobin saturation on the 
principal that oxygenated and deoxygenated haemoglobin absorb different amounts of the 
red light. The accuracy of ambulatory oximetry depends on many factors such as body 
habitus, underlying pulmonary disease affecting baseline saturation, proportion of 
sleep/wake during the night, and technical qualities such as sampling rate and oximetry 
recording rate. The measurements are taken by performing a “running average” with a 
moving window that varies from 1 to 15 s in length and the speed of response to onset of 
oxygen breathing is on average 9 to 10 s with finger and ear probes.  
The interpretation skill of overnight pulse oximetry begins with knowledge of normal 
oxygen saturation values during sleep. In a key validation study published in 1996, the 
authors noted normal overnight mean saturations of 96.5% in 350 healthy subjects (Gries et 
al. 1996). Nocturnal oxygen saturation decreased slightly with increasing age. The values 
ranging from 96.8% in the age group of 1- to 10-year-old patients to 95.1% in the age group 
>60 years (Gries et al. 1996).  No uniform definition of an oxygen desaturation exists for a 
normal or abnormal oxygen desaturation index (ODI, oxygen desaturations per hour of 
sleep). There are generally three cut-off points for an abnormal ODI that mirror the severity 
definition of abnormal AHI.  
Over the last decade, a debate in the literature has questioned whether or not pulse 
oximetry could effectively screen patients for SDB. Quoted values for sensitivity range from 
31 to 98% and for specificity from 41 to 100% and several studies reported that sensitivity 
increases with severity of OSA (Netzer et al. 2001). In one study in patients with an AHI >25 
events per hour, the sensitivity was 100% and the specificity 95%, in patients with AHI > 15 
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events per hour, these values decreased to 75% and 86% and in patients with AHI > 5 
events per hour, to 60% and 80%, respectively. The authors concluded that pulse oximetry 
is an effective screening tool for patients with moderate to severe OSA (Cooper et al. 1991). 
A problem with interpreting these results reflecting sensitivity and specificity of oximetry 
which vary significantly between the individual studies is that authors looked only at a limited 
patient group in the spectrum of severity of OSA and findings from these studies may not be 
applicable to OSA patients with different levels of severity from those studied. It was 
suggested that the combination of a questionnaire and pulse oximetry doubles the specificity 
of oximetry as a screening tool for sleep apnea (Nuber et al. 2000) but this approach 
requires further validation.  
Chiner et al. analysed how many PSG studies could be saved by overnight pulse 
oximetry in the initial diagnosis for patients with various severities of OSA. They found that in 
275 suspected cases, 216 patients were confirmed to have OSA and  pulse oximetry could 
have saved 140 PSG studies in the group with a respiratory disturbance index (RDI) >5, 119 
in the group with an RDI >10, and 10 in the group with an RDI > 15 (Chiner et al. 1999). In 
addition, there is evidence that PSG is not superior to oximetry when identifying patients with 
OSA whose quality of life will improve with treatment with CPAP. This is an important 
consideration as the main purpose of screening and offering diagnostic tests to patients is to 
identify patients with OSA who will benefit from treatment rather than measure accurate AHI 
(Whitelaw et al. 2005).  
Overnight pulse oximetry is a very useful tool for the diagnosis of SDB and 
establishing a final diagnosis is very difficult without oximetry data. As a screening tool for 
the diagnosis of OSA, pulse oximetry is cost-effective and shows substantial accuracy as 
described above. Sensitivity and specificity remain controversial and deserve further 
clarification through controlled studies. Technical limitations, limited user knowledge, and the 
lack of consensus on interpretation of data all play a role in diminishing the value of pulse 
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oximetry as a diagnostic tool.  It has been proposed that patients with suspicion of OSA are 
screened with nocturnal oximetry and those with symptoms and ODI>15 are offered 
treatment and patients with an ODI<15 are assessed further by PSG (Netzer et al. 2001) .  
Although pulse oximetry represents a useful tool for screening and diagnosis of OSA 
at the present time there is no internationally standardised technical specification or 
standardisation of signal processing of oximeters but the minimum standard criteria set by 
the AASM includes a sample rate of 25 Hz with an average of three values (Berry et al. 
2012)  and a resolution of 0.1% (Bohning et al. 2010). The current desaturation definitions 
usually revolve around a decrease of ≥4% from baseline saturations but, there is no 
unanimity in terms of what constitutes a normal or abnormal desaturation index (Netzer et al. 
2001). Additional limitations of pulse oximetry include potential problems with blood flow and 
haemoglobinopathies, tissue optics in the very obese and an inability to detect other forms of 
sleep disordered breathing. Movement artefact needs to be taken into account as there can 
be significant measurement inaccuracies of ±2% in saturations (Bohning et al. 2010). 
Assessment of sleepiness 
Sleepiness has been very difficult to define and can range from normal sleepiness 
related to circadian rhythm to pathological sleepiness related to sleep scheduling or primary 
sleep disorders such as sleep disordered breathing. Cluydts et al. identified  that sleepiness 
can be investigated  using different tools including “i) assessment of behaviours such as 
yawning frequency, actigraphy, facial expression or assessment using performance tests 
such as driving simulators, psychomotor vigilance tests, or reaction time test;  ii) self-
evaluation using rating scales such as ESS, or Stanford Sleepiness scale and iii) direct 
electrophysiological measurements such as in multiple sleep latency test (MSLT) (Cluydts et 
al. 2002).  
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With respect to assessing sleepiness in patients with OSAS, the most widely used 
assessment tool is the ESS score developed in 1991. It is administered as a questionnaire 
and measures the tendency to fall asleep in 8 specific situations where the patient estimates 
the likelihood of falling asleep on a 3 point scale (0- never fall asleep to 3-high possibility of 
falling asleep) for each of 8 questions. The total score ranges between 0-24, with normal 
being ≤11(Johns 1991). The ESS aims to measure general level of sleepiness and has 
satisfactory test to retest reliability and helps to distinguish between normal and pathological 
sleepiness (Johns 1992). One  limitation of the ESS is that it is subjective and some patients 
may not score high on the ESS scale despite feeling sleepy. The accuracy also depends on 
the awareness of falling asleep which may not always be present (Reyner et al. 1998). It has 
been shown that grading of one’s sleepiness may be more precise by another person 
(Kingshott et al. 1995).  
The Epwoth Sleepiness Scale score  does not correlate strongly with more objective 
assessment of sleepiness such as MSLT’s (Benbadis et al. 1999) but this is in keeping with 
the fact that these tests assess different aspects of sleepiness and supports the difficulty of a 
definition of sleepiness.  The MSLT was developed in 1970 as an objective laboratory test to 
assess  sleepiness. It is performed during the day following an in laboratory PSG to 
evidence a good quality and quantity of sleep during the preceding night. It consists of 4 nap 
opportunities separated by 2 hours, lasting for up to 20 minutes and assesses the mean 
sleep time latency and presence of REM sleep during these naps (Carskadon et al. 1986). 
The MSLT is not routinely indicated for diagnosis of OSAS but can be useful in cases of 
persistent EDS despite adequate treatment of OSA.  
 Treatment of OSA 
General therapeutic options including life style adjustments such as reduction in body 
weight, abstinence from both alcohol and sedatives and positional therapy should always be 
considered in all OSA patients (Shneerson et al. 2001). In addition, upper airway surgery in 
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patients with obvious anatomical abnormalities or bariatric surgery for patients with morbid 
obesity could be considered (Spicuzza et al. 2015). Oral appliances  can be effective for 
patients with mild to moderate OSA and some patients prefer such treatment to CPAP 
(Ngiam et al. 2013). Oral appliances  promote UA patency by holding the tongue forward 
and repositioning the mandible forward with the attached tongue.  
The most effective treatment of OSA is CPAP. The CPAP acts as a pneumatic splint 
to prevent upper airway collapse. It has been shown to reduce nocturnal oxygen 
desaturations, excessive daytime sleepiness and improve cognitive function (Engleman et 
al. 1994; Giles et al. 2006). From the available evidence, CPAP therapy is indicated in 
patients with moderate/severe OSA (AHI≥15) associated with symptoms, including 
excessive daytime sleepiness with its established clinical and cost effectiveness (Giles et al. 
2006). Although, various cardiovascular benefits of CPAP have been noted (Marin et al. 
2005; Buchner et al. 2007; Duran-Cantolla et al. 2009) indication for treatment of 
asymptomatic, moderate/severe OSA patients with cardiovascular disease is not clear due 
to the lack of long term outcome studies and randomised controlled trials(McEvoy et al. 
2016). 
Treatment with CPAP may have less desirable metabolic effects. Quan et al. recently 
examined the effect of 6 months of therapeutic versus sham CPAP on weight, in 812 
patients from the Apnoea Positive Pressure Long-term Efficacy Study (APPLES) (Quan et al. 
2013). They found that subjects treated with therapeutic CPAP gained 0.35 kg while those 
treated with sham lost 0.70 kg, and greater adherence to therapy correlated with more 
weight gain. Consistent with this evidence, Drager et al. (Drager et al. 2015) published a 
meta-analysis of 25 CPAP studies confirming modest weight gain with CPAP treatment with 
proposed explanations including reductions in energy spent during sleep, elimination of 
hypoxia-induced anorexia, and decrease of lipolysis (Patel 2015). 
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OSA and cardiovascular disease 
Mechanical effect 
OSA causes increased ventricular preload and afterload and reduces cardiac output 
(Stoohs et al. 1992). This may contribute to cardiac remodelling, hypertrophy and 
development of cardiac failure over time by the proposed following mechanism. The 
increase in the negative inspiratory inthrathoracic pressure during an airway obstruction 
leads to increase in left ventricular (LV) transmural pressure, LV afterload (Bradley et al. 
2001) and myocardial oxygen demand which is further impaired by apnoea/hypopnea 
related hypoxia which can precipitate myocardial ischemia (Bradley et al. 2001; Bradley et 
al. 2003; Bradley et al. 2003). There is an increase in venous return to the right heart 
(increased right ventricular (RV) preload) causing enlargement of the right heart and left 
septal displacement during diastole which can further diminish left ventricular filling and 
output (Brinker et al. 1980; Bradley et al. 2003). OSA related hypoxia leads to pulmonary 
vasoconstriction and thus increases RV afterload.  
Autonomic effect 
Patients with OSA have increased sympathetic neural activity during the night 
associated with apnoeas (Hedner et al. 1988). This sympathetic nerve activity is not limited 
to the night but persists during the daytime as evidenced by norepinephrine concentration in 
the blood and the urine and muscle sympathetic nerve activity (Somers et al. 1989; 
Narkiewicz et al. 2003). Compared to healthy controls, OSA patients have higher heart rates, 
blunted heart rate variability and higher blood pressure during the day (Fletcher 2003; 
Narkiewicz et al. 2003). 
Oxidative, inflammatory and vascular endothelial effects 
Intermittent hypoxia and reoxygenation leads to oxidative stress, development of 
reactive oxygen species and inflammation diminishing nitric oxide levels and endothelially 
mediated vasodilation contributing to hypertension and increased risk of cardiovascular 
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events (Carlson et al. 1996; Bonetti et al. 2003). Reactive oxygen species have been shown 
to activate nuclear transcriptional factors stimulating production of inflammatory mediators 
and adhesion molecules leading to endothelial damage and atherosclerosis (Garvey et al. 
2009). Another proposed contributor to the development of atherosclerosis in OSA subjects 
is increased level of haematocrit, plasma fibrinogen and blood viscosity leading to increasing 
susceptibility to clot formation. Studies examining carotid artery intima-media thickness 
report an association of intima-media thickness with nocturnal desaturations and positive 
correlation with serum concentrations of inflammatory mediators (Minoguchi et al. 2005; 
Schulz et al. 2005). 
Cardiovascular consequences of OSA 
Cardiovascular and cerebrovascular disease 
OSA and coronary artery disease share common risk factors including obesity, male 
sex and advanced age (Young et al. 1993; Young et al. 2002) and therefore a higher 
prevalence of OSA could be expected in patients with cardiovascular disease. How much 
OSA influences cardiovascular outcomes remains unknown. Moreover,  it is unclear whether 
it is due to mechanisms other than hypertension which has been shown to be associated 
with OSA even after adjusting for excess weight and other potential confounding factors 
(Young et al. 2002). Proposed physiological mechanisms for the effect of OSA on 
cardiovascular health are described above in the paragraph “Cardiovascular effects of OSA”.  
There is evidence that nocturnal myocardial ischemia can be triggered by OSA, in 
patients with coronary artery disease (CAD) but there is no evidence for this in patients 
without CAD (Andreas et al. 1991; Hanly et al. 1993; Franklin et al. 1995). Several case 
control studies reported a high prevalence of OSA in patients with cardiovascular disease. 
OSA defined as AHI >10/h has been found in 37% of men with CAD diagnosed by 
angiography (Mooe et al. 1996). Other studies in patients with CAD reported prevalences 
between 31-50% (Mooe et al. 1996; Peker et al. 1999; Sanner et al. 2001).  In addition, 
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about a quarter of patients with systemic hypertension (Schulz et al. 2006) and 83% of 
patients with drug resistant hypertension (Logan et al. 2001) have been found to have OSA.  
The prevalence of OSA in patients with heart failure has been reported between 12% 
and 53% (Ferrier et al. 2005; Javaheri 2006; Vazir et al. 2007). OSA in patients with heart 
failure is more common in men (Yumino et al. 2009) and more are habitual snorers, 
compared to the general population. (Javaheri et al. 1998). However, the prevalence of OSA 
is likely to be higher than in the general population due to common risk factors, which may 
not have been adjusted for. The effect of heart function on sleep apnoea, in particular central 
sleep apnoea, as well as the effect of medications and myocardial infarction on OSA severity 
also need to be considered.  
Cross-sectional studies have objectively measured OSA and its association with 
cardiovascular disease and report an association but of a lesser magnitude that case control 
studies. One  study examining for an association of OSA with cardiovascular disease in 
1,222 Hispanic Americans (Schmidt-Nowara et al. 1990) found a non-significant increase in 
the odds ratio of 1.8 (95% CI 0.9-3.6).  
In the Sleep Heart Health study, with over 6000 participants, Shahar et al. reported 
that those with an AHI>11/hr had a 42% (95% CI 13-78%) greater risk of cardiovascular 
disease (coronary artery disease, stroke, congestive heart failure) than participants with 
AHI<1.3/hr after adjusting for multiple potential confounders (Shahar et al. 2001). This 
analysis was adjusted for hypertension, suggesting that hypertension is not the only 
mechanism by which OSA can influence cardiovascular outcomes and that treatment of 
hypertension does not fully protect patients against increased cardiovascular risk.  More 
recently an odds ratio  of 2.87 for fatal and 3.17 for non-fatal cardiovascular events was 
found  in a severe, untreated OSA cohort, compared to healthy controls (Marin et al. 2005).   
Similar findings came from large population based studies where Hu et al reported 
significant association between self-reported snoring and cardiovascular disease in nearly 
72,000 women monitored for up to 8 years in Nurse’s Health study (Hu et al. 2000) and 
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Koskenvuo surveyed 3,847 male participants on snoring status and found an odds ratio for 
ischaemic heart disease of 1.4 (95% CI 1.2-1.7) for regular vs infrequent snores adjusted for 
BMI, age, smoking, alcohol and hypertension 3 years later (Koskenvuo et al. 1987). A similar 
study, on 2,937 patients did not find significant association between snoring and 
cardiovascular disease assessed up to 6  years later (Jennum et al. 1995). It is interesting  
that the study by Jenum et al, although using  similar methodsdiffers from the 
aforementioned Scandinavian studies. Jenum et al. sampled an older population of 54-74 
years old compared to a population of 40-69 years in the study by Keskenvuo. This raises 
the hypothesis that the association of OSA and cardiovascular disease only exists in 
younger patients, less than 54 years old.  
Stroke has been linked to OSA in case-control and cross-sectional studies. In the 
Sleep Heart Health study the odds ratio for stroke adjusted for multiple confounding factors 
was 1.6 (95% CI 1.02-2.46) for AHI >11/hr compared to AHI<1.3/hr (Shahar et al. 2001). In 
case control studies snorers have been found to have an odds ratio of 2 to 10 for developing 
a  stroke compared to controls (Young et al. 2002). To clearly confirm the link, more 
prospective studies are necessary to confirm that the OSA precedes the stroke rather than 
being a consequence of acute stroke. 
Cardiac arrhythmia and sudden cardiac death 
There is some evidence for an association between OSA and ventricular arrhythmia 
and sudden cardiac death, especially in patients with concomitant structural heart disease. 
The Sleep Heart Health study showed that after adjusting for confounding factors, including 
coronary artery disease, patients with severe OSA were three times as likely to develop non 
sustained ventricular tachycardia and twice as likely to develop complex ventricular ectopy. 
In the same study, the odds ratio for developing atrial fibrillation compared to matched 
controlled subjects was 4.5 (Mehra et al. 2006). In one study, patients with OSA had a 
significant peak in sudden death during sleep, compared to patients without OSA (Gami et 
al. 2005). Studies on patients in sleep clinics have reported that patients with OSA treated 
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conservatively (advised weight loss) compared to patients treated with tracheostomy had 
significantly higher mortality (Partinen et al. 1988; Partinen et al. 1990).  
An association between AHI and all-cause mortality has also been examined in 
several population based studies. In the earlier studies, Lindberg et al. looked at mortality of 
3,100 men, 30-60 years old over a 10 year period and did not report an association between 
snoring and mortality but those less than 60 years of age with snoring and excessive 
sleepiness were twice as likely to die as those without these symptoms with relative risk 2.2, 
95% CI 1.3-3.8 after adjusting for several confounding factors (Lindberg et al. 1998). 
Evidence supporting an association of OSA and increased risk of mortality comes from more 
recent population based studies (Marshall et al. 2008; Young et al. 2008).  
The Wisconsin Sleep Cohort and the Busselton Sleep Cohort studies show an 
independent association between sleep disordered breathing and all-cause mortality. In the 
Wisconsin study, the fully adjusted hazard ratio for all-cause mortality comparing people with 
severe disease (AHI≥30 events/h) to those without disease (AHI<5 events/h) was 2.7 (95% 
CI: 1.3–5.7). Cardiovascular disease-related mortality in the Wisconsin study was also 
higher in people with severe disease than those without disease (hazard ratio: 5.2; 95% CI: 
1.4–19.2) (Young et al. 2008), whilst the Busselton study found that moderate-to-severe 
sleep-disordered breathing was associated with all-cause mortality with an adjusted hazard 
ratio of 6.2 (95% CI: 2.0–19.4) (Marshall et al. 2008). The result from the Sleep Heart Health 
study complimented this finding and demonstrate that, independent of several confounding 
variables, sleep-disordered breathing was associated with all-cause and cardiovascular 
disease–related mortality (Punjabi et al. 2009). The association was most apparent in men 
aged 40–70 y with severe disease (AHI≥30 events/h). This study also reported that excess 
mortality was most apparent in men aged ≤70 years.  
More persuasive evidence of causation might come from randomized controlled trials 
of treatment effect of CPAP. However, a recent, large randomised controlled trial looking at  
death from cardiovascular causes,  myocardial infarction, stroke, hospitalisation for unstable 
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angiana, transient ischaemic attack or heart failure, as the primary end point, in patients with 
moderate to severe OSA, unexpectadly showed that treatment with CPAP and usual care 
versus usual care alone did not prevent cardiovascular events in patients with established 
cardiovascular disease (McEvoy et al. 2016). A potential limitation of the study was poor 
compliance in the treatment group with average compliance of 3.3 hours. Subgroup analysis 
of patients who used the CPAP for >4 hours (42%) showed trend towards slight reduction in 
primary endpoint but the samle size was too low to have sufficient statistical power to show 
the difference. In addition, factors like variable access to resources in some geographical 
areas, and power recalculation due to difficulty in recruiting may have led to type 2 error in 
this study. More importantly, the inclusion criteria for participation in this study was presence 
of coronary artery disease or cerebrovascular disease. Therefore this study did not assess 
the effect of CPAP on primary but secondary prevention of cardiovascular disease. In 
addition, the mean age of patients in this study was 61 years which is not representative of 
typical OSA population. Taken together, this largest RCT to date has multiple 
methodological flaws and the results remain inconclusive. Furher research is needed to 
answer the question regarding the true effect of CPAP on cardiovascular disease, both, in 
terms of primary and secondary prevention. Similarly, the Multicentre Obstructive Sleep 
Apnoea Interventional Cardiovascular trial (MOSAIC), a randomised, 6-month controlled trial 
in minimally symptomatic patients with OSA reported that 6 months of CPAP therapy 
improved daytime sleepiness and self-assessed health status, but did not improve the 
calculated 5-year risk of a fatal cardiovascular event, or any of its component parts (Craig et 
al. 2012). The compliance in this trial was low (median compliance 2.8 hrs/night) but on 
subsequent analysis, there was no difference in primary outcomes in patients who complied 
with CPAP for >4 hours. It is also possible that the cardiovascular score used in this trial was 
not sensitive enough to pick up the improvement or 6 moths treatment was not long enough 
to effect cardiovascular score. Subsequent analysis on MOSAIC cohort, however, showed 
improvement in endothelial function but no arterial stiffness or inflammatory markers. It is 
possible that the negative outcomes in terms of reduction in cardiovascular risk and arterial 
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stiffness is due to selected population of more elderly patients with previous cardiovascular 
morbidity which could have dampened the effect of CPAP in this group. Similarly to above 
mentioned study by MacEvoy, this study recruited patients with established cardiovascular 
disease which could have reduced the effect of CPAP on cardiovascular disease and larger 
and longer trials are needed to show the effect. In addition, future trials should also 
concentrate on patients without pre-existing cardiovascular disease as it is possible that the 
effct of CPAP on cardiovascular risk in these patients may be greater. In a study by Ancoli-
Israel conducted in 426 older people over 8 to 10 years no significant association between 
OSA and mortality was found in multiple regression models. However, the true association 
could have been underestimated as adjustment was made for cardiovascular disease, one 
of the most important mechanism by which OSA contributes to death (Ancoli-Israel et al. 
1996). Negative findings for any association between AHI and mortality in elderly people was 
also reported by Mant et al. at the 4 year follow up (Mant et al. 1995).  
Although clinic based studies report higher mortality in patients with untreated OSA 
without randomisation to treatment groups it is not possible to draw any definite conclusion 
(Young et al. 2002). In addition, it is possible that the patients with most severe OSA were 
treated, which could have confounded the presented results. The most convincing evidence 
comes from the aforementioned large population based studies. Studies by Lindberg and 
Punjabi showing an association in middle aged men only and in under 70 years old 
respectively suggest that elderly patients may be more resistant to the consequences of 
OSA represents a different disease in the older population. However, with increasing age the 
likelihood of death from other causes rises and therefore quantifying the potential 
association between sleep disordered breathing and mortality becomes more difficult. In 
conclusion, it is possible that OSA  increases the risk of mortality but large population based 
studies where OSA is objectively assessed are needed to confirm this hypothesis and 
similarly, the evidence regarding the effect of OSA on cardiovascular outcomes, independent 
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of hypertension, as well as the evidence of treatment with CPAP on cardiovascular 
outcomes in patients with OSA is still awaited.  
Arterial hypertension 
OSA has been a recognised cause of hypertension in two large studies. The Sleep 
Heart Health Study analysed data on >6000 participants and reported an independent 
association between severity of OSA and hypertension (Nieto et al. 2000) and the Wisconsin 
Sleep Cohort Study showed an association between severity of OSA and hypertension 
(Peppard et al. 2000) with stronger association found in the younger subjects. Due to cross-
sectional design, these studies were not able to establish causation or  that OSA predated 
hypertension. In the Wisconsin sleep cohort even minimally elevated AHI of >0 and <5 was 
associated with 42% (95% CI 13-78%) increased odds of developing hypertension over 4 
years follow up (Peppard et al. 2000). Stradling et al. reported attenuated night time blood 
pressure dipping in patients with OSA proportional to oxygen desaturation index (Stradling et 
al. 2000).  
Stronger evidence for causation comes from randomised controlled trials. Meta-
analysis of seven randomized controlled trials reporting 24-hour ambulatory blood pressure 
showed that CPAP was associated with significant reductions in 24-hour ambulatory systolic 
blood pressure (SBP) of -2.32 mmHg (95% CI -3.65 to -1.00) and diastolic blood pressure 
(DBP) of -1.98 mmHg (95%CI -2.82 to -1.14). CPAP led to a more significant improvement in 
nocturnal SBP than that in diurnal SBP (Hu et al. 2015). The clinical significance of these 
blood pressure changes is likely modest and whether the long term effect of CPAP on blood 
pressure in patients with OSA is greater remains unanswered.   
Effect of CPAP on cardiovascular disease and mortality 
CPAP has been reported to reduce nocturnal sympathetic activation, heart rate, 
variability in blood pressure (Sforza et al. 1992; Somers et al. 1995; Bonsignore et al. 2006) 
as well as pre-load and after-load in patients with chronic heart failure (Naughton et al. 1995; 
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Narkiewicz et al. 1999). In addition it has been found to reduce 24-h mean blood pressure by 
around 2mmHg, particularly at night, with the largest effect observed in patients with 
symptomatic and severe OSA (Duran-Cantolla et al. 2009). CPAP has been found to affect 
cardiovascular outcomes in patients with increased cardiovascular risk or presence of 
coronary artery disease with reduction in new cardiovascular events (Milleron et al. 2004) 
and death from cardiovascular disease (Doherty et al. 2005). The strongest evidence for an 
effect of CPAP on cardiovascular outcomes comes from (Marin et al. 2005). This 
observational study in 1651 participants over a 10 years period showed that the risk for fatal 
and non-fatal cardiovascular events was significantly increased in severe untreated or non-
compliant OSA patients (OR 2.9 and 3.2 respectively), compared to healthy participants. In 
patients with mild to moderate OSA, CPAP has been  associated with a 64% cardiovascular 
risk reduction, independent of age and pre-existing cardiovascular comorbidities (Buchner et 
al. 2007). However, there are no randomised controlled trials confirming this benefit and a 
recent, large, randomized controlled trial of adults with moderate to severe OSA and pre-
existing cardiovascular disease showed that the use of CPAP had no significant effect on the 
prevention of recurrent serious cardiovascular events (McEvoy et al. 2016). It is possible that 
patients with compliance exceeding 4h/night may benefit in terms of cardiac outcomes but 
further research is needed to clarify this benefit (Abuzaid et al. 2017; Khan et al. 2017). 
Obstructive sleep apnoea in surgical populations 
Prevalence of OSA in surgical population 
No epidemiological studies have been conducted to assess true prevalence of OSA 
in patients undergoing surgical procedures. Estimated prevalence varies and depends on 
surgical population, diagnostic criteria of OSA and the sleep diagnostic used. A large 
retrospective study examining 43,576 adult cases undergoing anesthesia and general 
surgery found a prevalence rate for OSA of 7-10% (Ramachandran et al. 2010). Higher 
prevalence, was reported in certain surgical populations (Auckley 2003). Using PSG as a 
screening method for OSA (defined as AHI>5/hour), it was found in 71% of patients 
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undergoing bariatric surgery, compared to 9.5% of patients undergoing general surgery, 
excluding cardiac surgery.  High prevalence (85%) was recently reported in patients 
undergoing surgery for severe peripheral vascular disease, using an overnight 
polysomnography (Utriainen et al. 2013). As OSA and cardiovascular disease share 
common risk factors it is likely that higher prevalence is found in highly selected 
cardiovascular cohorts. In addition, not surprisingly, higher prevalence may be reported 
using tools with high sensitivity and low specificity. For example, Hwang et al. screened 
patients undergoing general surgery with nocturnal oximetry and found that 57% of patients 
had sleep apnoea defined as 4% ODI>5/hour (Hwang et al. 2008).  
Assessing prevalence using tools such as questionnaires without objective 
assessment of respiratory disturbance may be misleading and  high prevalence has been 
reported in such studies. Prevalence of sleep apnoea in patients undergoing CABG, 
screened using the Berlin Questionnaire estimated that 67% of patients were at high risk of 
OSA compared to 24% of patients undergoing general surgery (Chung et al. 2007). In 
another study of elective surgical patients, using STOP-BANG questionnaire, 41% were said 
to be at high risk of OSA (Vasu et al. 2010).  
A major difficulty in assessing prevalence of OSA in surgical population is that PSG 
is labour and resource intensive and may cause delay to surgery and it is therefore difficult 
to recruit patients to such studies. One study reported that only 44% of patients identified as 
high risk for OSA prior surgery agreed to undergo  PSG to confirm the diagnosis (Fidan et al. 
2006). A high proportion, 78% of patients, who agreed to undergo PSG in this study, had a 
diagnosis of OSA, evidenced by AHI > 5/hour (Vasu et al. 2010). Currently, estimated 
prevalence may represent a conservative estimate as it has been shown that 60% of OSA 
patients assessed for OSA in preadmission clinics are not suspected to suffer with OSA 
based on simple clinical assessment (Finkel et al. 2009; Singh et al. 2013). Moreover, it has 
been estimated that 82% of men and 92% of females with moderate to severe OSA remain 
undiagnosed (Ancoli-Israel et al. 1991) and may be presenting for the surgery without 
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previous diagnosis or treatment posing a potential challenge to the anaesthetist in the 
perioperative period. 
Screening tools for OSA prior to surgery 
In view of the increasing prevalence of OSA in the last two decades and due to 
emerging evidence of its association with worse postoperative outcomes clinicians have 
sought to enable screening for sleep disordered breathing in various surgical populations. 
Methods include using a combination of clinical variables such as BMI, neck circumference, 
jaw structure, snoring, reports of nocturnal breathing disturbances and the presence of 
hypertension. The sensitivity of these methods is high (78-95%) but the specificity tends to 
be low (41-63%) (Rowley et al. 2000). 
In terms of objective assessment, the use of PSG, due to its technical complexity, 
time requirement, cost and availability, is limited. Other multichannel portable sleep devices, 
although more accessible, also require a trained and experienced sleep physician or sleep 
technician to analyse the study. In UK clinical practice access to sleep diagnostics and 
assessment by sleep physicians are limited. Around two thirds of sleep studies in UK are 
oximetry alone and 20 % are limited multi-channel sleep studies with only 10% being PSG’s 
(Flemons et al. 2004). A high resolution oximeter represents an economic and practical 
screening tool requiring little training for both patient and sleep clinician. The devices are 
available as a watch oximeter with a high sampling frequency detecting intermittent drops in 
oxygen saturations usually reported as 4% oxygen desaturation index. The data are 
analysed automatically by computer programs with an acceptable accuracy.  
This method of screening has been validated in sleep centres and in a general 
surgical population, where the ODI >10 was found to have a sensitivity of 93% and 
specificity of 75% to detect moderate and severe sleep disordered breathing (Chung et al. 
2012). When compared to PSG, oximetry has an accuracy of 86–94 % for detecting 
moderate to severe OSA in patients undergoing general surgery (Chung et al. 2012; Hang 
et al. 2015). Although OSA can be missed on nocturnal oximetry, there is emerging 
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evidence that ODI from high resolution nocturnal oximetry can be a useful tool for risk 
stratifying patients prior to surgery and identifying patients who are at risk of postoperative 
complications (Hwang et al. 2008; Chung et al. 2014). Nocturnal oximetry has been 
validated against portable monitoring in patients undergoing bariatric surgery where the 3% 
ODI measured by nocturnal oximetry could rule out or detect moderate to severe OSA with 
reasonable accuracy (Malbois et al. 2010). 
A number of screening questionnaires, to identify patients who are at high risk of 
sleep apnoea, have been developed. These tools have been validated against full sleep 
diagnostics in preselected surgical populations. They should not be applied without 
validation in other  cohorts. The accuracy of screening questionnaires has been examined in 
recent reviews. Most of the screening tools including: STOP questionnaire, STOP-Bang 
questionnaire, Berlin questionnaire, Sleep Apnea Clinical Screen (SACS) questionnaire, 
American Society of Anesthesiology (ASA) checklist have been found to have reasonable 
sensitivities (70–85 %) and positive predictive values (72–90 %) but poor specificities (40–
55 %) and negative predictive values (40–60 %) (Ramachandran et al. 2009; Abrishami et 
al. 2010).   
The review by Ramachandran found no clinical tool as an ideal pre-operative 
screening test (Ramachandran et al. 2009). Diagnostic odds ratio (DOR) which combines 
data on sensitivity and specificity and represents the ability of test to rule out or rule in the 
condition was used to interpret the data in this review. A DOR of >81 represents an excellent 
test because it indicates that both sensitivity and specificity are >0.9 (Deeks 2001). The 
STOP-Bang questionnaire with DOR of 142 was found an excellent questionnaire for 
predicting the presence of severe OSA (AHI>30). However the test accuracy for individual 
screening tools defined by DOR was poorly reproducible in multiple validation studies. 
Based on false negative rates and heterogeneity none of the questionnaires or clinical 
models were found to be satisfactory. A more recent review suggested that STOP and 
STOP-Bang questionnaires for screening of OSA in a general surgical population are 
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superior due to their higher methodological quality and easy-to-use features (Abrishami et al. 
2010) and recent meta-analysis of the STOP-Bang questionnaire has confirmed its high 
performance in sleep clinics and surgical patients (Nagappa et al. 2015). 
STOP-BANG questionnaire 
The STOP-Bang questionnaire (Snoring, Tiredness, Observed apnoeas, high blood 
Pressure, BMI >35 kg/m2, Age >50 years, Neck circumference >40cm, male Gender) is a 
scoring model consisting of 8 questions with yes/no responses. The total score can range 
from 0-8 according to the number of positive answers. Patients scoring >3 on STOP-Bang 
are perceived to be at high risk of OSA. The STOP-Bang questionnaire was developed and 
validated in a general surgical population (Chung et al. 2008) and has been adopted as a 
screening tool in surgical pre-assessment clinics for its easy use. In the original population 
the sensitivity and specificity for moderate OSA were found to be 93% and 43% respectively 
and for severe OSA 100% and 37% with a negative predictive value of 100% for severe 
OSA (Chung et al. 2008). In systematic reviews of screening questionnaires for OSA, the 
STOP-Bang questionnaire had the highest methodological validity, moderately high 
sensitivity and best negative predictive value for assessing the risk of moderate/severe OSA 
(Abrishami et al. 2010; Chiu et al. 2017). The high sensitivity means that STOP-Bang of 0-2 
would with high accuracy exclude patients with OSA but low specificity means that 
significant number of patients with scores of ≥3 would screen falsely positive.  
To deal with the issue of low specificity several aspects of STOP-Bang scoring have 
been explored. A relationship between STOP-Bang scores and the predicted probability of 
OSA was examined and found that the higher the STOP-Bang score the greater probability 
of OSA (Nagappa et al. 2015). In this pooled surgical population of 957 patients, the 
probability of moderate-to-severe OSA for a score of 3 was 40% and the higher the STOP-
Bang score, the greater was the probability of OSA. The addition of serum bicarbonate level 
HCO3- to STOP-Bang scores has been explored and it was shown that the addition of serum 
HCO3- of at least 28 mmol/l to a STOP-Bang score of ≥3 improves the specificity to predict 
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moderate-to-severe OSA, but decreases significantly its sensitivity (Chung et al. 2016). The 
predictive performance of various individual items of STOP-Bang has been examined. 
Specificity in detecting moderate to severe OSA increased based on different combinations: 
85% for a STOP score at least 2 + BMI more than 35 kg/ m2; 79% for a STOP score at least 
2 + neck circumference more than 40 cm and 77% for a STOP score at least 2 + male 
(Chung et al. 2014). 
Based on these results a two step approach has been proposed (Chung et al. 2014) 
in that if patients score 0-2, there is a low risk of moderate to severe OSA. If a patient scores 
≥5 they have high probability for moderate to severe OSA and further assessment by sleep 
physician may be needed. The intermediate risk are patients with scores 3, 4 can be further 
stratified as high risk of OSA based on STOP score at least 2 + BMI more than 35 kg/m2 or 
STOP score at least 2 + male or STOP score at least 2 + neck circumference more than 40 
cm. In addition, patients with STOP-Bang score at least 3 can be further classified as high-
risk for moderate-to-severe OSA if the serum HCO3- is at least 28mmol/L. However, this 
two-step algorithm makes the simple question more complex and needs further prospective 
validation.  
The STOP-Bang questionnaire has been validated in different populations, but a 
selection bias such as referring patients with suspected sleep-related concerns from sleep 
clinics or in studies targeting surgical patients and, a self-selection bias from patients with 
preexisting sleep symptoms could exist in some of the validation studies. This, along with 
high prevalence of OSA in the studied population may have influenced the results and 
therefore validation in specific target populations is recommended (Chung et al. 2016). 
Some studies have shown that the STOP-Bang score might predict increased risk of 
postoperative pulmonary and cardiac complications in patients undergoing various surgical 
procedures (Nagappa et al. 2017). Data from a large prospective study (n=3,452 patients) 
showed that patients with high risk of OSA, compared to low risk, on the STOP-Bang 
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questionnaire had a higher rate of postoperative complications in terms of difficult intubation 
(20% vs 9%) and difficult mask ventilation (23% vs 7%) (Corso et al. 2014).  
Peri-operative risks in patients with of OSA 
Surgery and the postoperative period may represent a vulnerable time for patients 
with OSA due to potential deleterious effects of sedatives and opioids, supine position 
following surgery as well as possible REM sleep rebound reported after surgery, all of which 
may worsen the severity of OSA (Kaw et al. 2006). It has been hypothesised that the 
worsening severity of sleep-disordered breathing after surgery may be responsible for an 
increased incidence of postoperative complications in patients with OSA and that  
understanding the mechanism of the postoperative deterioration of sleep-disordered 
breathing may help with the perioperative management of patients with OSA (Chung et al. 
2014).  
Several studies have reported worsening of OSA in the postoperative period with one 
study reporting peak worsening of sleep disordered breathing on postoperative night three 
which recovered to preoperative level of severity on postoperative night seven (Chung et al. 
2014). Rosenberg et al.  reported that postoperative rebound of nocturnal REM sleep might 
contribute to the development of sleep-disordered breathing and nocturnal episodic 
hypoxemia (Rosenberg et al. 1994). A prospective study of 376 patients undergoing various 
surgical procedures showed that factors associated with worsening of OSA after surgery 
were preoperative severity of OSA (as evidenced by AHI), age, and 72-h opioid dose. 
(Chung et al. 2014). The mechanisms by which sleep apnoea might affect postoperative 
outcomes are unknown but one study by Gögenur et al. demonstrated that postoperative 
nocturnal hypoxemia was associated with tachycardia and myocardial ischemia (Gogenur et 
al. 2004). 
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Impact of sedation, anaesthesia and opioid analgesia on OSA 
The cardinal feature of OSA is recurrent UA obstruction due to imbalance between 
collapsing and dilating UA forces. It has been reported that general anaesthetics reduce UA 
dilator muscles activity and impair arousal responses to hypoxia (Vasu et al. 2012) leading to 
increased upper airway collapsibility and worsening OSA.  A study of 12 healthy volunteers 
undergoing minor surgery showed that increased depth of propofol anaesthesia was 
associated with an increase in critical upper airway pressure and airway collapsibility due to 
reduced genioglossus activity (Eastwood et al. 2005; Hillman et al. 2009).   
Opiates/opioids in OSA 
The use of opioids is prevalent in Western societies and opioids are commonly used 
in the management of postoperative pain but use in patients with OSA may be limited by 
concerns regarding respiratory depression (Wang et al. 2007). Opiates are naturally 
occurring compounds whereas opioids are synthetic agents and both are widely used as 
analgesics following major surgery. Opiates and opioids bind to four different classes of 
receptors, namely δ, κ, µ and the nociception/orphanin receptor (Pattinson 2008). It has 
been shown that opioids inhibit brainstem arousal centres and could therefore cause 
reduced consciousness. Opiates/opioids exercise their negative effect on ventilation by 
reducing the respiratory rate and tidal volume as well as  decreasing chemoresponsivness to 
hypoxia and hypercapnia and reducing UA muscle tone (Lalley 2008; Van Ryswyk et al. 
2016) . Opioid receptors are located in the nuclei that are active in sleep regulation and 
opioids have been reported to  impair basic sleep–wake mechanisms (Lydic et al. 2005) by 
inhibiting central cholinergic (Lydic et al. 1993) and adenosinergic (Nelson et al. 2009) 
transmission. Opioids with µ receptor stimulating action can lead to inhibition of REM sleep 
(Cronin et al. 1995).   
The effects of opioids on respiration share common physiological pathways with OSA 
and thus could increase susceptibility to sleep disordered breathing. Patients suffering from 
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sleep-disordered breathing may be vulnerable to the central opioid effects such as sedation, 
diminished central respiratory drive as well as  peripheral effects including increased airway 
collapsibility. Certain pathophysiological features of OSA including sleep fragmentation, 
intermittent hypoxemia, and systemic inflammation have been found to influence pain 
behaviour and/or increase sensitivity to opioids as described in the following paragraphs 
(Wang et al. 2007; Doufas et al. 2013). 
The effect of opioids on sleep was not studied in surgical patients with OSA and 
there are only limited studies in non-surgical populations examining the effect of acute opioid 
administration on sleep apnoea. To date, there is only one randomised controlled trial 
examining the effect of the opioid, remifentanil. Nineteen subjects were studied and a 
reduction in obstructive apnoeic events along with an increase in central sleep apnoea 
frequency and significant reduction in minimal nocturnal oxygen saturation were observed 
(Bernards et al. 2009). This may be related to the REM-suppressing effect of the opioid. 
Caution is needed as discontinuation of opiods and REM rebound after the third 
postoperative night may worsen the severity of OSA in patients with REM-predominant 
apnea/hypopnea events and the obstructive events may recur with increased frequency and 
severity during an intense REM sleep rebound after the third postoperative night (Knill et al. 
1990). The the clinical impact of this phenomenon is yet to be shown (Macintyre et al. 2011).  
In one retrospective case series patients undergoing UA surgery for OSA treated with 
acutely administered opioids had increased extubation complications (Esclamado et al. 
1989). Another case series described postoperative respiratory arrest in patients receiving 
epidural opioids (Ostermeier et al. 1997) and pronounced episodic oxygen desaturation in 
the postoperative period in patients with OSA treated with acute intravenous opioid 
analgesia has also been noticed (Catley et al. 1985). Apnoeas, respiratory depression and 
cyanosis were  also described in patient with a history suggestive of OSA receiving 
postoperative epidural morphine (Lamarche et al. 1986). It has  been described that 
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morphine can exacerbate upper airway obstruction in patients with established upper airway 
compromise due to enlarged tonsils or upper airway tumour with death reported after 
administration of morphine (Byard et al. 2005).  
Considering the relatively high prevalence of OSA in the surgical population there are 
perhaps surprisingly few anecdotal reports of deleterious effects of morphine on patients 
with OSA after surgery. This may be due to careful monitoring of these patients following 
surgery or may support the hypothesis that only a small group of OSA patients are at 
increased risk for opioid-induced ventilatory compromise. Although, administration of oxygen 
(Hudgel et al. 1988; Mokhlesi et al. 2011) and sedatives(Eckert et al. 2011) may stabilise 
ventilatory control and benefit OSA patients with increased loop gain and low arousal 
thresholds, the same intervention could prolong the duration of airway obstruction, leading to 
severe hypoxemia, in patients with decreased ventilatory responses to hypoxia/hypercapnia 
and high arousal thresholds (Hudgel et al. 1988).   
Although this group of patients with increased loop gain represents a minority 
amongst  OSA cohort (Eckert et al. 2014) they might be at a greater risk of deleterious 
opioid-related respiratory events after surgery because they rely heavily on arousal to 
restore UP patency and normalise blood gas tensions. Opioids, by inhibiting chemical, 
behavioural, and motor control of respiration (Koo 2011), could further raise arousal 
thresholds, prolong airway obstruction, and precipitate hypoxemia. It was observed that fatal 
episodes were more likely to occur during the night-time in patients who were difficult to 
arouse (Ramachandran et al. 2011), which may suggest that OSA patients with high arousal 
thresholds, longer obstructive events, and potentially larger arterial desaturations may have 
a lower reserve to tolerate a significant respiratory event after surgery than patients with a 
different OSA phenotype presenting with frequent obstructive events and mild-to-moderate 
hypoxemia. In these patients the sedative effect of opioids may stabilise airway patency and 
breathing and improve OSA (Wang et al. 2013). 
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There is a growing body of experimental and clinical evidence supporting an 
association between OSA and/or intermittent hypoxia with increased sensitivity to the opioid 
analgesic effect. Children living at high altitude under conditions of chronic sustained 
hypoxia with resting oxyhemoglobin saturation of 92% consumed 40% less fentanyl peri-
operatively, compared with children living at sea level (Rabbitts et al. 2010). Consistent with 
this report, in a retrospective cohort of 46 children undergoing adenotonsillectomy for OSA it 
was shown that recurrent nocturnal hypoxemia was associated with lower opioid 
consumption in the perioperative period (Brown et al. 2004) and in a prospective study in a 
paediatric population of 22 children it was reported that children with a nocturnal nadir 
SaO2 <85% needed half of the total dose of morphine required to treat post 
adenotonsillectomy pain than children with a nadir SaO2 ≥85% (Brown et al. 2006). These 
findings were also supported by independent experiments showing that intermittent hypoxia 
upregulated μ-opioid receptors in the developing rat (Laferriere et al. 2003) which may be 
responsible for an increased sensitivity to the analgesic and respiratory effects of opioids 
(Moss et al. 2006). Similarly, it was reported that in adult volunteers suffering OSA, both 
nocturnal nadir SaO2 and insulin-like growth factor-binding protein 1, a serum marker of 
hypoxia, were significantly associated with increased sensitivity to the analgesic effect of 
remifentanil. (Doufas et al. 2013).A recent retrospective analysis of 218 obese adults with 
OSA, who underwent bariatric surgery, demonstrated that the percentage of total sleep time 
spent with SaO2 <90% was inversely associated with total postoperative opioid consumption 
(Turan et al. 2015).  
In addition, experimental and clinical evidence suggest that sleep disruption and 
nocturnal intermittent hypoxemia, cardinal features of OSA, could enhance pain either acting 
directly or via complex inflammatory pathways (Abrishami et al. 2010). In view of this 
evidence, both intermittent hypoxia and sleep disruption augment pain, and intermittent 
hypoxia may also potentiate opioid analgesic responses and OSA. This may complicate 
opioid-based perioperative management of pain by altering both pain processing and 
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sensitivity to opioid effects in OSA individuals. Given the variability of OSA phenotypes and 
pain/analgesia responses in humans, there is a need for large prospective trials examining 
the effect of the various OSA phenotypes on postoperative pain as well as the effect of 
opioid analgesia on these various OSA subtypes.  
 Opioid administration after surgery is often via  patient controlled analgesia (PCA).  
A standard regime includes a 1mg bolus followed by 5-10 minutes of lock out period via the 
PCA device. Two retrospective reviews of over a thousand patients reported 1-2% risk of 
developing respiratory depression with PCA extending to 31 hours after initiation of 
analgesia, emphasising the importance of short and long term monitoring of patients with 
OSA. The American Society of Anaesthesiologist has issued practice guidelines regarding 
the management of patients with OSA, including use of opioids and other compounds 
suppressing respiration or having a negative impact on upper airway dilator muscles and 
advise that the smallest possible doses should be used (Gross et al. 2006). 
Impact of REM sleep rebound on OSA 
Although the exact mechanism for worsening of sleep apnoea in the postoperative 
period and effect of sleep apnoea on worse postoperative outcomes is unknown, the effect 
of REM sleep rebound has been proposed. Studies have shown that following surgery, 
patients have highly fragmented sleep during the second postoperative night with a 
reduction in REM sleep, slow wave sleep (SWS) and an increase in stage two sleep (Vasu 
et al. 2012). It appears that type of surgery plays an important role with more pronounced 
disruption in REM sleep and SWS noticed after major surgery for example gastrectomy as 
oppose to minor surgery such hernia repair (Vasu et al. 2012). Surgical trauma leads to 
increased levels of cortisol and pro-inflammatory mediators such tumour necrosis factor α , 
interleucin1 (IL-1) and interleukin 6 (IL-6), which have been shown to reduce  REM sleep 
(Opp et al. 1992; Lin et al. 2000). REM sleep is mainly reduced on post-operative night 1 
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and 2 which is followed by REM sleep rebound during the postoperative nights 3-5 (Vasu et 
al. 2012).  
It has been shown that during  REM sleep pharyngeal muscle activity is minimal 
predisposing to upper airway closure and leading to intermittent hypoxia causing brief 
arousal leading to increase sympathetic surge, and causing tachyarrhythmia, haemodynamic 
instability and myocardial ischaemia (Gogenur et al. 2004). Episodes of hypoxaemia and 
complications, after surgery, have been described to occur mostly between night 3-5 after 
the surgery (Vasu et al. 2010). Episodic hypoxia has been previously linked to an increased 
risk of wound infections, cerebral dysfunction and cardiac arrhythmias (Kehlet et al. 1995). 
The incidence of myocardial infarction has been reported to peak on day 3 after the surgery 
(Tarhan et al. 1972) and delirium, nightmares, and psychomotor dysfunction have all been 
reported as increasing between nights 3 and 5 following surgery (Vasu et al. 2010). This 
anecdotal evidence supports the hypothesis of REM sleep rebound and its effect on 
worsening of sleep apnoea as well as worse postoperative outcomes in patients with OSA 
but more evidence needed to confirm this hypothesis.   
Obstructive sleep apnoea and postoperative complications 
  Many factors have been shown to influence surgical outcomes including American 
Association of Anaesthesiology (ASA) class, age, type of paralytics, smoking status, low 
albumin, duration of surgery and presence of comorbidities such chronic obstructive 
pulmonary disease (COPD), renal failure and coronary artery disease (Vasu et al. 2012). It 
has also been reported that certain surgical procedures are associated with higher risks 
including cardiothoracic, abdominal, vascular and neck surgery (Vasu et al. 2012).  A risk 
model have been developed to calculate the risk of mortality after cardiac surgery.  
EuroSCORE (European System for Cardiac Operative Risk Evaluation) is a risk model 
consisting of 17 items, developed between 1995 and 1999 to provide a simple, additive risk 
model of perioperative mortality (Geissler et al. 2000).  
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In the last decade, significant research effort has been placed on examining an 
association between OSA and postoperative outcomes with emerging evidence of worse 
outcomes in patients with unrecognised or untreated OSA. The evidence comes from 
studies of varied quality with perhaps the strongest evidence coming from studies of national 
databases of million patients. The accuracy of studies that use International Classification of 
Diseases, Ninth Revision (ICD-9) coding to identify patients with OSA may be criticised as 
coding systems may label a mixture of OSA and non OSA in study group and the control 
group may not represent a true negative control. However, considering the fact that patients 
with an ICD-9 code of OSA are likely to have the disease, and many who remain 
undiagnosed are included in the control group as is likely the case in database studies, the 
associations found in these analyses could actually underestimate the true effects.  
Memtsoudis et al. examined a database of over 6 million patients undergoing general 
and orthopaedic surgery and found the prevalence of sleep apnoea of 1.4% and 2.5% 
respectively. Sleep apnoea was associated with a significantly higher adjusted OR of 
developing pulmonary complications after both orthopaedic and general surgical procedures, 
respectively, with the exception of pulmonary embolus. The OR for aspiration pneumonia 
was 1.41 [95% CI 1.35, 1.47] and 1.37 [95% CI 1.33, 1.41], for ARDS: 2.39 [95% CI 2.28, 
2.51] and 1.58 [95% CI 1.54, 1.62], and for intubation/mechanical ventilation 5.20 [95% CI 
5.05, 5.37] and 1.95 [95% CI 1.91, 1.98] (Memtsoudis et al. 2011). In a similarly designed 
study, Memtsoudis et al. analysed entries of 530,089 patients undergoing total hip and knee 
arthroplasty and found the prevalence of sleep apnoea was  8.4%. Sleep apnoea was found 
to be an independent risk factor for major postoperative complications (OR 1.47; 95% CI 
1.39-1.55) in particular pulmonary complications were 1.86 (95% CI, 1.65-2.09) times more 
likely and cardiac complications 1.59 (95% CI, 1.48-1.71) times more likely to occur in 
patients with sleep apnoea (Memtsoudis et al. 2014). In addition, sleep apnoea patients 
were more likely to receive ventilatory support, use more intensive care resource and have 
longer lengths of hospitalization (Memtsoudis et al. 2014).  In line with these reports, 
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Mokhlesi et al. showed that sleep apnoea was independently associated with 
cardiopulmonary complications (Mokhlesi et al. 2013).  
These studies have several limitations that are mainly related to the analysis of large 
administrative databases including the inability to ascertain the presence or absence of 
sleep apnoea and its severity, lack of information about home CPAP therapy or CPAP 
use/compliance during the postoperative period. In addition, information on all potential 
confounders, such as BMI was not available and therefore it is impossible to be sure that the 
worse postoperative outcomes are independent of obesity, one of the most significant risk 
factors for OSA. 
Along with these large scale studies several single centre studies have been 
performed and outcomes analysed in 2 meta-analyses, including 13 and 17 studies (Kaw et 
al. 2012; Hai et al. 2014). The meta-analysis of 13 studies where the majority of patients 
were confirmed to have OSA by polysomnography, showed increased risks of post-operative 
cardiac events OR 2.07, acute respiratory failure OR 2.43, desaturations OR 2.27 and ICU 
transfers OR 2.81(Kaw et al. 2012). Data from several large studies, described above, using 
a diagnosis of OSA based on international code system were not included in these meta- 
analyses (Memtsoudis et al. 2011; Mokhlesi et al. 2013; Mokhlesi et al. 2013). The 
conclusions from these meta-analyse s suggest that due to heterogeneity of settings, sleep 
diagnostic used, definition of OSA and the outcomes measured it is not possible, with 
confidence, to determine that OSA is an independent risk factor for worse postoperative 
outcomes. 
Although, the majority of studies reporting an association between OSA and 
postoperative outcomes were  observational and given the limitations described, there is 
moderate evidence for an association between OSA and deleterious pulmonary and 
cardiovascular outcomes in patients undergoing general surgery. It is, however, impossible 
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to conclude the causation and to be certain that this association is independent of obesity 
and other cardiovascular comorbidities often found in these patients. 
The literature regarding an association between OSA and mortality is less clear with 
some of the current evidence supporting improved 30 day mortality in patients with OSA. 
The evidence comes mainly from large population database analysis based on ICD-9 code 
diagnosis and confirming causality is therefore not possible (Nguyen et al. 2011; Mokhlesi et 
al. 2013; Mokhlesi et al. 2013). One possible mechanism for reduction in mortality in patients 
with SDB may be ischaemic preconditioning. Studies have reported that in patients with 
acute myocardial infarction, those with SDB and intermittent hypoxemia during sleep have 
better coronary collateral circulation and less severe cardiac injury (Shah et al. 2013).  The 
majority of other studies report no association between OSA and postoperative mortality 
(Opperer et al. 2016) and one study suggests increase mortality in patients with OSA 
(D'Apuzzo et al. 2012).  
Data in patients undergoing cardiac surgery are inconsistent with some results 
suggesting an association between OSA and postoperative complications and others not 
supporting this association (Foldvary-Schaefer et al. 2015; Uchoa et al. 2015). A study of 67 
prospectively recruited participants, assessed for OSA by PSG showed no association 
between OSA and short term complications but reported that the OSA was independently 
associated with a higher rate of long-term cardiovascular events after CABG (Uchoa et al. 
2015). Another study by Foldvary-Schaefer et al. recruited prospectively 107 patients and 
showed that OSA was not significantly associated with worse postoperative outcomes but 
the authors commented that the relatively small study sample could have influenced results 
(Foldvary-Schaefer et al. 2015).  
A recent meta-analysis reported a positive association between OSA and 
postoperative complications in patients undergoing cardiac surgery (Nagappa et al. 2017). It 
included 11 studies and showed a higher chance of adverse cardiac and cerebrovascular 
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events with an odds ratio (OR) of 2.4; 95% CI 1.38-4.2; p=0.002, as well as newly 
documented postoperative atrial fibrillation OR = 1.94; CI 1.13-3.33; p=0.02 in patients with 
OSA compared to non OSA patients (Nagappa et al. 2017). There was no significant 
difference in the number of Intensive Care Unit readmissions, infection or sepsis, Intensive 
Care Unit lengths of stay, and hospital lengths of stay. The majority of patients in this meta-
analysis were newly diagnosed, untreated patients with OSA. The studies included were of 
mixed quality. Only five out of 11 of the studies were prospective and used recognised sleep 
diagnostic (PSG or watch-PAT) to diagnose OSA (Mooe et al. 1996; Bhama et al. 2006; 
Foldvary-Schaefer et al. 2015; Uchoa et al. 2015; Zhao et al. 2015)  whilst the rest were 
either retrospective cohort assessments or used questionnaires to estimate the risk of OSA.  
Out of the five higher quality studies, two reported no association between OSA and 
postoperative outcomes (Foldvary-Schaefer et al. 2015; Uchoa et al. 2015), two reported an 
association between OSA and post-operative atrial fibrillation (Mooe et al. 1996; Zhao et al. 
2015) and one showed prolonged ventilation, tracheostomy duration, Intensive Care Unit 
and hospital duration of stay (Bhama et al. 2006).  
A reason why studies reach different conclusions may be inconsistency in definition 
of OSA, sleep diagnostic used, small sample size for given outcomes and number of various 
reported outcomes. Overall, there is currently no compelling evidence for an increased risk 
of postoperative complications in patients with OSA independent of obesity and other 
comorbidities in patients undergoing cardiac surgery.  
 
Perioperative management of patients with OSA 
In 2006 the American Society of Anaesthesiologists and in 2016 the Society of 
Anaesthesia and Sleep Medicine published guidelines on perioperative management of 
patients with OSA with the following recommendations (Gross et al. 2006; Chung et al. 
2016): 
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1. Perioperative evaluation  
“A thorough clinical and sleep history should focus on symptoms associated with 
OSA including snoring, witnessed apnoeas, disrupted sleep, nocturnal chocking, 
morning headaches, and excessive daytime sleepiness. Physical examination 
including neck circumference, BMI, tongue size, tonsillar size and nasopharyngeal 
assessment should be undertaken.” A screening questionnaire can be administered 
with clear plan for further investigation if felt appropriate by surgeon or anaesthetist 
but at present there is limited evidence to support the use of preoperative screening 
tools as a routine practice to reduce postoperative complications (Lockhart et al. 
2013). Identifying patients at risk of OSA prior to surgery may allow perioperative 
precautions and interventions which may mitigate patients’ risks, for example 
avoidance of general anaesthesia in patients with OSA undergoing joint arthroplasty 
(Memtsoudis et al. 2013). Local services should decide the threshold for screening 
test taking into account implications of missed diagnosis and cost of care. There is 
currently insufficient evidence for cancelling or delaying surgery to perform a sleep 
test to diagnose OSA in those with suspected disease. The best opportunity for 
diagnosis of OSA would come with earlier diagnosis such as in the surgical pre-
assessment clinics to allow time for diagnosis and optimisation of treatment. 
Although AHI is the most commonly used metric for OSA other parameters such as 
ODI or % of time of oxygen saturation<90% from nocturnal oximetry may improve 
prediction of postoperative complications (Chung et al. 2014) and nocturnal oximetry 
may represent a useful tool for screening for OSA before surgery. 
2. Intraoperative management 
“Surgical stress and duration of surgery should be minimised as these have been 
shown to be associated with increased risk of postoperative complications. Use of 
regional anaesthesia when possible is preferable to general anaesthesia. Patient 
should be extubated when fully awake, preferably in the semi-erect position.” 
3. Postoperative management 
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“Patients with OSA at increased perioperative risk should be closely monitored at the 
post anaesthesia care unit for hypoxaemia with continuous pulse oximetry and other 
complications. Patients should be placed in non-supine position. Use of opioids and 
benzodiazepines should be minimised and other analgesia such NSAID’s, tramadol, 
regional anaesthesia and dexmedetomidine for its opioid sparing effect and the lack 
of respiratory depression should be used preferably. CPAP should be used after the 
surgery in patients with known OSA. “ 
 
Use of peri-operative CPAP 
CPAP acts as a pneumatic splint and prevents upper airway collapse, maintains 
airway patency, improves functional residual capacity, nocturnal oxygen saturations and 
reduces work of breathing, resulting in reduction in OSA severity with reduction in excessive 
daytime sleepiness and improvement in cognitive function (Engleman et al. 1994; Giles et al. 
2006). It is apparent, from the presented evidence, that OSA is common in the cardiac 
surgical population and that it is associated with worse postoperative complications (Kua et 
al. 2016; Mason et al. 2017; Nagappa et al. 2017). Although  CPAP is the conventional 
treatment for patients with OSA syndrome with established clinical and cost effectiveness 
(Giles et al. 2006) its effect for patients with OSA in perioperative settings has yet to be 
demonstrated.  
A reduction in pulmonary complications, in patients without a diagnosis of OSA, 
undergoing thoraco-abdominal and cardiac surgery has been reported (Kindgen-Milles et al. 
2005; Zarbock et al. 2009) but the evidence supporting the application of perioperative 
CPAP to patients with OSA is currently lacking. A recent meta-analysis of 6 studies including 
904 patients showed no significant difference in post-operative adverse events between 
CPAP and non-CPAP treatment groups in patients undergoing general surgery (Nagappa et 
al. 2015). There is some evidence for improvement in cardiovascular morbidity in a 
retrospective cohort of 26,842 patients with OSA undergoing vascular surgery where those 
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not treated with positive airway pressure preoperatively were at increased risks for 
cardiopulmonary complications including unplanned reintubations (OR 2.5) and myocardial 
infarction (OR 2.6) compared with treated OSA patients (Abdelsattar et al. 2015). In one 
study it was noted that OSA patients who were compliant with CPAP had a reduced rate of 
postoperative complications (Gupta et al. 2001) and similarly in another study patients non-
compliant with CPAP had a higher rate of postoperative complications (Liao et al. 2009). The 
effect of CPAP on patients with OSA undergoing cardiac surgery has not been examined in 
randomized controlled trials. 
OVERALL RESEARCH AIM 
The studies proposed in this thesis have examined:  
1. The prevalence of undiagnosed sleep apnoea in patients attending for cardiac 
surgery 
2. Whether undiagnosed sleep apnoea is associated with worse post-operative 
outcomes in patients attending for cardiac surgery 
3. Whether the STOP-Bang questionnaire reliably identifies pre-operative patient with 
sleep apnoea attending for major cardiac surgery 
4.  Effect of opiates on postoperative outcomes following cardiac surgery in patients 
with and without sleep apnoea  
5. Whether acutely administered intravenous morphine sulphate, changes the severity 
of OSA in patients with known moderate OSA 
6. The extant literature regarding the effects of opioids/opiates and other sedative and 
hypnotic drugs on the severity of sleep apnoea in patients with established diagnosis 
of OSA.  
Taken together, this thesis will inform our understanding of any excess risk associated with 
undiagnosed OSA in patients undergoing major cardiac surgery and of the safety of 
morphine, a routine post-operative analgesia, in patients with OSA. 
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Chapter 2 
An association of sleep apnoea with postoperative outcomes in patients undergoing 
cardiac surgery; observational cohort study (SACS) 
        My personal involvement in this study includes: developing the research hypothesis as 
well as writing up the protocol and application for ethical approval. I have screened patients 
suitable for participation as well as recruited patients to the study. In addition, I have 
reviewed results from overnight oximetry and made decision regarding the need for CPAP 
treatment. Following completion of the study I have collected data on postoperative 
complications from patient’s case notes. Statistical analysis was performed by Dr Jules-
Fernandez-Sanches and Dr Linda Sharples. Dr Ian Smith helped with developing of the 
research hypothesis and protocol and was overlooking the whole project. I have published 
these results in the following papers (attached in Appendix 4): 
1. Mason M, Hernandez-Sanchez J, Vuylsteke A, Smith I. Association between severity 
of untreated sleep apnoea and postoperative complications following major cardiac 
surgery: a prospective observational cohort study. Sleep Med.2017 Sep; 37:141-146 
2. Mason M, Hernandez-Sanchez J, Vuylsteke A, Smith I Usefulness of the STOP-Bang 
questionnaire in a cardiac surgical population. J Cardiothorac Vasc Anesth. 2018 
Dec;32(6):2694-2699 
 
Null Hypothesis 
Undiagnosed sleep apnoea is not a risk factor for a prolonged stay on ICU and 
postoperative complications in patients undergoing cardiac revascularisation surgery with 
and without  valve surgery. 
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Introduction 
The prevalence of OSA in the adult population has been increasing (Peppard et al. 
2013). Severe OSA has been associated with increased risk of fatal and non-fatal 
cardiovascular events (Marin et al. 2005). OSA shares some risk factors with coronary artery 
disease (Mooe et al. 1996) and so while the exact prevalence of OSA among people 
undergoing coronary artery bypass surgery is unknown we might expect it to be higher than 
in the general adult population. 
Association between OSA and postoperative complications in patients undergoing cardiac 
surgery  has previously been reported in retrospective reviews and studies using screening 
questionnaires to diagnose OSA (Bhama et al. 2006; Kaw et al. 2006; Mungan et al. 2013; 
Amra et al. 2014; van Oosten et al. 2014; Zhao et al. 2015; Kua et al. 2016). Two 
prospective studies reported an association between OSA and postoperative atrial fibrillation 
and delirium in patients undergoing cardiac surgery, using respiratory polygraphy to 
diagnose sleep apnoea (Mooe et al. 1996; Roggenbach et al. 2014). Two subsequent  
prospective observational studies using polysomnography as a sleep diagnostic showed no 
association between OSA and adverse short term postoperative complications (Foldvary-
Schaefer et al. 2015; Uchoa et al. 2015). These studies were conducted before the current 
study but published in 2015 shortly after completed recruitment but are also smaller than the 
current study. 
Central sleep apnoea is characterised by pauses in breathing along with reduced or 
absent respiratoty effort and no apparent occlusion of the airway. It can be associated with 
symptoms including excessive daytime sleepiness, frequent nocturnal awakenings, or both. 
The International Classification of Sleep Disorders (ICSD)– 2 identifies 6 different forms of 
central sleep apnoea:  Primary Central Sleep Apnea, Central Sleep Apnea Due to Cheyne 
Stokes Breathing Pattern, Central Sleep Apnea Due to Medical Condition (Not Cheyne 
Stokes), Central Sleep Apnea Due to High-Altitude Periodic Breathing, Central Sleep Apnea 
Due to Drug or Substance, and Primary Sleep Apnea of Infancy (Aurora et al. 2016). The 
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underlying pathophysiology of central sleep apnea is due to hyperventilation such as in 
congestive heart failure, high altitude sickness, and primary central sleep apnoea or 
hypoventilation in patients with central nervous system disease, neuromuscular disease, or 
severe abnormalities in pulmonary mechanics, for example kyphoscoliosis. Cheyne-Stokes 
respiration is characterized by an absence of air flow and respiratory effort which is followed 
by hyperventilation (a crescendo-decrescendo pattern). Cheyne-Stokes respiration most 
often occurs in patients with congestive heart failure. The prevalence is estimated to be 
approximately 30% to 40% in patients with congestive cardiac failure (Aurora et al. 2016). 
However, this respiratory pattern can also be seen in patients with stroke or renal failure. 
There are no published data on its impact on surgical outcomes though it has been 
implicated in adverse outcomes for patients with cardiac disease (Aurora et al. 2012).  
There is currently limited evidence specifically linking OSA or central sleep apnoea, 
to postoperative complications. Moreover, there are currently no data showing that the 
application of perioperative continuous positive airway pressure therapy to patients with 
sleep apnoea reduces the risk of perioperative complications (Nagappa et al. 2015). Despite 
this lack of robust evidence screening pre-operatively for OSA is now the norm in some parts 
of the United Kingdom, leading to additional National Health Service cost and a potential 
delay in surgery. I designed a prospective observational study to examine whether untreated 
sleep apnoea is associated with prolonged ICU stay and increased frequency of 
postoperative ICU complications, in patients undergoing major cardiac surgery. 
Methods 
Design 
This prospective observational cohort study recruited patients who were undergoing 
elective CABG with or without cardiac valve surgery at Papworth Hospital, a specialist 
cardiothoracic centre.  Patients were screened for sleep apnoea the night before their 
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surgery.  The primary aim of the study was to assess whether sleep apnoea was associated 
with a prolonged stay in ICU.  
Ethical approval was granted by The National Research Ethics Service East Midlands 
Northampton Proportionate Review Sub-committee on 20 December 2012 (12/WM/0433). 
All participants who agreed to enter the study gave signed, informed consent. 
This study was conducted at Papworth Hospital NHS Foundation Trust. Papworth 
Hospital is cardiothoracic hospital with a 32 bedded critical care area and eight cardiac 
recovery beds dedicated to the care of patients for the first 24 hours following cardiac 
surgery. The Respiratory Support and Sleep Centre (RSSC) is a Tertiary Centre with 
specialist expertise in various sleep disorders including the diagnosis, treatment and follow 
up of patients with OSA. Patients in this study were recruited from the adult patients 
population attending surgical preadmission clinics and undergoing elective surgical coronary 
artery revascularisation with or without cardiac valve surgery. The majority of surgical 
procedures undertaken at Papworth Hospital cardiothoracic unit include coronary artery 
revascularisation surgery with or without valve surgery. To minimise  recruitment bias it was 
felt essential to recruit patients from the homogeneous surgical cohort and as many patients 
undergoing CABG surgery will simultaneously undergo cardiac valve surgery and vice versa 
and as the complexity of these surgical interventions was considered similar, patients 
undergoing such surgical interventions were chosen. 
 
Population 
Inclusion Criteria 
 Age >18 years 
 Listed for elective surgical coronary revascularisation with or without cardiac valve 
surgery 
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Exclusion Criteria 
 Inability to give informed consent or comply with the protocol 
 Emergency surgical coronary revascularization or valve surgery 
 Tracheostomy before surgery 
 Enrolment in another concurrent interventional research study likely to impact of 
study outcomes 
Eligible participants were admitted on the night before surgery and had medical history 
and clinical measurements recorded including weight, height, body mass index and neck 
circumference. All participants completed the STOP-Bang questionnaire and Epworth 
Sleepiness Scale. The EuroSCORE, a mortality risk score developed for patients undergoing 
cardiac surgery, was calculated for all patients (Nashef et al. 1999).  It is  an additive score 
of predicted post-operative mortality, where scores of 1-2 determine  low risk group with 
predicted post-operative mortality rate of 0.8%, scores of 3-5 put patients in medium risk 
group with predicted mortality of 3% and scores of >6 reflect high risk group with predicted 
mortality of 11%. The risk factors incorporated in the additive EuroSCORE include: age, 
gender, presence of chronic pulmonary disease, extracardiac arteriopathy, neurological 
dysfunction disease, previous cardiac surgery, serum creatinine >200 micromol/Lilitre 
preoperatively, active endocarditis, critical preoperative state, unstable angina, LV 
dysfunction, recent myocardial infarct, pulmonary hypertension, emergency procedure, other 
than isolated CABG, surgery on thoracic aorta, post-infarct septal rupture. 
The STOP-Bang questionnaire has been developed and validated as a pre-operative  
screening tool for assessing the risk of OSA in general surgical population in 2008 by Chung 
et al (Chung et al. 2008). It is a self-administered and easy to use tool comprising eight 
questions with yes/no responses, each positive response scoring one point. A high risk of 
sleep apnoea has been defined as a score of ≥3 and a low risk  as a score 0-2. (Figure 2.1) 
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Figure 2.1 STOP-Bang Questionnaire 
 
The Epworth sleepiness scale was introduced in 1991 by Dr Murray Johns of Epworth 
Hospital in Melbourne, Australia. The ESS in an internationally accepted scale used to 
assess patient’s subjective daytime sleepiness. It estimates the chance of falling asleep in 
eight different situations where subjects rate their tendency to fall asleep on a scale of 0 to 3. 
0= no chance of dozing, 1=mild chance, 2=moderate chance and 3 a high chance of dozing. 
A score of <11 is considered to be normal and a value of ≥ 11 suggests excessive daytime 
sleepiness (Figure 2.2). 
 
 
 
 
 
 
 
 
 
79 
 
Figure 2.2. The Epworth Sleepiness Scale  
 
 
Outcome measures 
A range of objective outcome measures were used. 
Pulse Oximetry: Patients were screened for the presence of sleep apnoea with nocturnal 
oximetry (Konica-Minolta PULSOX-300i) while self-ventilated on room air the night before 
surgery. Finger probes were used (Figure 3.1) with a wristwatch oximeter with a 300 hour 
memory capacity, resolution of 0.1% SpO2, stored at 1Hz and 30 hr battery life. These data  
are downloaded to and stored centrally by  the RSSC on a single server and analysed using 
an automated system (Download 2000, Stowood Scientific instruments, Oxford, UK). 
Calculated values for the period monitored include a 4% desaturation index (number of 
desaturations of 4% or over per hour), mean heart rate, mean and minimum SpO2 values. 
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Sleep apnoea was defined as an arterial oxygen desaturation index (ODI=dips of oxygen 
greater than 4% or more, per hour sleep) of greater than 5 measured using nocturnal 
oximetry. Records without at least 4 hours adequate recording time were excluded as per 
our local  practice.  
Figure 2. 3. Nocturnal oximetry (Konica-Minolta PULSOX-300i) 
 
 
 
Figure 2.4. An example of recording from nocturnal oximetry 
 
 
 
Intermittent oxygen desaturations during the 
night consistent with sleep apnoea 
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The primary outcome variable was length of stay (LoS) in  the ICU, measured from arrival to 
ICU to discharge. Secondary outcomes included:  
 duration of invasive ventilation (from intubation in theatre until extubation on ICU),  
 need for continuous positive airway pressure (CPAP)/bi-level positive pressure 
ventilation after extubation,  
 need for re-intubation,  
 occurrence of new arrhythmias necessitating further monitoring or drug treatment or 
other  intervention,  
 need for additional organ support (intra-aortic balloon pump/ haemofiltration),  
 major organ complication requiring further monitoring, treatment or other intervention 
including: cardiovascular, respiratory, renal, neurological, hepatic, coagulation,   
 readmission to ICU   
 30 days mortality. 
Recruitment 
We recruited patients over 18 years of age, undergoing elective cardiac surgery and 
excluded patients who were participating in other interventional studies, those not able to 
give informed consent or comply with the protocol and patients with a tracheostomy before 
surgery. In addition, patients requiring emergency CABG/valve surgery and those admitted 
on the day of surgery (thereby not allowing in hospital overnight oximetry the night before 
surgery) were excluded. Some patients were subsequently excluded as intraoperative 
events or findings led them to have a different operation which did not meet our entry 
criteria. Patients with a previous diagnosis of OSA treated with CPAP were excluded from 
the final analysis (Figure 2.5). 
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Figure 2.5. Study Consort diagram 
 
 
 
 
 
 
 
 
 
Data Collection 
Patients underwent inpatient overnight oximetry (Konica-Minolta PULSOX-300i) while 
self-ventilating in room air on the night prior to their surgery. The oximetry results were 
automatically analyzed (Visidownload, Stowood Ltd, Oxford UK) and reviewed by a sleep 
physician, blinded to all clinical data. The anesthetic and surgical teams had no access to 
the results of preoperative nocturnal oximetry. Since oximetry alone cannot differentiate 
obstructive from central apnoea, the results are reported as sleep apnoea, which was 
diagnosed in patients with an arterial oxygen desaturation index (ODI) ≥ 5. The ODI was 
defined as the number of dips in oxygen saturations of greater than 4% relative to the 
moving average, per hour of sleep. The oximeter was programmed to average 
measurements over 1 second. As per our usual clinical practice, oximetry records without at 
least 4 hours of adequate data were excluded. Demographic variables, co-morbidities and 
the Epworth Sleepiness Scale (ESS) score (Johns 1991) were recorded on the night of 
332 patients assessed for 
eligibility 
152 patients enrolled in the 
study and underwent 
preoperative evaluation and 
overnight sleep study 
4 ineligible (enrolment in other 
studies) 
44 ineligible (not meeting 
inclusion criteria due to type of 
surgery) 
132 did not wish  to participate 
 
16 excluded (insufficient sleep 
study, technically poor or less 
than 4 hours recording)  
7 excluded from final analysis 
as not meeting inclusion 
criteria due to type of surgery, 
changed ad hoc according to 
clinical needs 
7 patients with previous 
diagnosis of OSA and using 
CPAP 
 
122 patients included in final 
analysis 
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admission for surgery. The EuroSCORE, a mortality risk score developed for patients 
undergoing cardiac surgery, was calculated for all patients (Nashef et al. 1999).  Data 
regarding postoperative complications were collected from the digital Clinical Information 
System in the ICU.  
Outcomes 
The primary outcome was length of stay (LoS) in ICU (days) a key performance 
indicator for assessing impact on resources. The secondary outcome was a composite 
measure of post-operative complications in ICU that included: use of continuous positive 
airway pressure/bi-level positive pressure ventilation via a mask after extubation, re-
intubation, occurrence of new arrhythmias necessitating drug treatment or intervention, need 
for additional organ support (intra-aortic balloon pump/ haemofiltration), major organ 
complication (defined as those requiring treatment or intervention  for cardiovascular, 
respiratory, renal, neurological, hepatic, coagulation issues), readmission to ICU and  30 
days mortality. 
Predictor variables 
The primary predictor in all models was ODI analysed as a continuous variable. In 
view of its clinical relevance, sleep apnoea was divided into categories according to the ODI: 
mild if ODI ≥ 5 but <15, moderate if ODI was > 15 but <30 and severe when ODI ≥ 30. 
Additional predictor variables thought to be risk factors relevant to the outcomes included 
EuroSCORE, age, body mass index, surgery type, administration of intravenous opioid 
analgesia (either intravenous morphine sulphate or fentanyl) during the ICU stay, 
comorbidities and mean nocturnal oxygen saturations from the pre-operative oximetry.  
Although the euroSCORE has been reported to be the best predictive score of mortality for 
patients undergoing cardiac surgery, certain risk factors within the euroSCORE may have 
different statistical weight for predicting morbidity and thus individual components of the 
euroSCORE were used as additional predictor variables (Geissler et al. 2000). 
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Administration of opioids was selected as a predictor due to previously reported effects 
including suppression of ventilatory drive and reduction of upper airway dilator muscle 
activity, potentially exposing patients with sleep apnoea to additional risk  (Kaw et al. 2006).  
Sample size 
Through discussion with the Critical Care Team we determined a watershed LoS in 
ICU at 36 hours. Unpublished historical clinical data showed LoS<36 hours for 
approximately 75% of patients. The null hypothesis was that patients with sleep apnoea 
(ODI≥5) did not remain on ICU for >36 hours more frequently than patients without sleep 
apnoea. Fifty seven patients with sleep apnoea, and the same number without, were 
required to achieve 80% power at 5% significance with a 2-sided test for proportions, 
assuming the proportion of individuals staying longer than 36 hours at ICU was 40% in the 
presence of sleep apnoea compared to 15% in its absence (based on unpublished internal 
preliminary data).  
Statistical analyses 
A parametric accelerated failure time model (Weibull regression) was used to 
analyse LoS as a continuous response to preselected predictor variables. 
Postoperative complications were dichotomised (yes/no) and analysed with a binary logistic 
regression. The same predictors used to analyse LoS (except complications) were used. 
For all regressions, parsimonious models were developed using a combination of, removing 
predictors, step-wise and manually, and interactions that did not reach 5% significance level.  
Results 
All patients older than 18 years, between March 2013 and July 2014, were screened 
and contacted by letter prior to surgery. A total of 152 patients consented to participate in the 
study, of whom 30 were subsequently excluded (Figure 2.5). Of the 122 patients remaining, 
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57 (47%) had a new diagnosis of sleep apnoea. Table 2.1 shows characteristics of study 
participants.
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Table 2.1 Baseline characteristics of study subjects 
Demographics All 
n=122 
No Sleep Apnoea 
(ODI<5/hr) 
n=65 (53%) 
  Sleep Apnoea 
(ODI≥5/hr) 
n=57 (47%) 
p 
Age yrs 70.3 (0.80) 70.6 (1.08) 69.9 (1.19) 0.69a 
BMI kg/m2 29.0 (0.42) 28.0 (0.52) 30.1 (0.64) 0.01a 
ODI 6.2 (0.49) 3.0 (0.16) 11.3 (0.94) <0.001a 
Mean SpO2 94.4 (0.29) 94.4 (0.43) 93.5 (0.39) 0.12
a 
ESS 6.5 (0.32) 6.2 (0.43) 6.7 (0.49) 0.47a 
EuroSCORE 4.7 (0.27) 4.5 (0.36) 4.9 (0.41) 0.52a 
LVEF 55.7 (1.31) 58.0 (1.37) 52.7 (2.3) 0.05a 
Male 107 (88%) 57 (88%) 50 (88%) 1b 
Smoking    0.88b 
Non smoker 44 (36%) 24 (37%) 20 (35%)  
Ex-smoker 69 (57%) 37 (57%) 32 (56%)  
Smoker 9 (7%) 4 (6%) 5 (9%)  
Habitual snorers    0.78b 
Never 20 (16%) 12 (18%) 8 (14%)  
Sometimes 75 (61%) 40 (62%) 35 (61%)  
Most Nights 23 (19%) 11 (17%) 12 (21%)  
Diabetes mellitus II 38 (31%) 17 (26%) 21 (37%) 0.24b 
COPD 12 (10%) 6 (9%) 6 (11%) 1b 
IOA 70 (57%) 39 (60%) 31 (54%) 0.58b 
CABG 84 (69%) 43 (66%) 41 (71%) 0.56b 
Continuous variables: mean (standard error); Categorical variables: total (% out of 122 patients); IOA: 
Intravenous Opiate Analgesia (administration of morphine sulphate in terms of patient controlled analgesia 
(n=66) or intravenous fentanyl (n=4)); CABG: Coronary artery bypass grafting without valve replacement/repair 
(the other interventions included CABG and valve); BMI: body mass index; ODI: 4% oxygen desaturation index; 
ESS: Epworth Sleepiness Scale score; LVEF: left ventricular ejection fraction; COPD: chronic obstructive 
pulmonary disease. a: t-test, b: Fisher’s exact test 
Primary Outcome Analysis 
The ICU LoS varied from 0.6 to 27 days with 88 patients (72%) remaining on ICU for 
36 hours or less. The median LoS in ICU was 0.95 days (95%CI 0.91-1 days) [Figure 2.6]. 
There was no significant association between ODI and ICU LoS (HR 1.0, 95% CI 0.99-1.02; 
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p=0.12). The most significant association with ICU LoS was the presence of postoperative 
complications in ICU (HR 3.7, 95% CI 2.8-4.8; p<0.001). Multivariate analysis showed that 
the effect of complications on LoS was the same across both surgical interventions (CABG 
and CABG/valve surgery).  
Fig 2.6. Kaplan-Meier cumulative probability of being discharged from ICU alive 
(“recovery”) over time, with 95%CI 
 
All patients stayed in the ICU for one night of observation, irrespective of the time of 
day they were admitted after surgery. Patients operated on earlier in the day were more 
likely to stay in the ICU over 24 hours than those admitted to ICU at the end of the day but 
no association between finishing time of surgery and LoS in ICU was found among patients 
who stayed in ICU 36 hours or less, using a simple linear regression of LoS in ICU onto 
finishing time of surgery (R2=46%, p=0.24).  
An association between opioid use and LoS in ICU was examined. There was no 
significant association between intravenous opioid analgesia and LoS on ICU. The hazard 
ratio for intravenous opioid analgesia (yes/no) on ICU LoS was 0.866 with CI=(0.693 to 
1.083), p=0.205.  
Secondary Outcome Analysis 
Thirty six patients (30%) met our criteria for postoperative complications. Of these, 21 
(58%) had sleep apnoea. The frequency and type of encountered complications are 
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described in Table 2.2.  Patients with sleep apnoea were found to have significantly higher 
frequency of cardiovascular (p=0.05) and renal (p=0.02) complications, compared to patients 
without sleep apnoea. The majority of cardiovascular complications consisted of shock 
requiring treatment including fluid resuscitation and/or inotropic support and the majority of 
renal complications included acute kidney injury requiring treatment.  
Table 2.2 Frequency and type of ICU complications in patients with and without sleep 
apnoea  
Complication No Sleep Apnoea 
ODI<5/hr (n=65) 
Sleep Apnoea 
ODI≥5/hr (n=57) 
p 
Cardiovascular 3 (3%) 9 (7%) 0.05 
Respiratory 7 (6%) 12 (10%) 0.14 
Neurological 2 (2%) 2 (2%) 1 
Renal 2 (2%) 9 (7%) 0.02 
Coagulation 2 (2%) 2 (2%) 1 
Arrhythmia 12 (10%) 8 (7%) 0.63 
Infection 4 (3%) 2 (2%) 0.68 
Reintubation 3 (3%) 2 (2%) 1 
CPAP/bi-level PAP 8 (7%) 9 (7%) 0.61 
30 days mortality 3 (3%) 2 (2%) 1 
ICU readmissions 3 (3%) 1 (0%) 0.62 
 
There was a significant association between ODI and postoperative complications in 
the ICU (OR=1.1 for each unit increase in  ODI; 95% CI 1.02-1.17; p=0.014), that is the 
probability of developing complications rose with increasing ODI, hence severity of sleep 
apnoea (Figure 2.7). As an example of 100 patients with euroSCORE=5 and ODI of 20 we 
would predict approximately 1/3rd would have a post-operative complication. The other 
independent predictors of postoperative complications were administration of intravenous 
opioid analgesia, in particular morphine sulphate and fentanyl, (OR=3.6; 95% CI 1.41-10.06; 
p=0.010) and euroSCORE (OR=1.3; 95% CI 1.15-1.61; p<0.001) [Table 2.3]. BMI was not 
found to be an independent predictor of complications. 
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Table 2.3 Independent predictors for development of ICU complications 
Variable OR 95% CI p 
 IOA 
(Intravenous opioid analgesia) 
3.6 1.41-10.06 P=0.010 
euroSCORE 1.3 1.15-1.61 p<0.001 
ODI 
(4% oxygen desaturation index) 
1.1 1.02-1.17 P=0.014 
 
Sleep apnoea was found to have the strongest effect on postoperative complications. 
Patients with sleep apnoea, but also those without who received intravenous opioids during 
their stay in ICU, had a higher probability of suffering postoperative complications with little 
difference in the absolute risk increase (Table 2.4). In the same table, the relative risk 
appears higher for patients without sleep apnoea reflecting low baseline risk of suffering 
complications in patients without sleep apnoea. No significant association was found 
between dose of intravenous opioids and the risk of postoperative complications (OR=1; 
95% CI = 0.98, 1.04; p=0.62). This could be due to the loss of statistical power as only 70 
out of 122 patients received intravenous opioids. Compared to patients without sleep apnoea 
those with received  more intravenous opioid, 17.5mg vs 21mg, but this difference was not 
statistically significant (p=0.51). 
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Figure 2.7. Predicted probabilities of suffering a complication at Intensive Care Unit in 
patients with  a euroSCORE=5, according to sleep apnoea severity and administration 
of intravenous opioid analgesia  
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Table 2.4 Predicted percentage of patients with postoperative complications 
according to sleep apnoea severity and administration of additional intravenous 
opioid analgesia (IOA), in patients with euroSCORE 5 
 No SA 
(ODI 3/hr) 
Mild SA 
(ODI 8/hr) 
Moderate/Severe SA 
(ODI 22/hr) 
 
No IOA / IOA 
 
 
13% / 35% 
 
19% / 45% 
 
44% / 74% 
ARI / RRI 
 
 
0.22 / 2.7 0.26 / 2.4 
 
 
0.30 / 1.7 
 
Predicted proportions are representative of patients with euroSCORE of 5 and ODI of 3/hr, 8/hr and 22/hr. These 
values were the observed mean euroSCORE and mean ODI in each SA severity class in our study population. 
ARI: absolute risk increase; RRI: relative risk increase 
 
Discussion 
The results of this study show that untreated sleep apnoea in a population of patients 
undergoing major cardiac surgery at Papworth Hospital is associated with an increased risk 
of postoperative complications, even though no significant association was found with LoS in 
ICU. The LoS in ICU was chosen as the primary outcome for the study, due to its tangible 
impact on healthcare cost and resources. In contrast a previously reported study, of  
retrospective national database data for 530,089 patients undergoing orthopaedic surgery,  
found a significant association between sleep apnoea and utilization of critical care 
resources and lengths of stay (Memtsoudis et al. 2014). In that study sleep apnoea had 
been previously diagnosed, which may indicate a different degree of physiological impact 
compared to the largely asymptomatic patients found on screening in the currentstudy. In 
addition, asymptomatic sleep apnoea was not excluded in the comparator group. Both of 
these points are relevant in any discussion of the value of screening surgical patients for 
sleep apnoea. However it is possible that the negative finding in the current  study may be 
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due to the smaller cohort size. It may also reflect a difference due to surgical procedure and 
patient cohort. 
ICU discharge is a complex process and depends on local policies and the 
availability of beds on the receiving ward over and above the clinical condition of the patient. 
It has previously been reported that institutional polices regarding ICU discharge affect ICU 
LoS (Widyastuti et al. 2012). Although there was no significant correlation between finishing 
time of surgery and LoS in ICU among patients who stayed in ICU 36 hours or less, for 
future studies the incidence of complications may represent a more appropriate study 
primary outcome. 
Previous retrospective analyses reported a relationship between OSA and 
postoperative complications in patients undergoing cardiac surgery. Three studies 
demonstrated an increased risk of atrial fibrillation following CABG surgery (Mooe et al. 
1996; Mungan et al. 2013; van Oosten et al. 2014), two studies reported prolonged 
mechanical ventilation (Bhama et al. 2006; Amra et al. 2014), three prolonged ICU and 
hospital length of stay (Bhama et al. 2006; Kaw et al. 2006; van Oosten et al. 2014) and one, 
post-operative infection and encephalopathy (Kaw et al. 2006). In contrast, 3 studies found 
no association between OSA and post-operative complications in patients undergoing CABG 
(Netzer et al. 1999; Foldvary-Schaefer et al. 2015; Uchoa et al. 2015), two of which were of 
prospective design and used polysomnography to screen for OSA. A possible reason why 
Foldvary-Schaefer did not show positive association between OSA and postoperative 
complications could have been small sample size as due to difficulty in recruitment the study 
was terminated earlier before reaching target sample size (Foldvary-Schaefer et al. 2015). 
Another possible explanation is that enhanced care and observation after major cardiac 
surgery mitigates the impact of OSA on postoperative outcomes. The study of Uchoa et al. 
was negative for short term, 30 days, postoperative complications, but in the longer term 
(mean follow up of 4.5 years) OSA was associated with increased risk of a need for new 
revascularization (19% vs 0%, p=0.01), episodes of typical angina (30% vs 7%, p=0.02) and 
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atrial fibrillation (22% vs 0%, p=0.007). As described in Chapter 1, OSA has been associated 
with endothelial dysfunction, increased inflammation, oxidative stress, and surges in 
sympathetic drive which may contribute to progression of atherosclerosis in the longer period 
following cardiac revascularisation surgery. Furthermore, the majority of patients in the 
current study as well as in the previous studies (Foldvary-Schaefer et al. 2015; Uchoa et al. 
2015) were found to have impaired ejection fraction and it is possible that longer term impact 
of OSA on heart remodelling may be a contributory factor in triggering AF in these patents 
following cardiac surgery. The results of the current study raise an important question of the 
longer term clinical and economic impact of OSA, beyond the postoperative period as well 
as the role of screening for OSA in this high risk population and more importantly the role of 
treatment, on both, short and long term outcomes. Further research is needed to answer 
these important clinical and economic questions.   
A recent prospective study reported that OSA may be a risk factor for postoperative 
delirium (Roggenbach et al. 2014). Other studies reporting an association between sleep 
apnoea and atrial fibrillation show conflicting results. Two studies (Mungan et al. 2013) and 
(van Oosten et al. 2014) used sleep questionnaires to diagnose sleep apnoea and reported 
a positive association. Mooe et al. who recorded prospective pre-operative sleep studies 
(Mooe et al. 1996) also reported a relationship between ODI and post-operative atrial 
fibrillation. Interestingly, no association was found between AHI and AF which raises the 
possibility that intermittent nocturnal hypoxiaemia is  the main contributor to postoperative 
arrhythmia in this patient cohort. Other studies, (Uchoa et al. 2015) and (Unosawa et al. 
2012), however, found no significant difference in the risk of  developing postoperative AF in 
patients with, compared to patients without sleep apnoea. Similarly, there was not a 
significant difference in frequency of postoperative arrhythmia in patients with sleep apnoea, 
compared to those without such a diagnosis in the study reported in this thesis. The reason 
for this disagreement is not obvious and may require further, larger studies to settle the 
question.  
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There was an association of sleep apnoea with postoperative complications, in 
particular cardiovascular, and renal (AKI) in the current study. An association between sleep 
apnoea and postoperative AKI was reported in a recent retrospective analysis of 
prospectively collected data in a multi-ethnic Asian population. In this study sleep apnoea 
was defined as AHI≥15, diagnosed using a monitor of peripheral arterial tone, and as in our 
study no distinction between obstructive and central sleep apnoea was made (Kua et al. 
2016). Although different mechanisms of OSA may predominate in Asian and Caucasian 
populations, our study, in a Caucasian population complements this previous evidence.  
I have extended this evidence showing that even patients with mild sleep apnoea in 
my series presenting for CABG or CABG and valve surgery had a higher risk of 
postoperative complications and that this risk increased with the severity of sleep apnoea. 
Up until now, only one previous retrospective study reported an association between severity 
of sleep apnoea and risk of postoperative outcomes in patients undergoing various general 
surgical procedures (Mutter et al. 2014). In view of the observational nature of my study it 
must be noted that it is not possible to confirm the causal relationship between sleep apnoea 
and the risk of postoperative complications reported in this thesis. 
Another  predictor which associated  with postoperative complications in our patients 
was the administration of intravenous opioids on ICU. It is proposed that opiates/opioids 
could worsen the severity of OSA in perioperative settings due to their effect on ventilatory 
drive and upper airway dilator muscles (Kaw et al. 2006) but it is also reported that in the 
majority of OSA patients, with frequent obstructive events and mild-to-moderate hypoxemia, 
the sedative effect of opioids may stabilise airway patency and breathing and paradoxically 
improve OSA (Wang et al. 2013). In my cohort of patients the majority had  mild or  
moderate sleep apnoea.  
In the current study, patients with sleep apnoea, but also those without were found to 
be at higher risk of postoperative complications when given postoperative opioids and the 
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absolute risk increase did not differ significantly between the diagnostic groups, that is 
patients with and without sleep apnoea. I have not found that intravenous opioids 
lengthened overall LoS but they did  lengthens LoS in the CABG+valve type surgery. 
Although speculative, it is possible, that patients requiring intravenous opioids were a 
generally more vulnerable sub-population. As described in Chapter 1 in paragraph “Opiates 
and opioids in OSA”, both intermittent hypoxia and sleep disruption augment pain, but  
intermittent hypoxia may  potentiate opioid analgesic responses. Contrary to this hypothesis 
when I assessed the dose of opioids required for postoperative analgesia, patients without 
sleep apnoea compared to those with received on average less intravenous opioid, 17.5mg 
vs 21mg, a not significant difference. Clearly we failed to show lower doses in sleep apnoea 
patients.  
The result of my study complements the evidence for high prevalence of sleep 
apnoea (47% for ODI≥5/hr) amongst patients undergoing cardiac revascularisation 
procedures. In the two prospective studies in patients undergoing CABG surgery, 
undiagnosed OSA (AHI ≥5/hr) was found in 74% and 87% of patients on nocturnal 
polysomnography (Foldvary-Schaefer et al. 2015; Uchoa et al. 2015). The majority of 
breathing events in one study were reported as hypopneas and although polysomnography 
was used the authors comment on the inability to distinguish between obstructive and 
central hypopneas (Foldvary-Schaefer et al. 2015). It is possible that patients with central 
sleep apnoea were included in the quoted prevalence. The higher prevalence in these 
studies, compared to prevalence in the current study, may be explained by the diagnostic 
methods used. The severity of sleep disordered breathing recorded on polysomnography is 
likely to be higher than oximetry as the presence of apnoea or hypopnoea can be scored 
against 3% ODI and  nocturnal arousals.  
With regards to patients’ demographics, the current study showed that patients with 
sleep apnoea had significantly higher BMI, which is the strongest risk factor for OSA 
(Peppard et al. 2000) but there was no significant difference between the sleep apnoea and 
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non-sleep apnoea groups, in terms of other conventional risk factors for OSA such as age or 
sex. One  possible explanation for this finding may be that patients presenting for cardiac 
revascularisation surgery in general (but also in this study) do not represent a typical OSA 
cohort but are older (mean age 70yrs) and more predominantly male (88%).  
One demographic factor found in this patient cohort undergoing CABG surgery which 
has also previously been reported in aforementioned studies by Uchoa et al and Foldvary-
Schaefer etal. is that patients with sleep apnoea have lower left ventricular ejection fraction 
compared to those patients without sleep apnoea. An association of OSA and heart failure 
has previously been reported in the Sleep Heart Health Study of 6424 participants where 
OSA (defined as AHI ≥11/h) conferred a 2.38 relative increase in the likelihood of having 
heart failure, independent of other known risk factors (Shahar et al. 2001). In the two large 
case series of patients with heart failure undergoing polysomnography, OSA was identified 
in 37% of 450 participants (Javaheri et al. 1998) with the prevalence of OSA greater in men 
(38%) than in women (31%) (Sin et al. 1999). The reported risk factors for OSA differed 
between men and women with the main risk factor in men being obesity, whereas in women 
it was older age. Patients with OSA and concomitant heart failure and peripheral vascular 
disease have previously been shown  to have asymptomatic OSA (Somers et al. 2008; 
Utriainen et al. 2013). Similarly, the current cohort of patients, with significant ischaemic 
heart disease, presents in the main with asymptomatic sleep apnoea. There was no 
significant difference in mean ESS between patients with sleep apnoea and those without: 
6.2 (0.43) vs 6.7(0.49).  
This study has  limitations. Firstly, it is not possible to distinguish between central and 
obstructive sleep apnoea with nocturnal oximetry alone. In the UK, around two thirds of 
respiratory sleep studies do employ just oximetry (Flemons et al. 2004). A high resolution 
oximeter represents an economical and practical screening tool prior surgery and an ODI 
>10 was previously found to have a sensitivity of 93% and specificity of 75% against 
respiratory polygraphy to detect moderate and severe OSA in patients undergoing general 
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surgery (Chung et al. 2012). For the current study we were not able to perform respiratory 
polygraphy for practical reasons, mainly as respiratory polygraphy was felt to be more 
disruptive to the patient’s sleep on the night before major surgery.  In addition, relying on 
Electronic Medical Records as the main source of postoperative complications is opened to 
recording bias as not all of the complications may have been strictly recorded. There was a 
high rate of non-recruitment from potentially eligible participants which may affect the 
generalisation of our results. 
Conclusion 
Despite its limitations, this study is the first prospective study using recognised a sleep 
diagnostic that reports an association of increasing severity of sleep apnoea with 
postoperative complications in patients undergoing CABG and CABG/valve surgery. 
Interestingly, even patients with ODI 5-15/hr , often regarded as clinically insignificant, had a 
higher probability of developing post-operative complications than patients with no 
desaturations overnight preoperatively. There was no association between sleep apnoea 
and ICU LoS. This negative finding may be due a relatively small sample size in the current 
study or local discharge policy in ICU and larger future studies may clarify this finding. We 
also found that intravenous opioids administered after surgery were independently 
associated with postoperative complications both in patients with and without sleep apnoea.  
Future directions 
Acknowledging the study’s limitations, my results raise an interesting question worth 
further research. Examining the literature, the effect of opiates and opioids on post-operative 
outcomes in patients with sleep apnoea has to date been described in case reports and one 
retrospective review only (Esclamado et al. 1989; Ostermeier et al. 1997). The results of this 
study complement existing literature on the importance of sleep apnoea as a predictor of 
postoperative morbidity. There are currently no randomised controlled trials reporting any 
effects of perioperative continuous positive airway pressure on postoperative complications 
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in patients with OSA and the results of this study strengthen the case for further research to 
assess the clinical and economic impact of perioperative treatment with continuous positive 
airway pressure. 
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Chapter 3 
Utility of the STOP-Bang questionnaire in cardiac surgical cohort 
Null Hypothesis 
The STOP-Bang questionnaire cannot reliably identify patients at high risk of sleep 
apnoea and postoperative complications in pre-operative setting, in patients presenting for 
major cardiac surgery. 
Introduction 
In Chapter 2, I have reported a significant association between sleep apnoea 
(defined as continuous variable of ODI) and post-operative complications, in particular 
cardiovascular and renal, in patients with newly diagnosed, untreated sleep apnoea.  The 
aim of the study reported in this Chapter was to examine if the STOP-Bang questionnaire is 
a useful tool to identify patients who may benefit from a sleep study, such as oximetry, which 
in turn might identify those patients who are at higher risk of developing postoperative 
complications. I have also examined if the STOP-Bang score can predict those patients with 
worse postoperative outcomes. 
The STOP-Bang questionnaire was developed and validated in a general surgical 
population (Chung et al. 2008) and has been adopted as a screening tool in surgical pre-
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assessment clinics for its ease of  use. In systematic reviews of screening questionnaires for 
OSA, the STOP-Bang questionnaire had the highest methodological validity, moderately 
high sensitivity and best negative predictive value for assessing the risk of moderate/severe 
OSA (Abrishami et al. 2010; Chiu et al. 2017). It was found that the higher the STOP-Bang 
score the greater the probability of OSA (Nagappa et al. 2015) and a high risk STOP-Bang 
score could  predict an increased risk of postoperative pulmonary and cardiac complications 
in patients undergoing various surgical procedures (Nagappa et al. 2017). In the STOP-Bang 
validation studies, selection bias and high prevalence of OSA in the studied population may 
have influenced the results and therefore validation in specific target populations has been 
recommended (Chung et al. 2016). To my knowledge, the STOP-Bang questionnaire has 
not previously been validated in a surgical cohort undergoing cardiac bypass and valve 
surgery. 
In this study of patients undergoing elective coronary artery bypass grafting (CABG) 
with or without cardiac valve surgery, I examined the diagnostic performance of the STOP-
Bang questionnaire against an arterial oxygen desaturation index (ODI = number of dips of 
greater than 4% or more, per hour sleep), from nocturnal oximetry. I also explored 
associations between STOP-Bang scores and post-operative outcomes.  
Methods 
Ethical approval for this prospective observational cohort study was granted by The 
National Research Ethics Service East Midlands Northampton Proportionate Review Sub-
committee (12/WM/0433). All participants who agreed to enter the study gave signed, 
informed consent. 
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Population cohort 
Population 
Inclusion Criteria 
 Age >18 years 
 Listed for elective surgical coronary revascularisation with or without cardiac valve 
surgery 
Exclusion Criteria 
 Inability to give informed consent or comply with the protocol 
 Emergency surgical coronary revascularization or valve surgery 
 Tracheostomy before surgery 
 Enrolment in another concurrent interventional research study likely to impact of 
study outcomes 
Eligible participants were admitted on the night before surgery and had medical history 
and clinical measurements recorded including weight, height, body mass index and neck 
circumference. All participants completed the STOP-Bang questionnaire and Epworth 
Sleepiness Scale.  
Sleep apnoea assessment and data collection 
All participants included in this prospective observational cohort  study completed the 
STOP-Bang questionnaire (Figure 2.1) (Chung et al. 2008) which consists of 8 questions 
scored as yes/no response. The total score can range from 0-8 according to the number of 
positive answers. From previous data, patients scoring ≥3 on STOP-Bang have been 
perceived to be at high risk of OSA (Chung et al. 2008). 
In addition to the STOP-Bang score, all participants underwent nocturnal oximetry on 
the night before surgery while self-ventilating on room air. The oximetry results were 
automatically analysed (Visidownload, Stowood Ltd, Oxford UK) and reviewed by a sleep 
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physician, blinded to all clinical data. The anaesthetic and surgical teams had no access to 
the results of preoperative nocturnal oximetry. Sleep apnoea was diagnosed in patients with 
an ODI greater than 5. The oximeter was programmed to average measurements over 1 
second. Nocturnal monitoring without at least 4 hours of adequate data was excluded as per 
our usual accepted practice. The results are reported as sleep apnoea since nocturnal 
oximetry cannot distinguish between obstructive and central sleep apnoea. Demographic 
information, comorbidities, ESS (Johns 1991) and the EuroSCORE were recorded 
prospectively, on the night of admission.  The EuroSCORE, a mortality risk score developed 
for patients undergoing cardiac surgery, was calculated for all patients (Nashef et al. 1999). 
Data regarding postoperative complications were collected from the digital Clinical 
Information System in the ICU.  
Outcomes 
The primary outcome was to assess the diagnostic performance of the STOP-Bang 
questionnaire against ODI from nocturnal oximetry by calculating sensitivity, specificity, 
positive predictive value, negative predictive value and area under receiver operating 
characteristic curve.   
The secondary outcome was length of stay (LoS) in ICU (days) and a composite 
measure of post-operative complications in ICU that included: use of continuous positive 
airway pressure (CPAP)/bi-level positive pressure ventilation via a mask after extubation, re-
intubation, occurrence of new arrhythmias necessitating drug treatment or intervention, need 
for additional organ support (intra-aortic balloon pump/ haemofiltration), major organ 
complication (defined as those requiring treatment or intervention  for cardiovascular, 
respiratory, renal, neurological, hepatic, coagulation), readmission to ICU and  30 days 
mortality. 
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Predictor variables 
The primary predictor variable was the STOP-Bang score analysed as a continuous 
variable. Additional predictor variables thought to be risk factors relevant to the outcomes 
included EuroSCORE, age, body mass index, surgery type, administration of intravenous 
opioid analgesia (either intravenous morphine sulphate or fentanyl) during ICU stay, 
comorbidities and mean nocturnal oxygen saturations.   
Statistical analysis 
Descriptive statistics are shown for the variables used in this study (Table 3.1). 
Continuous variables are reported as mean (SE), categorical variables as percentages. The 
severity of SA according to ODI was defined as follows: no SA if ODI<5, mild SA if ODI≥5 
and <15, moderate SA if ODI≥15 and <30 and severe SA when ODI≥30. The prevalence of 
SA according to severity was calculated.  
The area under receiver operating characteristic curves (AUC-ROC) was calculated 
to assess discriminating ability of different STOP-Bang scores for sleep apnoea. The ROC 
curves were used to identify the best STOP-Bang discriminating score in terms of sensitivity 
and specificity for predicting sleep apnoea. The STOP-Bang diagnostic performance for mild 
and moderate/severe sleep apnoea, at both the conventional cut off value ≥3, and at the 
best discriminating value was assessed using multiple 2x2 contingency tables and 
expressed as sensitivity, specificity, positive predictive value (PPV) and negative predictive 
value (NPV). 
A parametric accelerated failure time model (Weibull regression) was used to 
analyse LoS as a continuous response to preselected predictor variables. Postoperative 
complications were dichotomised (yes/no) and analysed with a binary logistic regression 
using the same predictors used to analyse LoS. For all regressions, parsimonious models 
were obtained with a combination of step-wise and manually removing predictors and 
interactions that did not reach 5% significance level.  
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Results 
A total of 322 patients were screened for eligibility of whom 152 underwent 
preoperative evaluation with STOP-Bang questionnaire and nocturnal oximetry. Of these, 30 
patients were excluded (Figure 2.5). A total of 122 patients were included in the final 
analysis. Of those, 6 patients (5%) scored low risk for OSA using the STOP-Bang score 
whilst 116 (95%) scored high risk (STOP-Bang ≥ 3). Sleep apnoea was diagnosed by 
nocturnal oximetry in 57 patients (47%). Table 2.1 shows the demographics of individuals 
included.  
Diagnostic performance of STOP-Bang against ODI from nocturnal oximetry 
It was found that the STOP-Bang score poorly predicted patients with mild SA [AUC-
ROC 0.57 (95% CI 0.47-0.67)] but was better for patients with moderate SA [AUC-ROC 0.82 
(95% CI 0.69-0.95)]. Setting the STOP-Bang score at ≥6 improved the accuracy in terms of 
sensitivity (75%) and specificity (77%) in detecting moderate/severe SA (Figure 3.1).
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Figure 3.1. Receiver operating curves (ROC) for STOP-Bang to predict ODI≥5 and 
ODI≥15. The AU ROC curve was 0.57(CI: 0.47-0.67) for ODI≥5 and 0.82 (CI: 0.69-0.95) 
for ODI≥15  
 
At the conventional cut off value of ≥3, the STOP-Bang score demonstrated high 
sensitivity for mild (95%) and moderate/severe sleep apnoea (100%), but the specificity was 
very low (5% and 6% respectively). In view of 100% sensitivity and 100% NPV for 
moderate/severe sleep apnoea, STOP-Bang scores of 0-2 would confidently exclude 
patients with at least moderate sleep apnoea, in the cardiac pre-operative settings. However, 
in our population only 6/122 (5%) scored low risk for sleep apnoea. 
Assessing predictive value for severe sleep apnoea was not possible due to the lack 
of severe sleep apnoea cases. The sensitivity, specificity, NPV and PPV for STOP-Bang at 
cut off values ≥3 and ≥6 are summarised in Table 3.1. 
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Table 3.1 Sensitivity, Specificity, positive predictive value and negative predictive 
value of STOP-Bang questionnaire for predicting mild (ODI≥5) and moderate/severe 
SA (ODI≥15) 
 
 
 
 
 
 
 
 
 
 
 
NPV: negative predictive value; ODI: 4% oxygen desaturation index; PPV: positive  
predictive value; SA: sleep apnoea 
 
Secondary outcome analysis 
The median LoS in ICU was 0.95 days (95%CI 0.91-1 days). In the multiple logistic 
regression models we found that there was no significant association between STOP-Bang 
scores and LoS in ICU (HR 1.1, 95% CI 0.99-1.19; p=0.08) and no significant association 
between STOP-Bang scores and postoperative ICU complication (OR 1.0, 95% CI 0.59-
1.72; p=0.98). 
 
STOP-Bang ≥3 Mild SA 
(ODI ≥5-14 /hr) 
Moderate/Severe SA 
(ODI ≥15/hr) 
Sensitivity (%) 95 100 
Specificity (%) 5 6 
PPV (%) 47 10 
NPV (%) 50 100 
STOP-Bang≥6 Mild SA 
(ODI ≥5-14 /hr) 
Moderate/Severe SA 
(ODI ≥15/hr) 
Sensitivity (%) 32 75 
Specificity (%) 75 77 
PPV (%) 53 27 
NPV (%) 56 97 
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Discussion 
In our study population of predominantly men, all with cardiac disease, the STOP-
Bang questionnaire had poor diagnostic accuracy in detecting sleep apnoea. Many patients 
would be falsely positive when using the generally accepted cut off value of ≥3, leading to 
inappropriate utilization of sleep diagnostics and potentially delays in surgery. However, 
STOP-bang scores lower than 2 would allow confident exclusion of moderate/severe sleep 
apnoea in patients, but as only 5% of patients scored at that level, only a small proportion of 
patients not suffering from OSA would be excluded.  
The poor performance of the STOP-bang score in my patient cohort is explained by 
the inherent characteristics of the cardiac surgical population (male, older, majority suffering 
hypertension) that are common to the traits detected by the STOP-Bang questionnaire. 
The STOP-Bang questionnaire was introduced as a scoring model in the general surgical 
population to identify  patients at risk of  undiagnosed moderate/severe OSA prior to surgery. 
In the general surgical population, at a cut-off level of ≥3, it showed sensitivity and specificity 
for moderate OSA of 93% and 43% respectively and for severe OSA of 100% and 37% 
(Chung et al. 2008). The NPV for moderate and severe OSA was 90% and 100% 
respectively and therefore scores of 0-2 would, with high confidence, exclude patients with 
moderate to severe disease in patients presenting for general surgery. In view of its low 
specificity for moderate and severe OSA in the general surgical cohort, its predictive 
probability was examined at the higher scores and it was found that scores over 5 identified 
patients with high probability of moderate/severe OSA (Chung et al. 2012).   
In contrast to previous reports, where patients undergoing general surgery scoring 
high on STOP-Bang questionnaire had higher odds of developing post-operative 
complications (Nagappa et al. 2017) I have not shown a significant association between 
STOP-Bang scores and ICU LoS or risk of developing post-operative complications which 
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may be due to low specificity of the questionnaire at the conventional cut of value ≥ 3, falsely 
identifying patients with the disease. 
In the current patient cohort, I found that the best discriminating score for 
moderate/severe sleep apnoea was at ≥6. This score would decrease the false positive rates 
for predicting sleep apnoea, but at the expense of lower sensitivity and up to 25% of patients 
with moderate/severe sleep apnoea will still have either a falsely positive or negative results.  
In Chapter 3 I reported a significant association between sleep apnoea, defined as the 
continuous measure of ODI, with postoperative complications (Mason et al. 2017) which 
adds to the evidence of a positive association between untreated sleep apnoea and 
postoperative complications in patients undergoing cardiac surgery (Nagappa et al. 2017). 
The results of the current study suggest that a STOP-Bang score ≥6 in the cardiac surgical 
population could identify those in need of further screening for sleep apnoea. As ODI ≥5 
from nocturnal oximetry identified patients who had higher probability of developing 
cardiovascular and renal complications, using nocturnal oximetry in all patients scoring ≥6 on 
the STOP-Bang score could help with planning of perioperative care. Data from randomised 
controlled trials are still needed to define the clinical effectiveness and cost implications of 
screening and treatment of OSA prior surgery (Nagappa et al. 2015) but whilst this is 
awaited identifying patients with untreated sleep apnoea before cardiac surgery may help 
with perioperative precautions and airway management. In addition, it has been reported 
that patients with untreated OSA have increased risk of long term cardiovascular 
complications and therefore identifying and treating these patients may have long term 
benefits but further research is necessary to confirm this.  
The limitations of the current study include the lack of patients with severe SA and 
therefore the utility of STOP-Bang in such patients remains unknown. The STOP-Bang was 
not compared to formal polysomnography but in the UK around two thirds of respiratory 
sleep studies use oximetry alone (Flemons et al. 2004). It is possible that some of the 
patients with raised ODI had central sleep apnoea but in view of previously reported positive 
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association between oxygen desaturations from nocturnal oximetry (ODI) and worse 
postoperative outcomes in cardiac surgical cohort (Mason et al. 2017), identifying patients at 
risk of sleep apnoea with help of STOP-Bang questionnaire may help to recognise patients 
in need of nocturnal oximetry and subsequently those who may be at risk of postoperative 
complications. Patient selection bias may be responsible for the high prevalence of OSA 
found in our study.  
In conclusion, the STOP-Bang questionnaire had limited diagnostic value in 
identifying patients at high risk of SA prior to major cardiac surgery at the conventional cut of 
≥3, but scores ≤2 were highly predictive of the absence of SA. A STOP-Bang score ≥6 would 
be more accurate but still be falsely positive or negative in up to 25% of patients. Due to its 
high specificity, a STOP-Bang score ≥6 in the cardiac surgical population could identify 
some people for further screening for sleep apnoea using nocturnal oximetry. STOP-Bang 
scores were not significantly associated with worse post-operative outcomes in this cohort, 
contrary to previous reports in patients undergoing general surgical procedures.  
Future directions 
As described in Chapter 1 to deal with the low specificity issue of the STOP-Bang 
questionnaire specific aspects of STOP-Bang score have been evaluated in the general 
surgical population and found to increase the specificity including  BMI more than 35 kg/m2, 
male sex and neck circumference more than 40 cm. In addition, serum HCO3- of at least 
28mmol/L has also been reported to increase the specificity of STOP-Bang questionnaire 
(Chung et al. 2013). In this study, I have not evaluated the impact of these  aspects on the 
sensitivity and specificity of STOP-Bang questionnaire as when planning my research these 
results were not available. To increase the diagnostic value of the STOP-Bang questionnaire 
in a cardiac surgical population and to rationalise the use of sleep diagnostics before surgery 
these additional aspects may deserve further research. Based on the results of my study 
reported in this Chapter and previously proposed 2 step approach of screening for OSA in 
general surgical cohort, this approach may warrant validation in cardiac patients in that if 
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patients score 0-2, low risk of moderate to severe OSA is suspected. If patient scores ≥6 
they have high probability for moderate to severe OSA and further assessment by a sleep 
physician may be needed. The intermediate risk would represent patients with scores 3, 4 
and who could be further stratified as high risk of OSA based on the validation of 
aforementioned additional aspects of the STOP-Bang, namely:  BMI more than 35 kg/m2, 
male sex, neck circumference more than 40 cm along with the serum HCO3- of at least 
28mmol/L. It has to be remembered that before universal screening is adopted the effect of 
treatment needs evaluation. If no improvement in postoperative outcomes is achieved by 
treating OSA in surgical patients there may be no need for screening for this condition in 
preoperative setting.  
Chapter 4 
Systematic Cochrane review:  Effects of opioid, hypnotic and sedating medications 
on sleep-disordered breathing in adults with obstructive sleep apnoea 
My personal involvement in this research includes: Developing the idea for the review 
and writing up the protocol with help and overview of Dr Ian Smith. The electronic searches 
were performed by the Cochrane Airway group.  I have assessed the abstracts for eligibility 
along with Dr Kate Chong (KC). I and KC independently screened the full text, identified 
studies for inclusion and recorded reasons for exclusion of ineligible studies. I have 
extracted the data and transferred it into data manger (RevMan). I have analysed the data 
with the help of Dr Chris Cates from Cochrane Airway Group and written the review with help 
from Dr Ian Smith. 
The review was published in July 2015 (Mason M, Cates CJ, Smith I. Effects of 
opioid, hypnotic and sedating medications on sleep- disordered breathing in adults with 
obstructive sleep apnoea. Cochrane Database Syst. Rev. 2015 Jul 14;7:CD011090 
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Introduction 
The observational cohort study described in Chapter 3 showed an association between 
intravenous opioids and postoperative complications in patients undergoing cardiac surgery. 
This gave grounds for examining the current evidence base for the effect of opioids and 
sedatives on patients with OSA. Patients with OSA and those at risk for OSA along with the 
rest of population are likely to have conditions such as anxiety and chronic pain and may be 
presenting for surgery and may be in need of these pharmacological agents. Administration 
of such drugs to patients with OSA may exacerbate nocturnal hypoxaemia and the severity 
of SDB (Walker et al. 2007; Yue et al. 2010). It is proposed that opiates/opioids could 
worsen the severity of OSA in perioperative settings due to their effect on ventilatory drive 
and upper airway dilator muscles (Kaw et al. 2006). In the SACS study, described in Chapter 
3, not only patients with sleep apnoea, but also those without were found to be at higher risk 
of postoperative complications when given postoperative opioids. The British National 
Formulary (BNF) advises physicians not to prescribe hypnotics to patients with severe OSA 
and/or OSAS and to avoid opioids in patients suffering acute respiratory depression. Caution 
is also advised when administering such drugs to patients with OSA peri-operatively (Gross 
et al. 2006). This review examines the evidence concerning the safety of sedatives and 
hypnotics in patients with pre-existing OSA, especially regarding their effect on the 
frequency and/or severity of apnoeas and/ or hypopnoeas during sleep and addresses 
whether the anxieties regarding prescribing these drugs to patients with OSA are justified. 
This review was constructed using the Cochrane methodology with the assistance of 
Cochrane airway group and published in the Cochrane library (Mason et al. 2015) . 
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Description of conditions for which prescription of hypnotic or sedative drugs may be 
desirable 
Opiates and opioids 
Opiates and opioids are used to treat acute and chronic pain, as well as respiratory 
distress. Morphine is a strong opiate and is a valuable analgesic for severe pain including 
during palliative care. Codeine is a weak opiate that is used for the treatment of mild to 
moderate pain. Alfentanil, fentanyl and remifentanil are used intravenously to treat pain 
during surgery, and fentanyl is also available in a skin patch preparation to treat chronic 
intractable pain. Other opiate and opioid drugs are used during and after surgery. 
Sedatives and hypnotics 
Benzodiazepines (BZDs) are indicated for short-term relief of severe anxiety, 
behavioural disturbance or agitation, as well as panic disorders when antidepressants do not 
control symptoms. Furthermore, some BZDs are used to control and prevent seizure activity, 
to relieve chronic muscle spasm, in some sleep-related disorders including insomnia 
(difficulty initiating or maintaining sleep) and in conditions in which an increase in motor 
activity during sleep occurs, including REM behaviour disorders. Non-BZD gamma-
aminobutyric acid A (GABAA) receptor agonists (novel hypnotics and 'Z drugs') are licensed 
for treatment of sleep-onset insomnia (difficulty falling asleep) and sleep-maintenance 
insomnia, to be taken in the middle of the night should waking occur. Gabapentin and 
pregabalin are used for the  treatment of seizure activity and neuropathic pain. Pregabalin is 
also licensed for the treatment of anxiety. Sodium oxybate (SXB) is used in narcolepsy with 
cataplexy. People with narcolepsy and cataplexy experience periods of extreme daytime 
sleepiness and sudden loss of voluntary muscle tone in emotionally charged situations 
(cataplexy), which SXB can reduce. 
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Melatonin and melatonin-related drugs 
Melatonin is licensed for the short-term treatment of insomnia and can help to 
promote regular sleep-wake cycles with adaptation to time zone changes (jet lag). 
Description of intervention 
Opiates and opioids 
The term 'opiates' refers to the alkaloids found naturally in the opium poppy; 
examples include morphine, codeine and thebaine. Synthetic and semi synthetic drugs with 
opium- or morphine-like pharmacological action are referred to as opioids and include 
hydrocodone, hydromorphone, oxycodone and oxymorphone among others. Opiates and 
opioids bind to four different classes of receptors, namely δ, κ, µ and the 
nociception/orphanin receptor. These receptors mediate and regulate pain, stress responses 
and respiration. Ligands that stimulate κ and µ receptors suppress respiratory pattern 
generation, leading to a decrease in respiratory rate and tidal volume (Lalley 2008). Opiates 
and opioids are widely used for treatment of acute and chronic pain 
Sedatives and hypnotics 
Agents described in this review include BZDs, non-BZD GABAA receptor agonists 
(novel hypnotics and 'Z drugs'), gabapentin, pregabalin and SXB. Most hypnotics work as 
GABA receptor modifiers. BZDs interact with GABAA receptors and enhance the effects of 
GABA, leading to hypnosis, anxiolysis, muscle relaxation, amnesia and anticonvulsant 
effects. The pharmacokinetics of BZDs vary. They can be divided into short-, intermediate- 
and long-acting agents. Non-BZD GABAA receptor agonists also bind to the GABAA receptor 
complex but at a different site than BZDs. These agents also cause sedation but less 
prominent muscle relaxation and anxiolysis. They have rapid onset and a short to 
intermediate duration of action. Examples include zolpidem, zaleplon, zopiclone and 
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eszopiclone. They are used mainly for sleep-onset and sleep-maintenance insomnia. 
Gabapentin increases the GABA content of neurones, and pregabalin has an effect on 
GABA transmission. Both of these drugs increase deep sleep and thereby improve the 
subjective quality of sleep (Holsboer-Trachsler et al. 2013).Sodium oxybate is used in the 
treatment of narcolepsy with cataplexy. Its mechanism of action is uncertain, but it has some 
affinity for gamma-aminobutyric acid B (GABAB) receptors and is a potent hypnotic (Huang 
et al. 2009).   
Melatonin and melatonin-related drugs 
Melatonin is synthesised within and secreted from the pineal gland. Oral 
administration of melatonin induces drowsiness, particularly if administered during the day, 
when naturally produced melatonin levels are low. The melatonin receptor-agonist, 
ramelteon, has been developed with the advantage of a longer half-life and increased 
bioavailability. 
The pharmacological substances described in this review might affect the 
pathophysiology of OSA in many different ways but are largely thought to be deleterious 
(Younes 2004; Jordan et al. 2007). Caution, which is based on low-quality evidence, has 
been advised when such substances are prescribed for people with OSA. 
Many other agents have been noted to have soporific effects, including tricyclic 
antidepressants, antihistamines, antipsychotic drugs and alpha-adrenoceptor blockers. 
These agents are not approved sedatives or hypnotics and are beyond the scope of this 
review. The effects of antidepressants on OSA has been addressed in the Cochrane review, 
"Drug therapy for obstructive sleep apnoea in adults" (Mason et al. 2013). 
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How the intervention might work and what effects it may have on obstructive sleep 
apnoea 
Opiates/opioids reduce respiratory rate and tidal volume while decreasing UA muscle 
tone and the compensatory response to increased UA resistance (Santiago et al. 1985; 
Leino et al. 1999; Lalley 2008). This would suggest that opioids may have an adverse impact 
on respiratory function in people with SDB. Furthermore, opioids decrease 
chemoresponsiveness to hypercapnia/hypoxia, leading to concerns that ventilatory response 
in people with OSA who are given opioids will not be sufficient to restore normal arterial 
blood gas tension after an apnoea (Drummond 1983; Robinson et al. 1987). A deleterious 
effect of BZDs on people with OSA has been proposed as a result of their known muscle-
relaxing effects leading to reduced UA muscle tone and increased UA resistance. A further 
concern is blunting of the respiratory response to hypoxia (Bonora et al. 1985; Leiter et al. 
1985). Non-BZD GABAA receptor agonists have less effect on muscle tone, and it has been 
proposed that they are safer for people with SDB, including OSA (Rosenberg et al. 2007).  
Objectives   
1. To investigate whether administration of sedative and hypnotic drugs 
exacerbates the severity of OSA (as measured by AHI or 4% ODI) in people 
with known OSA. 
Methods 
Types of studies   
Randomised controlled trials, double- or single-blinded, of parallel-group or cross-
over design were included in this review. Studies included required a sleep study to confirm 
the diagnosis and severity of OSA and a subsequent sleep study on 
opioids/sedatives/hypnotics or placebo (or both in cross-over designs) as 
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comparator.  Studies reported as full text, abstract only and as unpublished data were all 
included. 
Types of participants   
Adult participants with an existing diagnosis of OSA based on a history of associated 
symptoms and results of sleep studies with an ODI or AHI of five or more per hour were 
included including participants already using continuous positive airway pressure (CPAP) or 
a mandibular advancement device. 
Types of interventions   
Trials in which participants were randomly assigned to use sedatives, hypnotics 
(including BZD, non-BZD GABAA receptor agonists (novel hypnotics and 'Z drugs'), 
gabapentin, pregabalin, sodium oxybate, melatonin or related drugs, opiates and opioids) or 
placebo were included. These drugs could be administered intravenously, orally or topically 
and no restriction was placed on study duration. 
Types of outcome measures   
All outcome variables were measured during the baseline sleep study and the sleep 
study during the study night during which participants received study medication. The sleep 
studies in question included nocturnal oximetry, rPG and full polysomnography.  
Primary outcomes   
 apnoea-hypopnoea index (AHI) 
 oxygen desaturation index (ODI) 
Secondary outcomes   
 time spent with arterial saturation less than 90% (TSpO2 < 90%) 
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 minimum arterial saturation during sleep (minimum SpO2) 
 respiratory disturbance index (RDI) is reported during polysomnography and includes 
AHI as well as respiratory effort related arousals recorded during sleep by EEG 
 arousal index- The number of arousals and awakenings registered in the study, and 
reported as a total number and frequency per hour of sleep 
 total sleep time (TST) – “The amount of actually sleep time in a sleep episode; 
this time is equal to the total sleep episode less the awake time. TST is the total of all 
REM and NREM sleep in a sleep episode” 
 apnoea index (AI)-number of apnoea events per hour sleep 
 hypopnoea index (HI)- number of hypopnoea events per hour sleep 
 objective measurement of daytime sleepiness including MSLT or MWT described in 
previous chapter 
 adverse events/side effects 
 ESS 
Search methods for identification of studies   
Electronic searches   
Trials were identified from the Cochrane Airways Group Specialised Register 
(CAGR), which is maintained by the Trials Search Co-ordinator for the group. This register 
contains trial reports identified through systematic searches of bibliographic databases 
including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, 
EMBASE, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), the Allied 
and Complementary Medicine Database (AMED) and PsycINFO, as well as by hand 
searching of respiratory journals and meeting abstracts. The latest search was conducted on 
4 March 2015. To identify the most current literature, additional searches were conducted of 
the following databases: CENTRAL (searched 4 March 2015 via the Cochrane Register of 
Studies Online); MEDLINE (searched 5 March 2015 via Ovid) and EMBASE (searched 5 
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March 2015 via Ovid). A search of ClinicalTrials.gov (www.ClinicalTrials.gov) and the World 
Health Organization trials portal (www.who.int/ictrp/en/) was also conducted. All databases 
from their inception with no restriction on language or type of publication were searched. 
Searching other resources   
Reference lists of all primary studies and review articles were checked for additional 
references and relevant manufacturers' websites for trial information. 
Selection of studies   
Two review contributors (MM and KC) independently screened titles and abstracts for 
inclusion of all potential studies identified as a result of the search and coded them as 
'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. The full-text study 
reports/publications were retrieved, and two review contributors (MM and KC) independently 
screened the full text, identified studies for inclusion and recorded reasons for exclusion of 
ineligible studies. Disagreements were resolved through discussion. Duplicates were 
identified and excluded. The selection process was recorded in sufficient detail to complete a 
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow 
diagram  
Data extraction and management   
One review author (MM) extracted the following study characteristics from included studies. 
 methods: study design, total duration of study, details of any 'run-in' period, number 
of study centres and locations, study setting, withdrawals and date of study 
 participants: number, mean age, age range, gender, severity of condition, diagnostic 
criteria, inclusion criteria and exclusion criteria 
 Iiterventions: intervention, comparison, concomitant medications and excluded 
medications 
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 outcomes: primary and secondary outcomes specified and collected and time points 
reported 
 notes: funding for trial and notable conflicts of interest for trial authors 
MM transferred data into Review Manager (RevMan 2012).  
Assessment of risk of bias in included studies   
MM independently assessed risk of bias for each study using the criteria outlined in 
the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). 
Disagreements were resolved by discussion or by consultation with the third review author 
(IS). The risk of bias was assessed according to the following domains. 
 random sequence generation 
 allocation concealment 
 blinding of participants and personnel 
 blinding of outcome assessment 
 incomplete outcome data 
 selective outcome reporting 
 other bias 
Each potential source of bias was graded as high, low or unclear and provided a quote from 
the study report together with a justification for judgement in the 'Risk of bias' table 
(Appendix 1).  
Assessment of bias in conducting the systematic review 
The review was conducted according to the published protocol. 
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Measures of treatment effect   
Dichotomous data were analysed as odds ratios (ORs) and continuous data as mean 
difference (MDs) or standardised mean differences (SMDs) with 95% confidence intervals 
(CI’s). 
Meta-analyses were undertaken only when this was meaningful (i.e. if treatments, 
participants and the underlying clinical question were similar enough for pooling to make 
sense).The skewed data reported as medians and interquartile ranges were narratively 
described.  
Unit of analysis issues   
For cross-over studies, estimates of effects using generic inverse variance (GIV) data 
were entered. MDs between treatment groups with variance were determined by the 
published 95% CI when available. When 95% CIs were not available, published p values 
from statistical tests for paired data was used (Higgins 2011). 
Assessment of heterogeneity   
The I2 statistic to measure heterogeneity among the trials in each analysis was used. 
'Summary of findings' table 
The 'Summary of findings' table using the following outcomes: AHI, ODI and adverse 
events/side effects was created (Table 4.1).  
Results of the search  
Fourteen studies met the entry criteria for this review (Figure 4.1) 
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Figure 4.1 Study consort diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1079 records identified 
through database 
searching 
0 additional records 
identified through 
other sources 
642 records identified 
after duplicates 
removed 
604 records excluded 
on the basis  of 
title/abstract 
38 full text articles 
assessed for eligibility 
14 studies included 
in qualitative 
synthesis 
24 full text articles 
excluded with reason   
2 studies included in 
quantitative synthesis 
(meta-analysis) 
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Included studies   
A full description of each study, was entered into the Cochrane Database software, 
Review manager 5.3 “Characteristics of included studies”  
Study design 
Most studies had a cross-over design with the exception of four studies, which had a 
parallel-group design (Camacho et al. 1995; Bernards et al. 2009; Gooneratne et al. 2010; 
George et al. 2011). All but one study (George et al. 2010) were double-blinded. Most 
studies took place at a single centre, three studies had two centres participating in data 
collection (Rosenberg et al. 2007; George et al. 2010; George et al. 2011) one was a five-
centre study (Kryger et al. 2007)  and one was described as a multi-centre trial (Camacho et 
al. 1995). 
Participants 
The 14 studies recruited a total of 293 participants. Five studies recruited fewer than 
15 participants (Cirignotta et al. 1988; Cirignotta et al. 1992; Höijer et al. 1994; Berry et al. 
1995; Camacho et al. 1995) and two recruited more than 40 participants (George et al. 2010; 
George et al. 2011). The mean age of participants ranged between 44 (Wang et al. 2011) 
and 74 years (Gooneratne et al. 2010). Two studies enrolled only people over 60 years of 
age with complaints of insomnia (Camacho et al. 1995; Gooneratne et al. 2010). When data 
on body mass index (BMI) were recorded, trial populations were overweight or clinically 
obese, with mean weights ranging from 25 kg/m2 (Gooneratne et al. 2010) to 36 kg/m2 
(Berry et al. 2006). All participants had OSA confirmed by full polysomnography. The 
severity of OSA as evidenced by AHI was generally mild to moderate, with mean baseline 
AHI ranging from 10.9 (Gooneratne et al. 2010) to 25.0 per hour (George et al. 2011). Three 
studies recruited participants with severe OSA (Berry et al. 1995; Berry et al. 2006; Eckert et 
al. 2011). In (Berry et al. 2006) and (Berry et al. 1995), no baseline AHI was described, but 
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participants with severe OSA compliant with CPAP for over six months and males with 
severe OSA were included, respectively. A total of 75 participants were using CPAP therapy 
before screening but not during the study night in three studies (Rosenberg et al. 2007; 
George et al. 2010; George et al. 2011). All participants in two studies (n = 37) were treated 
with CPAP, including during the study night (Berry et al. 2006; Gooneratne et al. 2010). In 
(Bernards et al. 2009), one of the inclusion criteria was that participants had to be off CPAP 
for seven nights or longer, but how many participants were treated with CPAP was not 
formally stated. Similarly, in six studies, participants were off CPAP during the study night, 
but how many could have been treated before the study is not clear (Cirignotta et al. 1988; 
Cirignotta et al. 1992; Höijer et al. 1994; Berry et al. 1995; Camacho et al. 1995; Wang et al. 
2011). In (Eckert et al. 2011) and (Kryger et al. 2007), participants were not treated with 
CPAP (n = 43). It is impossible to be certain that no patients with central sleep apnoeas 
were recruited. However, when participants were described as suffering from OSA, and AHIs 
were reported as outcomes, the patient populations in each study would have met entry 
criteria for OSA-specific studies. Cirignotta (Cirignotta et al. 1992) excluded patients with 
SpO2 levels less than 70% during apnoea. Eckert (Eckert et al. 2011) excluded patients with 
severe OSA (nadir overnight SpO2 < 70% and AHI > 60 events/h) as well as those with a 
high arousal threshold (-25 cm H2O to -63 cm H2O as measured by an epiglottic pressure 
catheter), and (Rosenberg et al. 2007) excluded patients with severe OSA, which was 
defined as AHI of 40 events or more/h. Two trials recruited participants with co-existing 
insomnia (Camacho et al. 1995; Gooneratne et al. 2010). 
Interventions 
A total of 10 different study drugs were compared with placebo. No studies with 
gabapentin, pregabalin or melatonin fulfilling the inclusion criteria were identified. 
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Opiates and opioids 
 Remifentanil (opioid-based analgesic) (Bernards et al. 2009). 
Sedatives and hypnotics 
 Eszopiclone: non-BZD GABAA receptor agonist (Rosenberg et al. 2007; Eckert et al. 
2011). 
 Zolpidem: non-BZD GABAA receptor agonist (Cirignotta et al. 1988; Berry et al. 
2006). 
 Flurazepam: benzodiazepine (Cirignotta et al. 1992). 
 Brotizolam: benzodiazepine analogue, similar in effect to short-acting 
benzodiazepines, which are not approved for sale in the UK (Cirignotta et al. 1992). 
 Temazepam: short-acting benzodiazepine with anxiolytic properties, for treatment of 
insomnia and used as pre-medication during the preoperative period (Camacho et al. 
1995; Wang et al. 2011). 
 Nitrazepam: long-acting benzodiazepine, used for short-term treatment of anxiety 
and insomnia (Höijer et al. 1994). 
 Triazolam: benzodiazepine (Berry et al. 1995). 
 Sodium oxybate: central nervous system depressant (George et al. 2010; George et 
al. 2011). 
Melatonin and melatonin-related drugs 
 Ramelteon: melatonin receptor agonist, indicated for treatment of insomnia (Kryger et 
al. 2007; Gooneratne et al. 2010) . 
All but one drug were administered orally. Remifentanil was administered as an 
intravenous infusion (Bernards et al. 2009). The duration of studies varied: Seven single-
night studies were conducted in laboratory settings (Cirignotta et al. 1988; Berry et al. 1995; 
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Berry et al. 2006; Kryger et al. 2007; George et al. 2010; Eckert et al. 2011; Wang et al. 
2011), three studies were run over two to three nights (Cirignotta et al. 1992; Höijer et al. 
1994; Rosenberg et al. 2007), one study was of two weeks' duration (George et al. 2011) 
and two were of one to two months' duration (Camacho et al. 1995; Gooneratne et al. 2010). 
Outcomes 
All studies reported the effects of drug therapy on at least some measurements of 
sleep-disordered breathing (namely, AHI; AI; HI; ODI; duration of apnoea and arousals). In 
addition, two studies reported outcomes of symptoms on the ESS (Gooneratne et al. 2010; 
George et al. 2011). Five studies reported TST [(Höijer et al. 1994; George et al. 2010; 
Gooneratne et al. 2010; George et al. 2011; Wang et al. 2011). 
Funding 
Five studies were supported by drug companies (Cirignotta et al. 1992; Kryger et al. 
2007; Rosenberg et al. 2007; Gooneratne et al. 2010; George et al. 2011), four were 
supported by grants from research councils (Höijer et al. 1994; Camacho et al. 1995; Berry 
et al. 2006; Bernards et al. 2009) and one study was supported by both (Eckert et al. 2011). 
Four studies did not clearly state funding (Cirignotta et al. 1988; Berry et al. 1995; George et 
al. 2010; Wang et al. 2011). 
Excluded studies   
A full description of each study, has been entered directly into Cochrane Database 
software Review Manager 5.3 “Characteristics of excluded studies”  
Risk of bias of included studies   
The risk of bias was assessed using the Cochrane risk of bias tool. For a summary of 
the risk of bias, see Figure 4.2, Appendix 1. 
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Allocation (selection bias)   
Only three studies reported adequate randomisation and allocation concealment 
procedures (Gooneratne et al. 2010; Eckert et al. 2011; Wang et al. 2011) all remaining 
studies were described as randomised, but no further information was provided on 
randomisation or concealment of allocation, making adequate judgement impossible. 
Blinding (performance bias and detection bias)   
Three studies described adequate blinding of participants and personnel 
(Gooneratne et al. 2010; Eckert et al. 2011; Wang et al. 2011). In Bernards 2009 (Bernards 
et al. 2009), blinding of participants and outcome assessors but not personnel was 
adequate. Three studies reported adequate blinding of outcome assessors (Bernards et al. 
2009; Eckert et al. 2011; Wang et al. 2011). The remaining studies did not report enough 
details on blinding. 
Incomplete outcome data (attrition bias)   
All randomly assigned participants completed the intervention in two studies, and the 
number of dropouts in seven studies did not cause particular concern (Höijer et al. 1994; 
Rosenberg et al. 2007; Bernards et al. 2009; George et al. 2010; Gooneratne et al. 2010; 
George et al. 2011; Wang et al. 2011). In five studies, details were insufficient to allow a 
judgement (Cirignotta et al. 1988; Cirignotta et al. 1992; Berry et al. 1995; Camacho et al. 
1995; Berry et al. 2006). 
Selective reporting (reporting bias)   
None of the studies appear to have issues with incomplete reporting of outcomes, although 
we did not have access to study protocols. 
126 
 
Other potential sources of bias   
One cross-over study (George et al. 2010) included no washout period, leading to the 
potential for differential carry-over effects. 
Effects of interventions   
Studies reported diverse outcome measures; however AHI as the common outcome 
measure allowed direct comparison between studies. For an overview of the results, see 
Table 4.1. 
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Table 4.1. Summary of findings  
Drug class Study Intervention Control N Change in AHI Change 
in mean 
SaO2 
Change in 
minimum 
SaO2 
Opioids/opiates Bernards 
2009 
remifentanil 
infusion 
(0.075 mcg 
/kg/h) 
placebo 19 No change Not 
reported 
Decrease 
“Z drugs” Rosenberg 
2007 
Eszopiclone 
3mg 
placebo 22 No change No 
change 
No change 
Eckert 2011 Eszopiclone 
3mg 
placebo 17 Decrease No 
change 
No change 
Berry 2006 Zolpidem 
10mg 
placebo 16 No change Not 
reported 
No change 
Cirignotta 
1988 
Zolpidem 
20mg 
placebo 12 No change Decrease Decrease 
Benzodiazepines Cirignotta 
1992 
Brtizolam 
0.25mg 
placebo 12 No change in RDI 
(number of O2 
deasturations  of >4% 
/hr sleep) 
No 
change 
No change 
Cirignotta 
1988 
Flurazepam 
30mg 
 
placebo 12 No change Decrease Decrease 
Cirignotta 
1992 
Flurazepam 
30mg  
 
placebo 12 No change in RDI 
(number of O2 
deasturations  of >4% 
/hr sleep) 
No 
change 
No change 
Höijer 1994 Nitrazepam 
5mg or 
10mg 
 
placebo 11 No change in AI Not 
reported 
No change 
Camacho 
1995) 
Temazepam 
15-30mg 
 
placebo 15 No change RDI(number 
apnoeas/hypopnoeas/hr 
sleep) 
Not 
reported 
Not 
reported 
Wang 2011  Temazepam 
10mg 
placebo 20 No change Not 
reported 
No change 
Berry 1995 Triazolam 
0.25 
placebo 12 No change Not 
reported 
Decrease 
SXB George 
2010 
SXB 9g placebo 42 No change No 
change 
Not 
reported 
George 
2011 
SXB 4.5g placebo 48 Decrease No 
change 
No change 
Melatonin and 
melatonin 
related drugs 
Gooneratne 
2010) 
Ramelteon 
8mg 
placebo 21 No change Not 
reported 
Not 
reported 
Kryger 2007 Ramelteon 
16mg 
placebo 26 No change No 
change 
Not 
reported 
AHI: apnoea-hypopnoea index; AI: apnoea index; mean SpO2: mean nocturnal oxygen 
saturation; minimum SpO2: minimum nocturnal oxygen saturation; RDI: respiratory disturbance 
index; SBX: sodium oxybate 
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Opiates and opioids 
Remifentanil versus placebo 
One parallel trial involving 19 adults with moderate OSA (Bernards et al. 2009) 
compared remifentanil infusion (0.075 mcg/kg/h) to placebo. Remifentanil infusion did not 
significantly change AHI [mean difference (MD) 10.00, 95% CI -9.83 to 29.83], however, it 
significantly decreased the number of obstructive apnoeas per hour (MD -9.00, 95% CI -
17.40 to -0.60) and significantly increased the number of central apnoeas (MD 16.00, 95% 
CI -2.21 to 34.21) The increase in the average number of central apnoeas in the remifentanil 
group was not uniform across the group and reflected very large increases in a subset of 
four participants. The central apnoea index for the subset of four participants at baseline was 
0.8 ± 0.9 apnoeas per hour, and during the intervention 43 ± 34 apnoeas per hour. In 
addition, remifentanil infusion significantly decreased minimum SpO2 (MD -7.00, 95% CI -
11.95 to -2.05) and increased the total arousal index. 
No significant adverse events were reported in the remifentanil group but one 
participant in this group was given supplemental oxygen as the result of a drop in SpO2 to 
less than 80% for longer than five minutes. 
Sedatives and hypnotics 
'Z drugs' 
Four cross-over studies comparing "Z drugs" with placebo recruited a total of 67 participants. 
Eszopiclone versus placebo 
Two trials with 39 participants (Rosenberg et al. 2007; Eckert et al. 2011) compared 
eszopiclone 3 mg versus placebo, and pooled data show no significant change in AHI (MD -
3.40, 95% CI -10.36 to 3.56; participants = 39; Figure 4.3), although in Eckert 2011, a single 
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administration of eszopiclone 3 mg significantly decreased AHI compared with placebo (24 ± 
4 vs 31 ± 5; p value < 0.05). In addition, (Rosenberg et al. 2007) found no significant 
differences in AI, HI and arousal indices. No adverse events led to discontinuation of 
treatment. Six participants treated with eszopiclone experienced an unpleasant taste, and 
two developed infection, which was deemed by investigators as not related to study drug. 
Figure 4.3. Eszopiclone vs placebo (outcome AHI events/h) 
Reproduced with permission from the Cochrane Database of Systematic Reviews 
Zolpidem versus placebo 
Two cross-over trials with 28 participants examined zolpidem versus placebo 
(Cirignotta et al. 1988; Berry et al. 2006). Short-term administration of zolpidem 10 mg to 16 
participants with severe OSA on CPAP for at least six months (Berry et al. 2006) did not 
significantly change AHI (2.7 ± 0.47 vs 4.8 ±1.4) or minimum SpO2 (91.0 ± 0.7 vs 91.4 ± 0.6 
). A small decrease in the arousal index was observed in the zolpidem group (16.5 ± 2 vs 19 
± 1.6; p value ≤ 0.03). Compared with placebo, a single dose of zolpidem 20 mg to 12 
participants (Cirignotta 1988) increased AHI, although not significantly (30.0 vs 17.0; p value 
= 0.12), and significantly lowered minimum SpO2 (76.8 vs 85.2; P value = 0.002). 
No adverse events were reported in these two cross-over trials. 
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Benzodiazepines 
Five trials comparing benzodiazepines to placebo recruited a total of 70 participants. 
Brotizolam versus placebo 
One cross-over trial with 12 participants reported brotizolam 0.25 mg versus placebo 
(Cirignotta et al. 1992). Compared with placebo, brotizolam 0.25 mg caused no significant 
change in RDI (15.9 ± 14.8 vs 18.5 ± 14.4), mean SpO2 (93.9 ± 1.6 vs 93.9 ± 1.4) or 
minimum SpO2 (88.5 ± 3.0 vs 88.5 ± 2.5). Investigators reported no adverse events. 
Flurazepam versus placebo 
Two cross-over trials with 24 participants compared flurazepam with placebo 
(Cirignotta et al. 1988; Cirignotta et al. 1992). In one cross-over trial with 12 participants 
flurazepam 30 mg in comparison with placebo led to a non-significant increase in AHI (21.5 
vs 17.0; p value = 0.12) and a significant decrease in minimum SpO2 (81.7 vs 85.2; P value 
= 0.002). In contrast, in Cirignotta 1992, flurazepam 30 mg compared with placebo (n = 12) 
did not significantly alter RDI (19.6 ± 15.9 vs 18.5 ± 14.4), mean SpO2 (93.7 ± 1.6 vs 93.9 ± 
1.4) or minimum SpO2 (88.5 ± 2.5 vs 88.5 ± 2.5). 
These trials reported no adverse events. 
Nitrazepam versus placebo 
One cross-over trial with 11 participants compared nitrazepam 5 mg and 10 mg to 
placebo (Höijer et al. 1994). Investigators found no significant change in apnoea index 
among participants receiving 5 mg and 10 mg, respectively (MD -0.64, 95% CI -3.98 to 2.70; 
MD -1.00, 95% CI -4.34 to 2.34). In addition, they reported no change in minimum SpO2 
between treatment groups receiving either 5 mg or 10 mg nitrazepam.  No adverse events 
were reported in this trial. 
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Temazepam versus placebo 
A parallel group study (Camacho et al. 1995) and a cross-over trial (Wang et al. 
2011) with 35 participants compared temazepam to placebo. Temazepam (15 mg to 30 mg) 
administered to 15 participants for eight weeks (Camacho 1995) did not significantly change 
RDI (MD -1.60, 95% CI -5.81 to 2.61). Compared with placebo, temazepam (10 mg) did not 
alter AHI (MD 1.18, 95% CI -1.76 to 4.12), apnoea index, minimum SpO2 nor arousal index 
(Wang 2011). 
The researchers reported no adverse events in these trials. 
Triazolam versus placebo 
One cross-over study with 12 participants examined triazolam 0.25 mg versus 
placebo (Berry et al. 1995). The AHI was slightly but not significantly higher on triazolam 
nights (84.1 ± 6.5 vs 77.9 ± 6.6 events/h). The minimum SpO2 was significantly lower in the 
triazolam group in both REM and NREM sleep (MD -14.00, 95% CI -21.84 to -6.16; MD -
10.20, 95% CI -16.08 to -4.32, respectively). 
This paper describes no adverse events. 
Sodium oxybate versus placebo 
Two trials with 90 participants compared sodium oxybate to placebo (George et al. 
2010; George et al. 2011). In one cross-over trial involving 42 participants (George 2010), 9 
g sodium oxybate did not significantly increase AHI compared with placebo (18.6 ± 11.1 vs 
22.5 ± 10.3; p value = 0.06) nor mean SpO2 (94.8 ± 1.4 vs 94.6 ± 2.5; p value = 0.03). 
However, CSA was increased in the sodium oxybate treatment group (mean 7.3 (SD 18)).A 
parallel-group trial (George 2011) found that compared with placebo (n = 22), administration 
of 4.5 g sodium oxybate (n = 26) significantly decreased AHI (MD -7.41, 95% CI -14.17 to -
0.65). In addition, investigators reported no differences between treatment groups in mean 
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SpO2, minimum SpO2 or arousal index. They reported no differences between treatment and 
placebo groups on ESS (MD 0.10, 95% CI -4.90 to 5.10). 
Adverse events, most commonly headache, were reported in nine of 26 participants 
and in six of 22 of those receiving sodium oxybate and placebo, respectively. 
Melatonin and melatonin-related drugs 
Ramelteon versus placebo 
Two trials with 47 participants compared ramelteon to placebo (Kryger et al. 2007; 
Gooneratne et al. 2010). Pooled data showed no significant change in AHI (MD 0.26, 95% 
CI -2.05 to 2.57; participants = 47; Figure 4.4). In a parallel-group trial, ramelteon 8 mg (n = 
8) compared with placebo (n = 13) did not significantly change AHI (MD 0.50, 95% CI -11.60 
to 12.60) or ESS (MD 0.10, 95% CI -4.90 to 5.10;) in participants using CPAP. In one cross-
over trial with 26 adults with mild to moderate OSA (Kryger 2007), ramelteon 16 mg 
compared with placebo did not significantly alter AHI (MD 0.25, 95% CI -2.10 to 2.60) or 
mean SpO2 (MD 0.50, 95% CI 0.00 to 1.00) among participants not using CPAP. 
In Gooneratne 2010, four adverse events were reported in the ramelteon treatment 
group (diarrhoea n = 1, skin ulcer n = 1, sinusitis n = 1, fracture after being hit by bicyclist n = 
1) and two in the placebo group (abdominal pain n = 1, nausea n = 1). None of the adverse 
events were thought to be serious or related to the study drugs. In Kryger 2007, adverse 
events were reported by three participants in the ramelteon group (headache n = 2, urinary 
tract infection n = 1). No adverse events were reported with placebo. 
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Figure 4.4. Ramelteon vs placebo (outcome AHI events/h) 
                                                                       
Reproduced with permission from the Cochrane Database of Systematic Reviews 
Discussion  
We identified 14 studies assessing the effects of 10 drugs on sleep-disordered 
breathing in patients with pre-existing OSA. Most studies were of short duration, involved 
only a small number of participants and poorly described methodology and outcomes.  
Aside from studies by (Gooneratne 2010) of 30 days' duration and (Camacho 1995) 
of eight to 10 weeks' duration, most trials lasted a single night only, and therefore long-term 
therapeutic and symptomatic benefits could not be concluded. Regarding the effects of the 
drugs on sleep-disordered breathing, 12 trials showed no significant change in AHI or RDI 
when study drug was compared with placebo. Two drugs eszopiclone (3 mg) and sodium 
oxybate (4.5 g) significantly decreased AHI. Compared with placebo, flurazepam (30 mg) 
and zolpidem (20 mg) (Cirignotta 1988) caused a significant decrease in both minimum and 
mean nocturnal SpO2, and triazolam 0.25 mg in Berry 1995 and remifentanil infusion in 
Bernards 2009 led to a significant decrease in minimum SpO2.  
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A single trial comparing an opiate (remifentanil) versus placebo was included. 
Although this trial did not report an overall significant change in AHI with remifentanil 
infusion, a significant decrease in obstructive apnoeas was noted. One possible explanation 
for this finding is that remifentanil reduced the amount of time spent in REM sleep. This 
effect may be only temporary, as REM suppression is often followed by REM rebound (Endo 
et al. 1997) which could potentially worsen obstructive events. The single-night design of this 
trial and the controlled research environment, which does not reflect the usual clinical 
conditions in which patients receive opiates/opioids, make it impossible for researchers to 
conclude on the effects of continuous administration of opiates/opioids on sleep apnoea. 
Remifentanil significantly increased central apnoeas in a subset of participants, who in this 
trial were older and less obese. This finding may have an implication for clinical practice in 
that these patients may be less likely identified on preoperative screening for sleep apnoea 
because of normal or low body mass index (BMI). In addition, remifentanil led to a 
statistically and clinically significant decrease in minimum SpO2 (MD -7.00, 95% CI -11.95 to 
-2.05). It must be noted that different OSA phenotypes, such as patients with more 
pronounced hypoxia, may respond differently to opiates/opioids.  Until further studies clarify 
the effects of opiates/opioids on patients with OSA, the advice that caution should be 
exercised when prescribing opioids to patients with OSA remains valid. 
Sodium oxybate is a standard treatment for patients with narcolepsy, a large 
proportion of whom may have concurrent OSA (Chokroverty 1986). Although results show 
no significant worsening in AHI and SpO2 with sodium oxybate, given the small sample size, 
short duration, worsening of CSA in a cross-over trial by George 2010 and potential night-to-
night variability in the severity of sleep-disordered breathing, larger studies are warranted to 
evaluate the long-term effect (over three months) of larger doses of sodium oxybate (6 to 9 
g) on sleep-disordered breathing. 
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As a combination of sleep apnoea and insomnia may pose a difficult clinical 
management challenge, (Camacho 1995 and Gooneratne 2010) assessed temazepam and 
ramelteon, respectively, for treatment of insomnia, in people over 60 years of age with OSA 
and insomnia and found no worsening in OSA. Although the sample size was small in both 
studies, both ramelteon and temazepam were well tolerated and did not adversely affect 
respiration. 
Two trials showed a beneficial effect of medication on OSA. Eckert 2011 showed that 
a single administration of eszopiclone (3 mg) significantly decreased AHI compared with 
placebo (24 ± 4 vs 31 ± 5; p value ≤ 0.05), and a parallel trial by George 2011 showed that, 
compared with placebo (n = 22), sodium oxybate (4.5 g) (n = 26) significantly decreased AHI 
(MD -7.41, 95% CI -14.17 to -0.65). In Eckert 2011, study authors postulated that the 
increased arousal threshold caused by eszopiclone led to a decrease in AHI, most markedly 
in a subgroup of participants with a low arousal threshold before the study night. These 
drugs may be of therapeutic benefit for a subgroup of patients with OSA. 
In conclusion, this review shows that currently no evidence indicates that the 
compounds assessed worsen OSA as evidenced by a change in AHI, but a decrease in 
minimum SpO2 was observed with remifentanil, zolpidem and triazolam. These results must 
be interpreted with caution, as only a single trial assessed the effects of an opioid 
(remifentanil), and in several studies, it was not clear how many participants were treated 
with CPAP in the past, and whether a residual treatment effect of CPAP could have 
lessened any deleterious impact of the drugs studied. Overall, the low quality of evidence 
with potential risk of bias due to lack of data on allocation of intervention, concealment of 
allocation and blinding must be borne in mind when the results of this review are interpreted. 
Prescribing such agents for patients with OSA, especially outside the doses and severity of 
the OSA cohorts studied in individual trials, merits caution. 
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Overall completeness and applicability of evidence   
Results of this review cannot be extrapolated to patients outside the severity of the 
OSA cohorts in the individual studies and the corresponding doses of compounds studied. 
Some drugs have been studied in patients with ongoing treatment with CPAP. 
Inter-participant variability is apparent in terms of the effects of the drugs 
administered in some studies. A subset of patients with a certain OSA phenotype may be 
more susceptible to potential harm and adverse effects associated with such agents. Owing 
to the small size and short duration of the studies included in this review, as well as the 
aforementioned individual variability in drug response, we cannot comment on long-term 
tolerability and likelihood of adverse events. 
Implications for research   
Larger, methodologically robust studies of longer duration including patients naive to 
or without additional CPAP treatment are needed to examine the effects of opioids/opiates, 
sedatives and hypnotics on patients with pre-existing OSA. 
Currently only one RCT has examined the effects of an opiate (remifentanil) on 
patients with OSA. The results of this trial provide some cause for concern regarding 
prescribing for patients with OSA. Further studies are needed to clarify these results, 
including the significance of increased central apnoeas, to help with planning of optimal 
perioperative care for patients with known OSA requiring opioid analgesia after major 
surgery. 
The apparently favourable effects of eszopiclone and sodium oxybate on severity of 
OSA may be due to chance, but further studies examining these agents as potential 
therapeutic options for patients with OSA could prove valuable. 
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Chapter 5 
The effect of acute intravenous morphine administration on sleep disordered 
breathing in patients with moderate obstructive sleep apnoea: A paired design trial; 
MIMOSA trial 
My personal involvement in this study includes: developing research hypothesis and 
writing up the protocol as well as applications for ethical approval and Medicines and 
Healthcare Products regulatory agency. I have been screening patients for availability to the 
trial as well as recruiting them to the study. I have also supervised the study night and 
administered the morphine to those eligible for study night. I have also collected all data. 
Statistical analysis was performed by Dr Jules Hernandez-Sanches and Dr Sofia Villar. 
Null hypothesis  
Administration of intravenous morphine sulphate to patients with moderate OSA does 
not worsen the severity of sleep disordered breathing as measured by change in AHI.  
Introduction 
The Cochrane review reported in Chapter 5 found that administration of opioids does 
not worsen OSA severity but there was only one RCT involving administration of an opioid 
(remifentanil) included in this review.  
Morphine and other opiates/opioids are the treatment of choice for moderate and 
severe pain after surgery. A large proportion of patients with OSA remain undiagnosed and 
may be presenting for surgery (Young et al. 1997) and receiving postoperative opioid 
analgesia.  It has been proposed that a sensitivity to such drugs puts patients with OSA at 
increased risk of respiratory depression in the post-operative period (Gross et al. 2006) and 
in anaesthetic guidance on the management of people with OSA, caution is recommended 
when using sedating drugs after the surgery (Network 2003). These anxieties are not 
justified on the basis of any high level published evidence and the current recommendation 
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from the American Society of Anaesthesiologists to limit the use of opioids in such patients, 
is based on expert opinion only (Gross et al. 2006).   
In our hospital, as in many other units, intravenous (iv) morphine is prescribed as the 
1st line drug for severe pain after cardiac surgery and remifentanil is only used for the 
provision of analgesia in theatres and occasionally in the critical care area in mechanically 
ventilated patients. To my knowledge there are no studies investigating the effect of 
intravenous morphine in adults with OSA. 
It is necessary to establishing the risk opioids may represent to patients with OSA to allow 
informed decisions when prescribing such substances to patients with OSA.   
Methods 
The local research committee, NRES Committee East of England, Cambridgeshire 
and Hertfordshire, gave ethical approval for the protocol on the 30th June 2015. The first 
subject was recruited in May 2016 and the last patient completed the trial on 3rd November 
2017. Data were collected prospectively and written consent was obtained from all 
participants recruited to the study. Papworth Hospital NHS Trust sponsored the trial. 
The study protocol illustrating the pathway of CPAP established and CPAP naïve individuals 
is depicted in Figure 5.1. 
Population cohort 
The study was conducted at the RSSC, Papworth Hospital NHS Foundation Trust 
which is an accredited sleep centre with specialist expertise in the diagnosis, treatment and 
follow up of patients with OSA as well as respiratory and non-respiratory sleep disorders with 
ready access to full electroencephalogram based polysomnography. The sleep centre offers 
specialist diagnostic tests, treatments and follow up to patients with a great range of sleep 
disorders and receives referrals from across the United Kingdom. To maximise patient 
safety, the study night took place in the RSSC main ward, where a team of qualified nurses 
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supervise patients during the night. There was a supervising clinician monitoring the 
patients, including nocturnal oxygen saturations throughout the night and another member of 
staff attended to allow for an appropriate rest break. A full resuscitation team was available 
with immediate response. 
Population 
The participants were recruited from the RSSC’s pool of patients with moderate OSA, 
established on treatment with CPAP as well as CPAP naïve patients. 
Rationale for patient selection 
I elected to study patients with moderate OSA, in order to maximise the chance of 
identifying any effect on AHI. In other studies drugs have increased and decreased AHI; an 
effect which might be obscured if AHI is at the physiological limits (low or high) at baseline. 
Patients with severe OSA may present as a high risk group and therefore a moderate OSA 
cohort was felt to be the most suitable population to study. To improve the recruitment 
process I opted to study patients with moderate OSA, already established on CPAP as there 
is large pool of these patients currently being cared for at the RSSC and as the recruitment 
process was slow we  also included newly diagnosed patients naïve to CPAP . To study the 
effect of morphine we employed the CPAP withdrawal model. This was first described in 
2011 (Kohler et al. 2011) and showed that withdrawal of CPAP is associated with return of 
OSA within the first night and the severity of OSA is not increased further after the first week 
of CPAP withdrawal. In addition, this trial showed a return of sleepiness associated with 
OSA after 2 weeks of CPAP withdrawal and therefore the patient’s quality of life should not 
be compromised by a shorter period without CPAP. I asked patients to remain off CPAP for 
6 nights prior to the study night. This model is useful to evaluate short term physiological 
effects of OSA as well as responses to various treatments (Kohler et al. 2011).  
I chose to exclude participants who did not have English as their first language and 
would require an interpreter, as they may experience difficulties in reporting any symptoms 
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associated with investigational medical product (IMP) administration to the supervising 
clinician. As the study was conducted out of hours, an interpreter may not have been readily 
available. To minimise bias of any non-investigational medical product (NIMP) on OSA, 
ondansetron was used as the antiemetic. Ondansetron has been studied in patients with 
OSA and shown to have no effect on AHI (Stradling et al. 2003). 
Inclusion criteria   
ALL participants 
1. Age ≥ 18 years 
Group A  
2. Patients with a diagnosis of moderate or severe OSA at diagnosis, diagnosed by 
nocturnal oximetry, rPG or PSG (defined as AHI  or ODI of 15-50 events/hour) 
established on CPAP  
3. and established on CPAP with confirmed moderate OSA (AHI 15-29 events/hr) 6 
nights after withdrawal of CPAP (confirmed at baseline rPG)  
Group B  
4. Patients diagnosed with moderate OSA by rPG or PSG, naïve to CPAP treatment 
  Exclusion Criteria 
1. Inability to give informed consent or comply with the   protocol 
2. Current, clinically significant acute respiratory tract infection (at screening and/or at 
study visit)   
3. Chronic respiratory disease (other than OSA), symptomatic ischaemic heart disease 
4. Pregnancy or suspected pregnancy/breast feeding 
5. Current or recent (within last week before entering the trial and for the duration of 
the trial) use of gabapentin, pregabalin, melatonin, mirtazapine, benzodiazepines, 
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barbiturates, sodium oxybate, ramelteon, Z-drugs and opiates/opioids  
6. Monoamine oxidase inhibitors (MAOIs), linezolid, taken within 2 weeks of 
participation in the trial 
7. A known allergy to the IMP or NIMP 
8. Patients with an inadequate command of English requiring an interpreter overnight 
9. Change in weight of > 5% since the baseline rPG (group A only) 
10. Vital signs recordings (oxygen saturations, blood pressure, pulse rate) that in 
clinicians opinion deem the patient unsafe to participate in the trial  
11. Clinician deems the patient unsafe to participate in the trial (e.g. severely sleepy 
patients who cannot withdraw from CPAP); group A only 
12. CPAP intolerant/poor responder  
13. History of drug abuse (oral or intravenous) including: alcohol, substituted 
amphetamines, barbiturates, benzodiazepines, cocaine, methaqualone, cannabis 
and opioids. 
14. A drop of oxygen saturations below 85% continuously for longer than five minutes 
during diagnostic study  (rPG/PSG). 
15. Professional driver (group A only) 
Intervention 
All patients enrolled were given 10 mg of iv morphine sulphate in two divided 5mg 
doses. Morphine sulphate injection (1mg/ml) is a phenanthrene-derivative opiate agonist. It 
is the principal alkaloid of opium. It is presented as a clear, colourless or almost colourless, 
sterile solution in a syringe for injection. Peak analgesia occurs 20 minutes following IV 
infusion. Maximal respiratory depression occurs within 3 - 7 minutes. Analgesia may be 
maintained for up to 7 hours. Although the sensitivity of the respiratory centre returns to 
normal within 2 - 3 hours, respiratory minute volumes may remain below normal for 4 - 5 
hours. Intravenous morphine sulphate is immediately bioavailable, since no absorption is 
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required. About 90% of the drug is excreted within 24 hours of giving the last dose. Morphine 
sulphate is a licensed medication manufactured by a number of licensed manufacturers 
within the UK. Routine clinical stocks held by the hospital pharmacy were used. 
Rationale and justification for the proposed morphine sulphate dose 
Opioid analgesia is commonly used to control pain after the surgery. The method of 
pain relief known as patient-controlled analgesia (PCA) enables patients to administer pain 
relief themselves – up to a preset limit – via a syringe driver attached to an intravenous drip 
or epidural catheter. It is widely used in hospitals and is an effective approach to limiting 
postoperative pain. The locally used PCA protocol for patients undergoing cardiac surgery in 
Papworth Hospital allows patients to administer 1mg of intravenous (iv) morphine sulphate 
as a bolus at five minutes intervals, totalling a maximum of 12 mg of iv morphine per hour. 
Yarmush et al. reported that a median number of two (0-5) 2 mg iv boluses of morphine 
sulphate were required for successful post-operative analgesia in surgical patients expected 
to experience moderate to severe pain (Yarmush et al. 1997). Similarly, Beloeil et al. found 
that median effective analgesic dose of morphine sulphate in sixty patients with mild to 
moderate pain after the minor surgery was 5mg (4-6mg) (Beloeil et al. 2004). Shaw et al 
investigated the  effect of iv morphine (0.1mg/kg) in seven healthy volunteers, with no 
serious adverse effects reported (Shaw et al. 2005). Given the above evidence, 5mg a dose 
of 5mg of morphine sulphate was chosen as it was felt bothe effective to control pos-
operative pain and safe. As respiratory minute volumes may remain below normal for 4 - 5 
hours after administration of morphine, second dose was administered 4 hours after the first 
dose was given. 
Outcomes 
Respiratory polygraphy (rPG) was performed using the Embletta portable device 
(ResMed) during the baseline study and study night. Both assessments were performed 6 
nights following CPAP withdrawal. Baseline rPG was recorded in the patient’s own home in 
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order to confirm moderate OSA (group A) and the study rPG in the RSSC. The rPG recorded 
for a minimum of 6 hours and a maximum of 10 hours. The following measurements were 
recorded during the rPG:  
1. Thorax and abdominal effort through XactTrace Respiratory Inductive 
Plethysmograph sensors  
2. Mean and minimum oxygen saturation (SpO2), percentage of time spent with 
nocturnal saturations of ≤ 90% (SpO2≤ 90%) and pulse rate via pulse oximetry 
3. Airflow via thermistor and pressure flow 
4.  Body position via body position sensor 
Data were downloaded to an  integrated system (Embla, ResMed, Bella Vista, Australia) 
and scored manually according to standardised criteria by a qualified sleep  
polysomnographer. An apnoea was defined as >90% reduction in air flow for ≥10 
seconds. These were scored as central if there was an accompanying cessation of  
chest and abdominal movements. Hypopnea was defined as a reduction in flow of 
between 50% and 90% lasting ≥10 seconds accompanied by ≥3% decrease in 
oxyhaemoglobin saturation (SpO2). OSA was defined as the presence of ≥5 episodes of 
obstructive apnoea and hypopnoea (AHI) per hour sleep. AHI cut off was used to define 
the severity of OSA. As such moderate OSA was defined as AHI 15-30 events /hour 
Primary outcome 
Change in Apnoea Hypopnoea Index (AHI) – change in mean number of apnoeas 
and hypopnoeas for time in bed from participant’s baseline rPG to study rPG 
Secondary outcomes 
Change in the following parameters from participant’s baseline rPG to study rPG: 
1. Change in 4 % oxygen desaturation index (ODI) between baseline and study night 
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2. Change in mean oxygen saturations between baseline and study night 
3. Change in minimum saturations between baseline and  study night 
4. Change in % time spent with saturations <90% between baseline and study night 
5. Change in total number of obstructive apnoeas (OA) and central apnoeas (CA)    
between baseline and study night 
6. To assess the number and severity of any adverse events associated with IMP 
Eligible participants were sent a Patient Information Sheet (PIS) and after a few days 
were approached by telephone to discuss the study and enquire about their interest to 
participate in the study. I have telephoned and screened for eligibility those who were 
interested to participate, mainly to assure that they were safe to stop the CPAP treatment 
(screening proforma is attached in Appendix 2). Patients who met the eligibility criteria were 
asked to remain without CPAP for 6 nights prior to Visit 1 to employ the CPAP withdrawal 
model (described in Chapter 2). During this visit, patients were set up with the rPG (baseline 
rPG) equipment for completion at home that night and were asked to return to the RSSC the 
following day (Visit 2) and then restarted CPAP treatment that evening. All sleep studies 
were analysed by the same polysomnographer to increase reproducibility. Patients with 
confirmed moderate obstructive sleep apnoea were booked to attend the RSSC for an 
overnight inpatient rPG to complete their Visit 3 (Study visit) and asked to stop CPAP 
treatment 6 nights prior to this visit. During this visit demographic variables describing the 
participants (including age, weight, height, BMI, neck circumference) were recorded along 
with medical, surgical and drug history. A full clinical examination was undertaken and vital 
signs recorded. An intravenous cannula was placed in a forearm vein. Participants received 
5mg of iv morphine sulphate with 4mg of iv ondansetron (to combat nausea, side effect of 
morphine sulphate) thirty minutes before lights went off and again 4 hours following the first 
dose. An overnight rPG was performed and patients were monitored with nocturnal oximetry 
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which was observed in real time by a clinician for safety resons. Patients were contacted 24 
hours following discharge from Visit 3 to review adverse events. 
Due to the difficulty recruiting, the trial steering committee and ethical committee 
agreed to include patients with moderate OSA who were newly diagnosed and not 
established on CPAP. These patients were given the PIS after their diagnostic study 
(polysomnography) and contacted a few days later to assess their interest in participating. If 
they agreed to participate they were screened by telephone to assess for eligibility and had 
the study visit booked (Visit 3), as described above. 
Despite including CPAP naïve patients in the screening cohort the recruitment of 
patients to the study was slow and extending the proposed period for the study stretched the 
financial support to the limits. The Trial Steering Committee therefore took the decision to 
halt the study prematurely, before reaching the recruitment target. 
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Figure 5.1        Study protocol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Telephone Screening Interview: telephone assessment by physician to 
check eligibility and ensure patient is safe to stop CPAP   
 Verbal consent to stop CPAP obtained and Visit 1 organised for patients 
treated with CPAP 
 CPAP naïve patients were booked for Visit 3 
 
 
 
 
 
Telephone 
Screening 
Interview 
 
 Eligibility confirmed 
 Written informed consent gained  
 rPSG equipment explained and given to patient to be performed at home 6 
nights after CPAP withdrawal 
 
 Patients meeting inclusion criteria recruited 
VISIT 1 
(patient collects 
sleep study 
equipment)) 
 rPSG equipment returned and analysed 
 Eligibility confirmed 
 Patient contacted by telephone to reconfirm interest and  visit  3 booked 
(remind to stop wearing CPAP 6 nights prior to visit 3) 
 Patients meeting inclusion criteria recruited 
 
VISIT 2  
(patient returns 
sleep study 
equipment) 
 Demographic data and physical examination recorded 
 Vital signs 
 IV cannula inserted 
VISIT 3  
(study visit) 
5 mg iv morphine sulphate (in 5mL normal saline) 
 30 minutes before lights off  plus 
 4mg iv Ondansetron 
5 mg iv morphine sulphate (in 5mL normal saline) 
 4 hours after the first dose plus 
 4mg iv Ondansetron 
 
 
Overnight inpatient 
respiratory 
polygraphy (rPSG) 
Oral ondansetron 4mg following day if required 
Scoring of respiratory polygraphy and data collection  
Adverse events (including 24 hour telephone follow up) 
Data analysis, writing, presentation 
 Patients with moderate OSA treated with CPAP identified from the database 
 PIS and trial summary sent to patients by letter. CPAP naïve patients were 
identified after polysomnography and given PIS. 
 Patients given a few days after receiving the information to decide if they 
are interested in taking part in the trial 
 Patients contacted by telephone to assess interest and suitability checked 
 
 
 
 
 
Screening 
(Patient 
Identification) 
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Statistical analysis 
A prospective power analysis was conducted for a single outcome variable (AHI) to 
determine sample size. This analysis indicated that 26 patients were needed. The 
assumptions for the power analysis were that alpha =0.05, power =0.8, SD =7, desired 
detectable difference =4, and statistical analysis conducted on paired samples and 
correlation for paired data =0.8. Descriptive statistics are shown for the variables used in this 
study (Table 6.1). Data were analysed using Wilcoxon signed-rank non-parametric test using 
statistical software R, version 3.4.1. Continuous variables are reported as median (IQR) and 
categorical variables as percentages. Results with p≤ 0.05 were considered to be significant. 
Results 
The total of 173 patients was screened for eligibility in the study, of which 18 were eligible for 
participation. Of these 6 were eligible to attend visit 3 and received intravenous morphine 
sulphate (Figure 5.2), of whom 2 were CPAP naïve patients and 4 were established on 
CPAP and had to withdraw from CPAP, six nights prior to study night (Figure 5.2)
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Figure 5.2 Study Consort diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demographics of all patients enrolled to the study and those who received intravenous 
morphine sulphate are populated in Table 5.1.
 41 interested to participate 
9 patients mild OSA 
1 patient severe OSA 
1 patient CSA 
1 lost follow up 
 
 173 patients assessed for eligibility   
92 not interested to participate  
31 were found to be ineligible at 
screening 
9 patients not contacted as the 
study was terminated 
 6 received iv morphine sulphate  
6 not eligible prior to telephone 
screening interview 
10 not eligible following telephone 
screening interview 
2 not interested to participate 
1 eligible cancelled study night 
1 eligible with limited time to 
attend 
3 not telephone screened as study 
terminated 
 
18 patients recruited to the study  
(2 CPAP naïve patients and 16 
established on CPAP) 
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Table 5.1 Patient demographics at baseline 
Demographics All recruited subjects 
n=18 
Subjects recruited to receive morphine 
n=6 
Age yrs  50 (42-58) 55 (44-58) 
 
Male (%) 13 (72%) 5 (83%) 
 
Weight kg 97(91-108) 103 (99-107) 
 
BMI kg/m2 
 
- 33 (31-35) 
AHI events/hr 
 
13 (4-19) 19 (17-20) 
 
Mean SpO2 % 
 
93 (92-94) 93 (92-94) 
Minimum SpO2 % 
 
85 (81-86) 83 (81-85) 
ESS 
 
- 8 (4-17) 
Neck circumference cm 
 
- 44 (43-45) 
Smoking   
Non smoker 
 
- 2 (33%) 
Ex-smoker 
 
- 2 (33%) 
Smoker 
 
- 2 (33%) 
Type 2 DM (%) - 0 (0%) 
COPD (%) 
 
- 0 (0%) 
Ischaemic Heart disease (%) 
 
- 0 (0%) 
Hypertension (%) 
 
- 1 (17%) 
Antidepressant (SSRI) (%) 
 
- 4 (67%) 
Systolic BP mmHg 
 
- 137 (127-160) 
Diastolic BP mmHg  
 
- 86 (83-89) 
Data presented as median (IQR) unless stated otherwise. BMI: Body mass index; AHI: apnoea/hypopnoea index; 
SpO2: peripheral oxygen saturations; ESS: Epworth Sleepiness Scale score; DM: diabetes mellitus; COPD: 
chronic obstructive pulmonary disease; BP: blood pressure 
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Primary outcome 
There was a non-significant fall in AHI (median difference (MD) -12.95; IQR 9.45; 
p=0.173) which was the primary outcome of the study using Wilcoxon signed-rank non-
parametric test. 
Secondary outcomes 
There was significant difference in three of the secondary outcomes (Table 5.2) 
namely the  total number of obstructive apnoeas MD -24, IQR 43.5, p=0.039 (Figure 5.3),  
total number of central apnoeas MD -3 IQR 2.75, p=0.027(Figure 5.4) and mean nocturnal 
SpO2 MD -0.9, IQR 0.83; p=0.05. To ensure that the difference in total number of OA and 
CA was not attributed to the rPG recording time, post hoc analysis of obstructive/central 
apnoea indexes was carried out. This showed that the obstructive apnoea index (MD -2.7, 
IQR 7.37, p=0.03) and central apnoea index (MD – 0.35, IQR 0.83, p=0.04) were both 
significantly reduced. 
Figure 5.3. Obstructive Apnoea Index pre and post administration of iv morphine 
sulphate 
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Figure 5.4. Central Apnoea Index pre and post administration of iv morphine sulphate 
 
 
Table 5.2 Secondary outcomes variables 
Variable  MD IQR p 
ODI -7.4 5.95 0.35 
Mean SpO2 -0.9 0.83 0.05 
Minimum SpO2 0 6.5 0.67 
% time spent with SpO2<90% -23.85 97.7 0.12 
Total number of OA -24.0 43.5 0.04 
Total number of CA -3.0 2.75 0.03 
MD: median difference; IQR: interquartile range; SpO2: peripheral arterial saturations 
Adverse events 
Two patients receiving iv morphine sulphate reported adverse events. One in terms 
of bradycardia that may not have been related to the IMP or NIMP and could represent 
physiological nocturnal bradycardia. For the safety reasons he did not received the second 
dose of the IMP. The second patient experienced headache which was possibly related to 
IMP but resolved promptly with administration of paracetamol. 
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Discussion 
In this small cohort of patients with moderate OSA administration of 10mg of  iv 
morphine during the night has not significantly worsened the severity of OSA in terms of an 
increase in AHI but has led to significant reduction of OAI and CAI as well as small decrease 
in mean nocturnal saturations. Given the small number of patients recruited to this study no 
robust conclusion can be drawn but these results raise the interesting hypothesis that 
opiates, in some OSA patient phenotypes, contrary to current beliefs, can stabilise 
respiration during the night and lead to a reduction of OSA severity.  
A similar outcome was reported from the RCT by Bernards et al. Remifentanil 
infusion did not significantly change AHI (MD 10.00, 95% CI -9.83 to 29.83) but led to a 
significant reduction in OAI (MD -9.00, 95% CI -17.40 to -0.60). Contrary to the improvement 
in CSI in our patients, remifentanil infusion led to a significant increase in the number of 
central apnoeas (MD 16.00, 95% CI -2.21 to 34.21) in patients with moderate OSA. This was 
not uniform across the group but reflected very large increases in a subset of four 
participants. These participants with significant increase in CSI were older (age, 56 ± 
11 vs.  46 ± 11 y) and less obese (BMI, 28 ± 7 vs. 33 ± 8), compared to patients in the 
remifentanil group in whom no significant increase in CSI was seen. It is possible that I have 
not observed a significant increase in CSI as my patient cohort was too small and 
participants were more obese and younger compared to those in the remifentanil trial.   
Opioids may reduce respiratory rate and tidal volume, decrease 
chemoresponsiveness to hypercapnia/hypoxia as well as decrease upper airway muscle 
tone which might impair respiratory function in patients with SDB (Koo 2011). Despite this 
fact, in several previous studies, excluded from the Cochrane review reported in Chapter 5 
due to not meeting inclusion criteria, the administration of a moderate opioid dose to opioid 
naive individuals without SDB did not lead to development of SDB . Bernards et al. and the 
current trial have shown an improvement in OAI in patients with diagnosed moderate OSA. 
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Bearing in mind the limitations of both studies, in particular the small size, these results 
nonetheless raise an interesting hypothesis that in certain people with OSA, administration 
of opioids may not be deleterious to the respiration but may lead to fewer obstructive events 
during the sleep. These trials were not designed to answer the pathophysiological 
mechanism of this finding but do provide pilot data and hypotheses for further trials. 
Recently, Rowsell et al. examined the effect of 40 mg, orally administered morphine to 60 
male patients with various OSA severity, in a single night, RCT trial and reported that this 
dose did not worsened nocturnal hypoxia or AHI but reduced minimal SpO2 by 1.3%. In 
ptients with severe OSA a lower baseline CO2 ventilatory response threshold correlated with 
worsening hypoxia, AHI and ODI. This may suggest that opiod response in patients with 
OSA realtes to baseline CO2 response threshold and that patients with more severe OSA 
may be more at risk when given opiods (Rowsell et al. 2019). 
The effect of iv morphine on sleep architecture has been studied.  Morphine reduces 
the amount of REM sleep during the night in healthy volunteers. (Shaw et al. 2005) but also 
in patients with moderate OSA (Bernards et al. 2009). Reduction in pharyngeal tone in REM 
sleep leading to an increase in UA resistance and worsening severity of OSA in REM sleep 
has been described (Horner et al. 1991; Horner 2007). It is possible that opioid induced REM 
sleep reduction may be responsible for the improvement in OAI with both remifentanil and in 
the current study. It has been shown that short term suppression of REM sleep leads to 
REM sleep rebound and as such short term suppression of REM sleep due to opioid 
administration in the postoperative period may lead to REM sleep rebound and worsen the 
severity of OSA once the opioids are withdrawn a few days post- operation. The exact effect 
of opioid related REM suppression together with previously reported postoperative REM 
suppression is unknown and will require further evaluation. 
The current study has significant limitations, mainly the small sample size. I have 
tried hard to maximise recruitment through various amendments in inclusion criteria of the 
studied population but despite all the efforts the recruitment remained below the target. The 
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current study aimed to provide pilot data for future a RCT evaluating the effect of opioids on 
patients with OSA and it became clear that a multicentre approach with dedicated research 
staff concentrating on patient recruitment will be needed. Another limitation of the current 
study is comparing the results of respiratory polygraphy undertaken in different environments 
(home and hospital) which may lead to different sleep quality potentially affecting the 
severity of SDB. Performing the baseline study at home was chosen to reduce the need for 
hospital visits to help with recruitment. I have only studied patients with moderate OSA 
without significant nocturnal hypoxia and it is possible that patient with more severe OSA 
with more pronounced desaturations during the night and out of the currently studied age 
group may respond differently to the administration of iv morphine.   
Future directions 
Due to the small sample size of currently available studies examining the effect of 
opioids on the patients with OSA, no recommendation or definite conclusions can be drawn. 
Given the difficulty in recruiting patients into the current trial the study is underpowered to 
provide meaningful results but it is the first trial examining the effect of iv morphine sulphate 
on patients with diagnosed OSA. The results of this pilot study provide a basis for further 
research examining the effect of opiods on patients with OSA. From anecdotal experience 
we know that only a small number of patients experience significant morbidity and mortality 
when treated with opioids in the postoperative setting and it is likely that specific OSA 
phenotypes are particularly at risk of opioid related morbidity and the aim of future research 
should be to identify these at risk patients and examine the mechanisms by which opioids 
affect respiratory physiology in them.  
Chapter 6 
Conclusion 
OSA is common and its prevalence is expected to rise with increasing obesity and 
aging of the population leading to the possibility of increasing numbers of patients with 
155 
 
unknown and untreated OSA presenting for surgical procedures. There is moderate 
evidence for an increased risks of postoperative complications in patients with OSA 
undergoing general and upper airway surgery. To date only a few studies have investigated 
the prevalence and postoperative outcomes in patients with OSA undergoing major cardiac 
surgery. These studies show conflicting results in terms of risk of post-operative 
complications with an increased risk of AF, prolonged mechanical ventilation, ICU and 
hospital LoS, post-operative infection and encephalopathy, all being reported. The main 
issue with these studies is that the majority has been either retrospective or used 
questionnaires to diagnose OSA and there are significant differences in reported outcomes 
and the definition of OSA which has changed over the years.  
Preoperative assessment is aimed at reducing the perioperative complications and 
identifying patients with significant respiratory or cardiac comorbidities. Standardised 
screening for OSA prior to surgery has not yet been established despite emerging evidence 
of an association of OSA and postoperative complications, although some centres in UK 
have started using screening questionnaire to screen for OSA before surgery. Perhaps the 
main reason for the lack of standardised screening is the lack of evidence that treating OSA 
pre or post-surgery significantly improves outcomes in these patients.   
Both surgeons and anaesthetists fail to identify a significant proportion of patients 
with symptomatic undiagnosed OSA during assessment in preoperative clinics (Singh et al. 
2013) and despite efforts to develop accurate and simple screening tools to identify patients 
with OSA most lack high enough sensitivity and specificity to be recommended for routine 
clinical practice. Their cost effectiveness has not been established. Patients with OSA are at 
increased risk during the perioperative period due to difficult intubation and a small 
proportion of OSA patients may be vulnerable to anaesthetic medication and opioid 
analgesia. These agents may worsen OSA by reducing UA dilator muscle tone and 
increasing UA resistance but may also impair ventilation which may be particularly important 
for patients with obesity related hypoventilation. However to date there is only one RCT 
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examining the effects of the opioid, remifentanil, on patients with OSA which shows that this 
drug does not worsen OSA. There are a few case reports describing deleterious effects of 
morphine on patients with OSA receiving opioid analgesia during surgery. This is important 
as the early postoperative period may represent a risky time for patients with OSA due to 
REM rebound and sleep fragmentation which have been shown to worsen nocturnal hypoxia 
and decrease pharyngeal muscle tone. However, the exact mechanisms for deleterious 
effects of OSA on postoperative outcomes remain unknown.  
This thesis aimed to investigate the prevalence of sleep apnoea and its association 
with postoperative complications in a very specific cohort of patients undergoing major 
cardiac surgery. It also explored the effect of intravenous opioid analgesia on postoperative 
outcomes in this patient cohort. As a separate study, I explored the effect of intravenous 
opiate, morphine sulphate, on the severity of OSA in patients with moderate OSA. 
Secondary research was undertaken to examine extant evidence of the effect of opioids and 
sedatives on patients with OSA. All the new findings are summarised in this chapter.  
The results of the SACS study reported in Chapter 2 show a high prevalence of OSA 
(47%) in cardiac patients requiring revascularisation surgery which may not be surprising 
given that coronary artery disease and OSA share common risk factors including obesity, 
age and male sex. The prevalence of sleep apnoea reported in this thesis is lower compared 
to the prevalence reported in other prospective studies in this surgical cohort which used 
polysomnography. This is likely due to the fact that polysomnography represents a more 
sensitive diagnostic tool compared to oximetry as used in my study. Diagnosis of sleep 
apnoea in this thesis was based on significant, intermittent oxygen desaturations reflected in 
4% ODI. Since oximetry cannot distinguish between central and obstructive sleep apnoea 
the reported prevalence is that of sleep apnoea as it is likely that some patients suffered with 
central sleep apnoea.  
157 
 
Regardless of the nature of sleep apnoea (central vs. obstructive) it was found that 
the probability of developing postoperative complications rose with severity of sleep apnoea, 
defined as oxygen desaturations during the night (OR1.1 for each unit increase in ODI, 
p=0.014)) suggesting that the intermittent nocturnal desaturations may be implicated in the 
pathophysiology of the effect of sleep apnoea on postoperative outcomes. This was the first 
prospective study in cardiac population showing a severity response effect and that even 
patients with mild sleep apnoea had a higher probability of developing postoperative 
complications than people with no desaturations at night. The mechanism of this effect is 
unknown and was not the focus of this thesis. The effect of central sleep apnoea on 
postoperative outcomes has not been studied but it is possible that some patents in my 
cohort had CSA and it is important that future studies use diagnostic methods able to 
distinguish obstructive and central breathing events and separately examine their 
association with postoperative outcomes.  
The association of OSA with health care utilisation including LoS on ICU, reintubation 
rate and in hospital LoS were examined as part of SACS. I did not find that an increased 
probability of developing complications in patients with sleep apnoea led to increased health 
care utilisation in this population. One possible explanation for this finding was small sample 
size but it is also possible that LoS depends on many non-biological factors including:  local 
ICU discharge policies, bed availability on the hospital ward and therefore LoS on ICU may 
not represent a robust primary outcome. For future studies complications may be a more 
appropriate primary outcome.  
Other independent risk factors for increased probability of developing postoperative 
complications in the SACS study were administration of IOA (OR 3.1, p=0.010) and 
EuroSCORE (OR 1.34, p<0.001). On further analysis it was found that patients with sleep 
apnoea but also those without had a higher probability of developing postoperative 
complications, when given intravenous opioid analgesia. When I examined for associations 
between the dose of morphine and postoperative complications, no significant association 
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was found but this could have been due to the loss of power for assessing this outcome. It is 
possible that there may be a dose association for worse postoperative outcomes in patients 
with OSA but larger trials are needed to clarify the effect.  
It is difficult to be dogmatic about the clinical implications of the association between 
morphine use and complications. Opioid analgesia remains widely used in the postoperative 
setting with no obvious viable alternative. Further research is needed to further explain this 
result. It is possible that patients who received iv morphine simply represented a more 
unwell group of patients with causation the other way around, namely complications required 
the use of morphine. For the moment intravenous opioids should still only be used with 
caution in this cohort of patients.  
Given the association between sleep apnoea and ICU complications it is possible 
that these complications are more likely to arise if responsible clinicians are unaware of the 
diagnosis of sleep apnoea in patients presenting for surgery. Identifying high risk patients, 
prior to surgery would allow for cautious monitoring and taking preventative measures in 
perioperative settings. A simple and cost effective screening tool could help with identifying 
such patients prior to surgery. The results of this thesis show that the STOP-Bang 
questionnaire, validated against nocturnal oximetry, at the conventional cut-off value, 
performed poorly to accurately identify patients at high risk for mild and moderate/severe SA 
but scores of 0-2 would with high confidence exclude those without the diagnosis. The best 
performance was found for moderate SA at cut-off value of ≥6 with moderately high 
sensitivity and specificity of 75%. Given the high specificity at this cut off in this cardiac, 
surgical cohort, all patients with the STOP-Bang ≥6 could be screened with nocturnal 
oximetry prior to surgery. I found that ODI is independently associated with increased risk of 
developing postoperative ICU complications and thus this simple screening method could 
identify patients who may be at higher risk and would allow for appropriate monitoring to 
mitigate the risks. At present, however, there is no evidence that this approach reduces the 
risks, and moreover no evidence that treating OSA with CPAP improves postoperative 
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outcomes. Future research should therefore concentrate on establishing the clinical and cost 
effectiveness of CPAP in the treatment of OSA in patients presenting for cardiac as well as 
general surgery. 
Following the results of SACS study and in particular, the effect of morphine on 
postoperative complications, the existing literature was examined via a Systematic Cochrane 
review for evidence of the effect of opiates/opioids, sedatives and hypnotics on patients with 
pre-existing OSA. This review examining evidence from RCT’s comparing these compounds 
with placebo, showed that there is currently no robust evidence to guide clinicians when 
prescribing these drugs to patients with OSA. The available evidence consists of short trials 
with small numbers of people randomly assigned to these treatments, with most trials 
unblinded and with unclear risk of selection bias. There was only one trial in this review 
examining the effect of an opioid, remifentanil, on patients with OSA. The result of the review 
showed that there is currently no available evidence supporting deleterious effects of the 
compounds, studied in the review, on worsening the severity of OSA as evidenced by 
change in AHI. There is nonetheless, a need for larger and methodologically robust trials to 
assess the true effect. 
Based on the conclusion from the Cochrane Systematic review and the 
aforementioned results from the prospective observational cohort trial, I studied the effect of 
intravenous morphine on patients with pre-existing moderate OSA, (MIMOSA). 
Unfortunately, despite the various measures to improve recruitment to this study I struggled 
with recruitment and the trial was stopped before reaching the target sample. Given the 
small sample size no definite no conclusion can be reached. Analysis of the data showed 
that morphine sulphate did not worsen the severity of OSA in terms of change in AHI but 
rather found that there was an improvement in OAI and CAI in my patient cohort, a finding 
similar to that shown with remifentanil infusion (Bernards et al. 2009). Both of these trials 
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included only a small number of participants but raise a hypothesis that morphine given to 
certain phenotype of OSA patients may have a protective effect.  
In conclusion, this thesis showed that sleep apnoea is prevalent in the cardiac 
surgical population as previously reported. More importantly, the hallmark of sleep apnoea, 
intermittent oxygen desaturations during the night were found to be an independent predictor 
for an increased risk of ICU complications in patients with undiagnosed sleep apnoea 
undergoing cardiac surgery. Even patients with mild sleep apnoea were found to have a 
higher probability of developing such complications and the probability rose with the severity 
of sleep apnoea. Patients presenting for cardiac surgery can be screened by the STOP-
Bang questionnaire, where a score 0-2 would , with high confidence exclude sleep apnoea 
but those scoring ≥ 6 could be tested with nocturnal oximetry prior to surgery to identify 
patients at risk. The administration of intravenous opioids was associated with worse 
postoperative outcomes among cardiac surgical patients. The effect of opiates and opioids 
on patients with OSA remains unknown as the current Cochrane review concluded that there 
is not enough evidence to advise regarding the safety of morphine on patients with OSA 
although there is currently no evidence for a deleterious effect. The MIMOSA trial, reported 
in this thesis, failed to clarify this clinical question as the trial had to be stopped prematurely 
due to difficulty recruiting eligible subjects. In the small numbers of participants studied all 
improved on measures of sleep apnoea rather than deteriorated. Further research in this 
area is needed. 
Reflection of the trial methodology 
The selected trial methodology was governed by a number of constraints including 
available financial resources, ethical considerations, population available for recruitment and 
technology available to measure study outcomes. On reflection of the methodology used in 
this thesis, changes in trial’s methodology may have improved the value of the research. 
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In the prospective observational cohort study, using nocturnal oximetry to diagnose 
sleep apnoea did not allow differentiation of central, obstructive of mixed sleep apnoea. If 
rPSG was used instead such distinction would be possible and would allow better 
understanding of association of type of sleep disordered breathing with postoperative 
complications and could possibly identify more patients in the severe spectrum of OSA. 
Using sleep diagnostics in the patient’s own home instead of in hospital, the night before 
surgery, could allow better sleep quality and possibly more accurate outcomes. The in 
hospital assessment was favoured to reduce patient’s travelling time for home studies.  
In the MIMOSA trial, a double blinded, RCT would provide the highest level of 
evidence on the effect of morphine on patients with OSA but in view of the high number of 
subjects needed to show a difference when the power calculation was employed it was 
decided that a paired design trial was more pragmatic. More accurate assessment of the 
effect of morphine on patients with moderate OSA would be available if patients were 
studied in hospital on both, the baseline and morphine night visits as different quality of 
sleep may be observed in hospital and at home introducing the possibility of assessment 
bias. It was felt that to minimise the hospital admissions for patients it was more pragmatic to 
perform baseline study at home.  
Areas for future study 
The results of this thesis show an association between sleep apnoea and an 
increased risk of postoperative complications. The next important question is to assess the 
effect of CPAP treatment on postoperative outcomes in patients with OSA presenting for 
surgery. To confirm the effect of morphine on patients with OSA and to identify phenotypes 
at risk the effect of opioids require a larger RCT. The results of the Cochrane review will 
require an update in due course to gather and report up to date evidence
162 
 
References 
American Academy of Sleep Medicine Task Force (1999). "Sleep-related breathing disorders in 
adults: recommendations for syndrome definition and measurement techniques in clinical 
research. The Report of an American Academy of Sleep Medicine Task Force." Sleep 22(5): 
667-689. 
Abdelsattar, Z. M., S. Hendren, S. L. Wong, D. A. Campbell, Jr. and S. K. Ramachandran (2015). "The 
Impact of Untreated Obstructive Sleep Apnea on Cardiopulmonary Complications in 
General and Vascular Surgery: A Cohort Study." Sleep 38(8): 1205-1210. 
Abrishami, A., A. Khajehdehi and F. Chung (2010). "A systematic review of screening 
questionnaires for obstructive sleep apnea." Can J Anaesth 57(5): 423-438. 
Abuzaid, A. S., H. S. Al Ashry, A. Elbadawi, H. Ld, M. Saad, I. Y. Elgendy, A. Elgendy, A. N. 
Mahmoud, A. Mentias, A. Barakat and C. Lal (2017). "Meta-Analysis of Cardiovascular 
Outcomes With Continuous Positive Airway Pressure Therapy in Patients With Obstructive 
Sleep Apnea." Am J Cardiol 120(4): 693-699. 
Amra, B., N. Niknam, M. M. Sadeghi, M. Rabbani, I. Fietze and T. Penzel (2014). "Obstructive sleep 
apnea and postoperative complications in patients undergoing coronary artery bypass 
graft surgery: a need for preventive strategies." Int J Prev Med 5(11): 1446-1451. 
Ancoli-Israel, S., P. Gehrman, D. F. Kripke, C. Stepnowsky, W. Mason, M. Cohen-Zion and M. 
Marler (2001). "Long-term follow-up of sleep disordered breathing in older adults." Sleep 
Med 2(6): 511-516. 
Ancoli-Israel, S., M. R. Klauber, C. Stepnowsky, E. Estline, A. Chinn and R. Fell (1995). "Sleep-
disordered breathing in African-American elderly." Am J Respir Crit Care Med 152(6 Pt 1): 
1946-1949. 
Ancoli-Israel, S., D. F. Kripke, M. R. Klauber, R. Fell, C. Stepnowsky, E. Estline, N. Khazeni and A. 
Chinn (1996). "Morbidity, mortality and sleep-disordered breathing in community dwelling 
elderly." Sleep 19(4): 277-282. 
Ancoli-Israel, S., D. F. Kripke, M. R. Klauber, W. J. Mason, R. Fell and O. Kaplan (1991). "Sleep-
disordered breathing in community-dwelling elderly." Sleep 14(6): 486-495. 
Andreas, S., G. Hajak, P. Natt, D. Auge, E. Ruther and H. Kreuzer (1991). "[ST segmental changes 
and arrhythmias in obstructive sleep apnea]." Pneumologie 45(9): 720-724. 
Arnardottir, E. S., M. Mackiewicz, T. Gislason, K. L. Teff and A. I. Pack (2009). "Molecular signatures 
of obstructive sleep apnea in adults: a review and perspective." Sleep 32(4): 447-470. 
Auckley, D. (2003). "Does screening for sleep apnoea with the Berlin Questionnaire prededict 
elective surgery postoperative complications?" Sleep 26((s)): A238-239. 
Aurora, R. N., S. R. Bista, K. R. Casey, S. Chowdhuri, D. A. Kristo, J. M. Mallea, K. Ramar, J. A. 
Rowley, R. S. Zak and J. L. Heald (2016). "Updated Adaptive Servo-Ventilation 
Recommendations for the 2012 AASM Guideline: "The Treatment of Central Sleep Apnea 
Syndromes in Adults: Practice Parameters with an Evidence-Based Literature Review and 
Meta-Analyses"." J Clin Sleep Med 12(5): 757-761. 
Aurora, R. N., S. Chowdhuri, K. Ramar, S. R. Bista, K. R. Casey, C. I. Lamm, D. A. Kristo, J. M. Mallea, 
J. A. Rowley, R. S. Zak and S. L. Tracy (2012). "The treatment of central sleep apnea 
syndromes in adults: practice parameters with an evidence-based literature review and 
meta-analyses." Sleep 35(1): 17-40. 
Basner, R. C., J. Ringler, R. M. Schwartzstein, S. E. Weinberger and J. W. Weiss (1991). "Phasic 
electromyographic activity of the genioglossus increases in normals during slow-wave 
sleep." Respir Physiol 83(2): 189-200. 
Beloeil, H., N. Delage, I. Negre, J. X. Mazoit and D. Benhamou (2004). "The median effective dose 
of nefopam and morphine administered intravenously for postoperative pain after minor 
surgery: a prospective randomized double-blinded isobolographic study of their analgesic 
action." Anesth Analg 98(2): 395-400, table of contents. 
163 
 
Benbadis, S. R., E. Mascha, M. C. Perry, B. R. Wolgamuth, L. A. Smolley and D. S. Dinner (1999). 
"Association between the Epworth sleepiness scale and the multiple sleep latency test in a 
clinical population." Ann Intern Med 130(4 Pt 1): 289-292. 
Bergeron, C., J. Kimoff and Q. Hamid (2005). "Obstructive sleep apnea syndrome and 
inflammation." J Allergy Clin Immunol 116(6): 1393-1396. 
Bernards, C. M., S. L. Knowlton, D. F. Schmidt, W. J. DePaso, M. K. Lee, S. B. McDonald and O. S. 
Bains (2009). "Respiratory and sleep effects of remifentanil in volunteers with moderate 
obstructive sleep apnea." Anesthesiology 110(1): 41-49. 
Berry, R. B., R. Budhiraja, D. J. Gottlieb, D. Gozal, C. Iber, V. K. Kapur, C. L. Marcus, R. Mehra, S. 
Parthasarathy, S. F. Quan, S. Redline, K. P. Strohl, S. L. Davidson Ward, M. M. Tangredi and 
M. American Academy of Sleep (2012). "Rules for scoring respiratory events in sleep: 
update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. 
Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep 
Medicine." J Clin Sleep Med 8(5): 597-619. 
Berry, R. B., K. Kouchi, J. Bower, G. Prosise and R. W. Light (1995). "Triazolam in patients with 
obstructive sleep apnea." American journal of respiratory and critical care medicine 151(2 
Pt 1): 450-454. 
Berry, R. B., K. G. Kouchi, D. E. Der, M. J. Dickel and R. W. Light (1996). "Sleep apnea impairs the 
arousal response to airway occlusion." Chest 109(6): 1490-1496. 
Berry, R. B. and P. B. Patel (2006). "Effect of zolpidem on the efficacy of continuous positive airway 
pressure as treatment for obstructive sleep apnea." Sleep 29(8): 1052-1056. 
Bhama, J. K., S. Spagnolo, E. P. Alexander, M. Greenberg and G. D. Trachiotis (2006). "Coronary 
revascularization in patients with obstructive sleep apnea syndrome." Heart Surg Forum 
9(6): E813-817. 
Bixler, E. O., A. N. Vgontzas, H. M. Lin, T. Ten Have, J. Rein, A. Vela-Bueno and A. Kales (2001). 
"Prevalence of sleep-disordered breathing in women: effects of gender." Am J Respir Crit 
Care Med 163(3 Pt 1): 608-613. 
Bixler, E. O., A. N. Vgontzas, T. Ten Have, K. Tyson and A. Kales (1998). "Effects of age on sleep 
apnea in men: I. Prevalence and severity." Am J Respir Crit Care Med 157(1): 144-148. 
Bliwise, D. L., N. G. Bliwise, M. Partinen, A. M. Pursley and W. C. Dement (1988). "Sleep apnea and 
mortality in an aged cohort." Am J Public Health 78(5): 544-547. 
Bohning, N., B. Schultheiss, S. Eilers, T. Penzel, W. Bohning and E. Schmittendorf (2010). 
"Comparability of pulse oximeters used in sleep medicine for the screening of OSA." 
Physiol Meas 31(7): 875-888. 
Bonetti, P. O., L. O. Lerman and A. Lerman (2003). "Endothelial dysfunction: a marker of 
atherosclerotic risk." Arterioscler Thromb Vasc Biol 23(2): 168-175. 
Bonora, M., W. M. St John and T. A. Bledsoe (1985). "Differential elevation by protriptyline and 
depression by diazepam of upper airway respiratory motor activity." Am Rev Respir Dis 
131(1): 41-45. 
Bonsignore, M. R., G. Parati, G. Insalaco, P. Castiglioni, O. Marrone, S. Romano, A. Salvaggio, G. 
Mancia, G. Bonsignore and M. Di Rienzo (2006). "Baroreflex control of heart rate during 
sleep in severe obstructive sleep apnoea: effects of acute CPAP." Eur Respir J 27(1): 128-
135. 
Bradley, T. D. and J. S. Floras (2003). "Sleep apnea and heart failure: Part I: obstructive sleep 
apnea." Circulation 107(12): 1671-1678. 
Bradley, T. D., M. J. Hall, S. Ando and J. S. Floras (2001). "Hemodynamic effects of simulated 
obstructive apneas in humans with and without heart failure." Chest 119(6): 1827-1835. 
Bradley, T. D., R. Tkacova, M. J. Hall, S. Ando and J. S. Floras (2003). "Augmented sympathetic 
neural response to simulated obstructive apnoea in human heart failure." Clin Sci (Lond) 
104(3): 231-238. 
164 
 
Brinker, J. A., J. L. Weiss, D. L. Lappe, J. L. Rabson, W. R. Summer, S. Permutt and M. L. Weisfeldt 
(1980). "Leftward septal displacement during right ventricular loading in man." Circulation 
61(3): 626-633. 
Broadbent, W. H. (1877). "The Causes of the Sounds of the Heart: Reply to Dr. Leared." Br Med J 
1(841): 160-161. 
Brown, K. A., A. Laferriere, I. Lakheeram and I. R. Moss (2006). "Recurrent hypoxemia in children is 
associated with increased analgesic sensitivity to opiates." Anesthesiology 105(4): 665-
669. 
Brown, K. A., A. Laferriere and I. R. Moss (2004). "Recurrent hypoxemia in young children with 
obstructive sleep apnea is associated with reduced opioid requirement for analgesia." 
Anesthesiology 100(4): 806-810; discussion 805A. 
Bucca, C. B., L. Brussino, A. Battisti, R. Mutani, G. Rolla, L. Mangiardi and A. Cicolin (2007). 
"Diuretics in obstructive sleep apnea with diastolic heart failure." Chest 132(2): 440-446. 
Buchner, N. J., B. M. Sanner, J. Borgel and L. C. Rump (2007). "Continuous positive airway pressure 
treatment of mild to moderate obstructive sleep apnea reduces cardiovascular risk." Am J 
Respir Crit Care Med 176(12): 1274-1280. 
Byard, R. W. and J. D. Gilbert (2005). "Narcotic administration and stenosing lesions of the upper 
airway--a potentially lethal combination." J Clin Forensic Med 12(1): 29-31. 
Cakirer, B., M. G. Hans, G. Graham, J. Aylor, P. V. Tishler and S. Redline (2001). "The relationship 
between craniofacial morphology and obstructive sleep apnea in whites and in African-
Americans." Am J Respir Crit Care Med 163(4): 947-950. 
Camacho, M. E. and C. M. Morin (1995). "The effect of temazepam on respiration in elderly 
insomniacs with mild sleep apnea." Sleep 18(8): 644-645. 
Carberry, J. C., L. P. Fisher, R. R. Grunstein, S. C. Gandevia, D. K. McKenzie, J. E. Butler and D. J. 
Eckert (2017). "Role of common hypnotics on the phenotypic causes of obstructive sleep 
apnoea: paradoxical effects of zolpidem." Eur Respir J 50(6). 
Carlson, J. T., C. Rangemark and J. A. Hedner (1996). "Attenuated endothelium-dependent vascular 
relaxation in patients with sleep apnoea." J Hypertens 14(5): 577-584. 
Carskadon, M. A., W. C. Dement, M. M. Mitler, T. Roth, P. R. Westbrook and S. Keenan (1986). 
"Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness." 
Sleep 9(4): 519-524. 
Catley, D. M., C. Thornton, C. Jordan, J. R. Lehane, D. Royston and J. G. Jones (1985). "Pronounced, 
episodic oxygen desaturation in the postoperative period: its association with ventilatory 
pattern and analgesic regimen." Anesthesiology 63(1): 20-28. 
Chiner, E., J. Signes-Costa, J. M. Arriero, J. Marco, I. Fuentes and A. Sergado (1999). "Nocturnal 
oximetry for the diagnosis of the sleep apnoea hypopnoea syndrome: a method to reduce 
the number of polysomnographies?" Thorax 54(11): 968-971. 
Chiu, H. Y., P. Y. Chen, L. P. Chuang, N. H. Chen, Y. K. Tu, Y. J. Hsieh, Y. C. Wang and C. 
Guilleminault (2017). "Diagnostic accuracy of the Berlin questionnaire, STOP-BANG, STOP, 
and Epworth sleepiness scale in detecting obstructive sleep apnea: A bivariate meta-
analysis." Sleep Med Rev 36: 57-70. 
Chiu, K. L., C. M. Ryan, S. Shiota, P. Ruttanaumpawan, M. Arzt, J. S. Haight, C. T. Chan, J. S. Floras 
and T. D. Bradley (2006). "Fluid shift by lower body positive pressure increases pharyngeal 
resistance in healthy subjects." Am J Respir Crit Care Med 174(12): 1378-1383. 
Chokroverty, S. (1986). "Sleep apnea in narcolepsy." Sleep 9(1 Pt 2): 250-253. 
Chung, F., H. R. Abdullah and P. Liao (2016). "STOP-Bang Questionnaire: A Practical Approach to 
Screen for Obstructive Sleep Apnea." Chest 149(3): 631-638. 
Chung, F., E. Chau, Y. Yang, P. Liao, R. Hall and B. Mokhlesi (2013). "Serum bicarbonate level 
improves specificity of STOP-Bang screening for obstructive sleep apnea." Chest 143(5): 
1284-1293. 
165 
 
Chung, F., P. Liao, H. Elsaid, S. Islam, C. M. Shapiro and Y. Sun (2012). "Oxygen desaturation index 
from nocturnal oximetry: a sensitive and specific tool to detect sleep-disordered breathing 
in surgical patients." Anesth Analg 114(5): 993-1000. 
Chung, F., P. Liao, H. Elsaid, C. M. Shapiro and W. Kang (2014). "Factors associated with 
postoperative exacerbation of sleep-disordered breathing." Anesthesiology 120(2): 299-
311. 
Chung, F., P. Liao, B. Yegneswaran, C. M. Shapiro and W. Kang (2014). "Postoperative changes in 
sleep-disordered breathing and sleep architecture in patients with obstructive sleep 
apnea." Anesthesiology 120(2): 287-298. 
Chung, F., S. G. Memtsoudis, S. K. Ramachandran, M. Nagappa, M. Opperer, C. Cozowicz, S. 
Patrawala, D. Lam, A. Kumar, G. P. Joshi, J. Fleetham, N. Ayas, N. Collop, A. G. Doufas, M. 
Eikermann, M. Englesakis, B. Gali, P. Gay, A. V. Hernandez, R. Kaw, E. J. Kezirian, A. 
Malhotra, B. Mokhlesi, S. Parthasarathy, T. Stierer, F. Wappler, D. R. Hillman and D. 
Auckley (2016). "Society of Anesthesia and Sleep Medicine Guidelines on Preoperative 
Screening and Assessment of Adult Patients With Obstructive Sleep Apnea." Anesth Analg 
123(2): 452-473. 
Chung, F., R. Subramanyam, P. Liao, E. Sasaki, C. Shapiro and Y. Sun (2012). "High STOP-Bang score 
indicates a high probability of obstructive sleep apnoea." Br J Anaesth 108(5): 768-775. 
Chung, F., B. Ward, J. Ho, H. Yuan, L. Kayumov and C. Shapiro (2007). "Preoperative identification 
of sleep apnea risk in elective surgical patients, using the Berlin questionnaire." J Clin 
Anesth 19(2): 130-134. 
Chung, F., Y. Yang, R. Brown and P. Liao (2014). "Alternative scoring models of STOP-bang 
questionnaire improve specificity to detect undiagnosed obstructive sleep apnea." J Clin 
Sleep Med 10(9): 951-958. 
Chung, F., B. Yegneswaran, P. Liao, S. A. Chung, S. Vairavanathan, S. Islam, A. Khajehdehi and C. M. 
Shapiro (2008). "STOP questionnaire: a tool to screen patients for obstructive sleep 
apnea." Anesthesiology 108(5): 812-821. 
Chung, F., L. Zhou and P. Liao (2014). "Parameters from preoperative overnight oximetry predict 
postoperative adverse events." Minerva Anestesiol 80(10): 1084-1095. 
Cirignotta, F., S. Mondini, R. Gerardi and M. Zucconi (1992). "Effect of brotizolam on sleep-
disordered breathing in heavy snorers with obstructive apnea." Current therapeutic 
research, clinical and experimental 51(3): 360-366. 
Cirignotta, F., S. Mondini, M. Zucconi, R. Gerardi, A. Farolfi and E. Lugaresi (1988). "Zolpidem-
polysomnographic study of the effect of a new hypnotic drug in sleep apnea syndrome." 
Pharmacology, biochemistry, and behavior 29(4): 807-809. 
Cluydts, R., E. De Valck, E. Verstraeten and P. Theys (2002). "Daytime sleepiness and its 
evaluation." Sleep Med Rev 6(2): 83-96. 
Collop, N. A., W. M. Anderson, B. Boehlecke, D. Claman, R. Goldberg, D. J. Gottlieb, D. Hudgel, M. 
Sateia, R. Schwab and M. Portable Monitoring Task Force of the American Academy of 
Sleep (2007). "Clinical guidelines for the use of unattended portable monitors in the 
diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of 
the American Academy of Sleep Medicine." J Clin Sleep Med 3(7): 737-747. 
Cooper, B. G., D. Veale, C. J. Griffiths and G. J. Gibson (1991). "Value of nocturnal oxygen 
saturation as a screening test for sleep apnoea." Thorax 46(8): 586-588. 
Corso, R. M., F. Petrini, M. Buccioli, O. Nanni, E. Carretta, A. Trolio, D. De Nuzzo, A. Pigna, I. Di 
Giacinto, V. Agnoletti and G. Gambale (2014). "Clinical utility of preoperative screening 
with STOP-Bang questionnaire in elective surgery." Minerva Anestesiol 80(8): 877-884. 
Craig, S. E., M. Kohler, D. Nicoll, D. J. Bratton, A. Nunn, R. Davies and J. Stradling (2012). 
"Continuous positive airway pressure improves sleepiness but not calculated vascular risk 
in patients with minimally symptomatic obstructive sleep apnoea: the MOSAIC 
randomised controlled trial." Thorax 67(12): 1090-1096. 
166 
 
Cronin, A., J. C. Keifer, H. A. Baghdoyan and R. Lydic (1995). "Opioid inhibition of rapid eye 
movement sleep by a specific mu receptor agonist." Br J Anaesth 74(2): 188-192. 
D'Apuzzo, M. R. and J. A. Browne (2012). "Obstructive sleep apnea as a risk factor for 
postoperative complications after revision joint arthroplasty." J Arthroplasty 27(8 Suppl): 
95-98. 
Davies, R. J. and J. R. Stradling (1996). "The epidemiology of sleep apnoea." Thorax 51 Suppl 2: 
S65-70. 
Deeks, J. J. (2001). "Systematic reviews in health care: Systematic reviews of evaluations of 
diagnostic and screening tests." BMJ 323(7305): 157-162. 
Doherty, L. S., J. L. Kiely, V. Swan and W. T. McNicholas (2005). "Long-term effects of nasal 
continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea 
syndrome." Chest 127(6): 2076-2084. 
Doufas, A. G., L. Tian, K. A. Padrez, P. Suwanprathes, J. A. Cardell, H. T. Maecker and P. Panousis 
(2013). "Experimental pain and opioid analgesia in volunteers at high risk for obstructive 
sleep apnea." PLoS One 8(1): e54807. 
Drager, L. F., A. R. Brunoni, R. Jenner, G. Lorenzi-Filho, I. M. Bensenor and P. A. Lotufo (2015). 
"Effects of CPAP on body weight in patients with obstructive sleep apnoea: a meta-
analysis of randomised trials." Thorax 70(3): 258-264. 
Drummond, G. B. (1983). "Comparison of decreases in ventilation caused by enflurane and 
fentanyl during anaesthesia." Br J Anaesth 55(9): 825-835. 
Duce, B., J. Milosavljevic and C. Hukins (2015). "The 2012 AASM Respiratory Event Criteria Increase 
the Incidence of Hypopneas in an Adult Sleep Center Population." J Clin Sleep Med 11(12): 
1425-1431. 
Duran-Cantolla, J., F. Aizpuru, C. Martinez-Null and F. Barbe-Illa (2009). "Obstructive sleep 
apnea/hypopnea and systemic hypertension." Sleep Med Rev 13(5): 323-331. 
Duran, J., S. Esnaola, R. Rubio and A. Iztueta (2001). "Obstructive sleep apnea-hypopnea and 
related clinical features in a population-based sample of subjects aged 30 to 70 yr." Am J 
Respir Crit Care Med 163(3 Pt 1): 685-689. 
Dyken, M. E., T. Yamada, C. L. Glenn and H. A. Berger (2004). "Obstructive sleep apnea associated 
with cerebral hypoxemia and death." Neurology 62(3): 491-493. 
Eastwood, P. R., P. R. Platt, K. Shepherd, K. Maddison and D. R. Hillman (2005). "Collapsibility of 
the upper airway at different concentrations of propofol anesthesia." Anesthesiology 
103(3): 470-477. 
Eckert, D. J., A. S. Jordan, P. Merchia and A. Malhotra (2007). "Central sleep apnea: 
Pathophysiology and treatment." Chest 131(2): 595-607. 
Eckert, D. J. and A. Malhotra (2008). "Pathophysiology of adult obstructive sleep apnea." Proc Am 
Thorac Soc 5(2): 144-153. 
Eckert, D. J., R. D. McEvoy, K. E. George, K. J. Thomson and P. G. Catcheside (2007). "Genioglossus 
reflex inhibition to upper-airway negative-pressure stimuli during wakefulness and sleep 
in healthy males." J Physiol 581(Pt 3): 1193-1205. 
Eckert, D. J., R. L. Owens, G. B. Kehlmann, A. Wellman, S. Rahangdale, S. Yim-Yeh, D. P. White and 
A. Malhotra (2011). "Eszopiclone increases the respiratory arousal threshold and lowers 
the apnoea/hypopnoea index in obstructive sleep apnoea patients with a low arousal 
threshold." Clinical science 120(12): 505-514. 
Eckert, D. J., R. L. Owens, G. B. Kehlmann, A. Wellman, S. Rahangdale, S. Yim-Yeh, D. P. White and 
A. Malhotra (2011). "Eszopiclone increases the respiratory arousal threshold and lowers 
the apnoea/hypopnoea index in obstructive sleep apnoea patients with a low arousal 
threshold." Clin Sci (Lond) 120(12): 505-514. 
Eckert, D. J. and M. K. Younes (2014). "Arousal from sleep: implications for obstructive sleep 
apnea pathogenesis and treatment." J Appl Physiol (1985) 116(3): 302-313. 
167 
 
Endo, T., B. Schwierin, A. A. Borbely and I. Tobler (1997). "Selective and total sleep deprivation: 
effect on the sleep EEG in the rat." Psychiatry Res 66(2-3): 97-110. 
Engleman, H. M., S. E. Martin, I. J. Deary and N. J. Douglas (1994). "Effect of continuous positive 
airway pressure treatment on daytime function in sleep apnoea/hypopnoea syndrome." 
Lancet 343(8897): 572-575. 
Esclamado, R. M., M. G. Glenn, T. M. McCulloch and C. W. Cummings (1989). "Perioperative 
complications and risk factors in the surgical treatment of obstructive sleep apnea 
syndrome." Laryngoscope 99(11): 1125-1129. 
Ferrier, K., A. Campbell, B. Yee, M. Richards, T. O'Meeghan, M. Weatherall and A. Neill (2005). 
"Sleep-disordered breathing occurs frequently in stable outpatients with congestive heart 
failure." Chest 128(4): 2116-2122. 
Fidan, H., F. Fidan, M. Unlu, Y. Ela, A. Ibis and L. Tetik (2006). "Prevalence of sleep apnoea in 
patients undergoing operation." Sleep Breath 10(3): 161-165. 
Findley, L. J., M. E. Unverzagt and P. M. Suratt (1988). "Automobile accidents involving patients 
with obstructive sleep apnea." Am Rev Respir Dis 138(2): 337-340. 
Finkel, K. J., A. C. Searleman, H. Tymkew, C. Y. Tanaka, L. Saager, E. Safer-Zadeh, M. Bottros, J. A. 
Selvidge, E. Jacobsohn, D. Pulley, S. Duntley, C. Becker and M. S. Avidan (2009). 
"Prevalence of undiagnosed obstructive sleep apnea among adult surgical patients in an 
academic medical center." Sleep Med 10(7): 753-758. 
Flemons, W. W., N. J. Douglas, S. T. Kuna, D. O. Rodenstein and J. Wheatley (2004). "Access to 
diagnosis and treatment of patients with suspected sleep apnea." Am J Respir Crit Care 
Med 169(6): 668-672. 
Fletcher, E. C. (2003). "Sympathetic over activity in the etiology of hypertension of obstructive 
sleep apnea." Sleep 26(1): 15-19. 
Foldvary-Schaefer, N., R. Kaw, N. Collop, N. D. Andrews, J. Bena, L. Wang, T. Stierer, M. Gillinov, 
M. Tarler and H. Kayyali (2015). "Prevalence of Undetected Sleep Apnea in Patients 
Undergoing Cardiovascular Surgery and Impact on Postoperative Outcomes." J Clin Sleep 
Med 11(10): 1083-1089. 
Franklin, K. A., J. B. Nilsson, C. Sahlin and U. Naslund (1995). "Sleep apnoea and nocturnal angina." 
Lancet 345(8957): 1085-1087. 
Gami, A. S., D. E. Howard, E. J. Olson and V. K. Somers (2005). "Day-night pattern of sudden death 
in obstructive sleep apnea." N Engl J Med 352(12): 1206-1214. 
Garvey, J. F., C. T. Taylor and W. T. McNicholas (2009). "Cardiovascular disease in obstructive sleep 
apnoea syndrome: the role of intermittent hypoxia and inflammation." Eur Respir J 33(5): 
1195-1205. 
Gastaut, H. (1965). "[Apropos of an international classification of epileptic seizures]." Mars Med 
102(5): 461-468. 
Gastaut, H., C. A. Tassinari and B. Duron (1965). "[Polygraphic study of diurnal and nocturnal 
(hypnic and respiratory) episodal manifestations of Pickwick syndrome]." Rev Neurol 
(Paris) 112(6): 568-579. 
Geissler, H. J., P. Holzl, S. Marohl, F. Kuhn-Regnier, U. Mehlhorn, M. Sudkamp and E. R. de Vivie 
(2000). "Risk stratification in heart surgery: comparison of six score systems." Eur J 
Cardiothorac Surg 17(4): 400-406. 
George, C. F., P. W. Nickerson, P. J. Hanly, T. W. Millar and M. H. Kryger (1987). "Sleep apnoea 
patients have more automobile accidents." Lancet 2(8556): 447. 
George, C. F. P., N. Feldman, N. Inhaber, T. L. Steininger, S. M. Grzeschik, C. Lai and Y. Zheng 
(2010). "A safety trial of sodium oxybate in patients with obstructive sleep apnea: Acute 
effects on sleep-disordered breathing." Sleep medicine 11(1): 38-42. 
George, C. F. P., N. Feldman, Y. Zheng, T. L. Steininger, S. M. Grzeschik, C. Lai and N. Inhaber 
(2011). "A 2-week, polysomnographic, safety study of sodium oxybate in obstructive sleep 
apnea syndrome." Schlaf & Atmung [Sleep & breathing] 15(1): 13-20. 
168 
 
Giles, T. L., T. J. Lasserson, B. H. Smith, J. White, J. Wright and C. J. Cates (2006). "Continuous 
positive airways pressure for obstructive sleep apnoea in adults." Cochrane Database Syst 
Rev(3): CD001106. 
Gleadhill, I. C., A. R. Schwartz, N. Schubert, R. A. Wise, S. Permutt and P. L. Smith (1991). "Upper 
airway collapsibility in snorers and in patients with obstructive hypopnea and apnea." Am 
Rev Respir Dis 143(6): 1300-1303. 
Gogenur, I., S. Rosenberg-Adamsen, C. Lie, M. Carstensen, V. Rasmussen and J. Rosenberg (2004). 
"Relationship between nocturnal hypoxaemia, tachycardia and myocardial ischaemia after 
major abdominal surgery." Br J Anaesth 93(3): 333-338. 
Gooneratne, N. S., P. Gehrman, I. Gurubhagavatula, E. Al-Shehabi, E. Marie and R. Schwab (2010). 
"Effectiveness of ramelteon for insomnia symptoms in older adults with obstructive sleep 
apnea: a randomized placebo-controlled pilot study." Journal of clinical sleep medicine 
6(6): 572-580. 
Gora, J., J. Trinder, R. Pierce and I. M. Colrain (2002). "Evidence of a sleep-specific blunted cortical 
response to inspiratory occlusions in mild obstructive sleep apnea syndrome." Am J Respir 
Crit Care Med 166(9): 1225-1234. 
Gottlieb, D. J., C. W. Whitney, W. H. Bonekat, C. Iber, G. D. James, M. Lebowitz, F. J. Nieto and C. E. 
Rosenberg (1999). "Relation of sleepiness to respiratory disturbance index: the Sleep 
Heart Health Study." Am J Respir Crit Care Med 159(2): 502-507. 
Gries, R. E. and L. J. Brooks (1996). "Normal oxyhemoglobin saturation during sleep. How low does 
it go?" Chest 110(6): 1489-1492. 
Gross, J. B., K. L. Bachenberg, J. L. Benumof, R. A. Caplan, R. T. Connis, C. J. Cote, D. G. Nickinovich, 
V. Prachand, D. S. Ward, E. M. Weaver, L. Ydens and S. Yu (2006). "Practice guidelines for 
the perioperative management of patients with obstructive sleep apnea: a report by the 
American Society of Anesthesiologists Task Force on Perioperative Management of 
patients with obstructive sleep apnea." Anesthesiology 104(5): 1081-1093; quiz 1117-1088. 
Gupta, R. M., J. Parvizi, A. D. Hanssen and P. C. Gay (2001). "Postoperative complications in 
patients with obstructive sleep apnea syndrome undergoing hip or knee replacement: a 
case-control study." Mayo Clin Proc 76(9): 897-905. 
Haas, D. C., G. L. Foster, F. J. Nieto, S. Redline, H. E. Resnick, J. A. Robbins, T. Young and T. G. 
Pickering (2005). "Age-dependent associations between sleep-disordered breathing and 
hypertension: importance of discriminating between systolic/diastolic hypertension and 
isolated systolic hypertension in the Sleep Heart Health Study." Circulation 111(5): 614-
621. 
Haba-Rubio, J., D. Andries, V. Rey-Bataillard, P. Michel, M. Tafti and R. Heinzer (2015). "Effect of 
transnasal insufflation on sleep-disordered breathing in acute stroke." Sleep Breath 19(1): 
3. 
Hader, C., A. Schroeder, M. Hinz, G. H. Micklefield and K. Rasche (2005). "Sleep disordered 
breathing in the elderly: comparison of women and men." J Physiol Pharmacol 56 Suppl 4: 
85-91. 
Hai, F., J. Porhomayon, L. Vermont, L. Frydrych, P. Jaoude and A. A. El-Solh (2014). "Postoperative 
complications in patients with obstructive sleep apnea: a meta-analysis." J Clin Anesth 
26(8): 591-600. 
Hang, L. W., H. L. Wang, J. H. Chen, J. C. Hsu, H. H. Lin, W. S. Chung and Y. F. Chen (2015). 
"Validation of overnight oximetry to diagnose patients with moderate to severe 
obstructive sleep apnea." BMC Pulm Med 15: 24. 
Hanly, P., Z. Sasson, N. Zuberi and K. Lunn (1993). "ST-segment depression during sleep in 
obstructive sleep apnea." Am J Cardiol 71(15): 1341-1345. 
Hedner, J., H. Ejnell, J. Sellgren, T. Hedner and G. Wallin (1988). "Is high and fluctuating muscle 
nerve sympathetic activity in the sleep apnoea syndrome of pathogenetic importance for 
the development of hypertension?" J Hypertens Suppl 6(4): S529-531. 
169 
 
Heinzer, R., S. Vat, P. Marques-Vidal, H. Marti-Soler, D. Andries, N. Tobback, V. Mooser, M. Preisig, 
A. Malhotra, G. Waeber, P. Vollenweider, M. Tafti and J. Haba-Rubio (2015). "Prevalence 
of sleep-disordered breathing in the general population: the HypnoLaus study." Lancet 
Respir Med 3(4): 310-318. 
Higgins, J. (2011). Cochrane Handbook for Systematic Reviews of Interventions. G. S. (editors), The 
Cochrane Collaboration. 
Hillman, D. R., J. H. Walsh, K. J. Maddison, P. R. Platt, J. P. Kirkness, W. J. Noffsinger and P. R. 
Eastwood (2009). "Evolution of changes in upper airway collapsibility during slow 
induction of anesthesia with propofol." Anesthesiology 111(1): 63-71. 
Hoffmann, M. S., P. Singh, R. Wolk, A. Romero-Corral, S. Raghavakaimal and V. K. Somers (2007). 
"Microarray studies of genomic oxidative stress and cell cycle responses in obstructive 
sleep apnea." Antioxid Redox Signal 9(6): 661-669. 
Hoffstein, V., N. Zamel and E. A. Phillipson (1984). "Lung volume dependence of pharyngeal cross-
sectional area in patients with obstructive sleep apnea." Am Rev Respir Dis 130(2): 175-
178. 
Höijer, U., J. Hedner, H. Ejnell, R. Grunstein, E. Odelberg and M. Elam (1994). "Nitrazepam in 
patients with sleep apnoea: a double-blind placebo-controlled study." European 
respiratory journal 7(11): 2011-2015. 
Holsboer-Trachsler, E. and R. Prieto (2013). "Effects of pregabalin on sleep in generalized anxiety 
disorder." Int J Neuropsychopharmacol 16(4): 925-936. 
Horner, R. L. (2007). "Respiratory motor activity: influence of neuromodulators and implications 
for sleep disordered breathing." Can J Physiol Pharmacol 85(1): 155-165. 
Horner, R. L., J. A. Innes, K. Murphy and A. Guz (1991). "Evidence for reflex upper airway dilator 
muscle activation by sudden negative airway pressure in man." J Physiol 436: 15-29. 
Hu, F. B., W. C. Willett, J. E. Manson, G. A. Colditz, E. B. Rimm, F. E. Speizer, C. H. Hennekens and 
M. J. Stampfer (2000). "Snoring and risk of cardiovascular disease in women." J Am Coll 
Cardiol 35(2): 308-313. 
Hu, X., J. Fan, S. Chen, Y. Yin and B. Zrenner (2015). "The role of continuous positive airway 
pressure in blood pressure control for patients with obstructive sleep apnea and 
hypertension: a meta-analysis of randomized controlled trials." J Clin Hypertens 
(Greenwich) 17(3): 215-222. 
Huang, Y. S. and C. Guilleminault (2009). "Narcolepsy: action of two gamma-aminobutyric acid 
type B agonists, baclofen and sodium oxybate." Pediatr Neurol 41(1): 9-16. 
Hudgel, D. W., C. Hendricks and A. Dadley (1988). "Alteration in obstructive apnea pattern induced 
by changes in oxygen- and carbon-dioxide-inspired concentrations." Am Rev Respir Dis 
138(1): 16-19. 
Hwang, D., N. Shakir, B. Limann, C. Sison, S. Kalra, L. Shulman, C. Souza Ade and H. Greenberg 
(2008). "Association of sleep-disordered breathing with postoperative complications." 
Chest 133(5): 1128-1134. 
Ip, M. S., B. Lam, I. J. Lauder, K. W. Tsang, K. F. Chung, Y. W. Mok and W. K. Lam (2001). "A 
community study of sleep-disordered breathing in middle-aged Chinese men in Hong 
Kong." Chest 119(1): 62-69. 
Ip, M. S., B. Lam, L. C. Tang, I. J. Lauder, T. Y. Ip and W. K. Lam (2004). "A community study of 
sleep-disordered breathing in middle-aged Chinese women in Hong Kong: prevalence and 
gender differences." Chest 125(1): 127-134. 
Isono, S., J. E. Remmers, A. Tanaka, Y. Sho, J. Sato and T. Nishino (1997). "Anatomy of pharynx in 
patients with obstructive sleep apnea and in normal subjects." J Appl Physiol (1985) 82(4): 
1319-1326. 
Javaheri, S. (2006). "Sleep disorders in systolic heart failure: a prospective study of 100 male 
patients. The final report." Int J Cardiol 106(1): 21-28. 
170 
 
Javaheri, S., T. J. Parker, J. D. Liming, W. S. Corbett, H. Nishiyama, L. Wexler and G. A. Roselle 
(1998). "Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and 
their prevalences, consequences, and presentations." Circulation 97(21): 2154-2159. 
Jennum, P., H. O. Hein, P. Suadicani and F. Gyntelberg (1995). "Risk of ischemic heart disease in 
self-reported snorers. A prospective study of 2,937 men aged 54 to 74 years: the 
Copenhagen Male Study." Chest 108(1): 138-142. 
Johns, M. W. (1991). "A new method for measuring daytime sleepiness: the Epworth sleepiness 
scale." Sleep 14(6): 540-545. 
Johns, M. W. (1992). "Reliability and factor analysis of the Epworth Sleepiness Scale." Sleep 15(4): 
376-381. 
Jordan, A. S., D. J. Eckert, P. G. Catcheside and R. D. McEvoy (2003). "Ventilatory response to brief 
arousal from non-rapid eye movement sleep is greater in men than in women." Am J 
Respir Crit Care Med 168(12): 1512-1519. 
Jordan, A. S., A. Wellman, R. C. Heinzer, Y. L. Lo, K. Schory, L. Dover, S. Gautam, A. Malhotra and D. 
P. White (2007). "Mechanisms used to restore ventilation after partial upper airway 
collapse during sleep in humans." Thorax 62(10): 861-867. 
Kairaitis, K., K. Byth, R. Parikh, R. Stavrinou, J. R. Wheatley and T. C. Amis (2007). "Tracheal 
traction effects on upper airway patency in rabbits: the role of tissue pressure." Sleep 
30(2): 179-186. 
Kapur, V. K., C. M. Baldwin, H. E. Resnick, D. J. Gottlieb and F. J. Nieto (2005). "Sleepiness in 
patients with moderate to severe sleep-disordered breathing." Sleep 28(4): 472-477. 
Kaw, R., F. Chung, V. Pasupuleti, J. Mehta, P. C. Gay and A. V. Hernandez (2012). "Meta-analysis of 
the association between obstructive sleep apnoea and postoperative outcome." Br J 
Anaesth 109(6): 897-906. 
Kaw, R., J. Golish, S. Ghamande, R. Burgess, N. Foldvary and E. Walker (2006). "Incremental risk of 
obstructive sleep apnea on cardiac surgical outcomes." J Cardiovasc Surg (Torino) 47(6): 
683-689. 
Kaw, R., F. Michota, A. Jaffer, S. Ghamande, D. Auckley and J. Golish (2006). "Unrecognized sleep 
apnea in the surgical patient: implications for the perioperative setting." Chest 129(1): 
198-205. 
Kehlet, H. and J. Rosenberg (1995). "Late post-operative hypoxaemia and organ dysfunction." Eur J 
Anaesthesiol Suppl 10: 31-34. 
Khan, S. U., C. A. Duran, H. Rahman, M. Lekkala, M. A. Saleem and E. Kaluski (2017). "A meta-
analysis of continuous positive airway pressure therapy in prevention of cardiovascular 
events in patients with obstructive sleep apnoea." Eur Heart J. 
Khoo, M. C., R. E. Kronauer, K. P. Strohl and A. S. Slutsky (1982). "Factors inducing periodic 
breathing in humans: a general model." J Appl Physiol Respir Environ Exerc Physiol 53(3): 
644-659. 
Kim, R. D., V. K. Kapur, J. Redline-Bruch, M. Rueschman, D. H. Auckley, R. M. Benca, N. R. Foldvary-
Schafer, C. Iber, P. C. Zee, C. L. Rosen, S. Redline and S. D. Ramsey (2015). "An Economic 
Evaluation of Home Versus Laboratory-Based Diagnosis of Obstructive Sleep Apnea." Sleep 
38(7): 1027-1037. 
Kindgen-Milles, D., E. Muller, R. Buhl, H. Bohner, D. Ritter, W. Sandmann and J. Tarnow (2005). 
"Nasal-continuous positive airway pressure reduces pulmonary morbidity and length of 
hospital stay following thoracoabdominal aortic surgery." Chest 128(2): 821-828. 
Kingshott, R. N., P. J. Sime, H. M. Engleman and N. J. Douglas (1995). "Self assessment of daytime 
sleepiness: patient versus partner." Thorax 50(9): 994-995. 
Knill, R. L., C. A. Moote, M. I. Skinner and E. A. Rose (1990). "Anesthesia with abdominal surgery 
leads to intense REM sleep during the first postoperative week." Anesthesiology 73(1): 52-
61. 
171 
 
Kohler, M., A. C. Stoewhas, L. Ayers, O. Senn, K. E. Bloch, E. W. Russi and J. R. Stradling (2011). 
"Effects of continuous positive airway pressure therapy withdrawal in patients with 
obstructive sleep apnea: a randomized controlled trial." Am J Respir Crit Care Med 
184(10): 1192-1199. 
Koo, C. Y. (2011). "Respiratory Effects of Opioids in Perioperative medicine." The Open 
Anesthesiology Journal((Suppl 1-M6)): 23-24. 
Koskenvuo, M., J. Kaprio, K. Heikkila, S. Sarna, T. Telakivi and M. Partinen (1987). "Snoring as a risk 
factor for ischaemic heart disease and stroke in men." Br Med J (Clin Res Ed) 294(6572): 
643. 
Krishna, J., Z. A. Shah, M. Merchant, J. B. Klein and D. Gozal (2006). "Urinary protein expression 
patterns in children with sleep-disordered breathing: preliminary findings." Sleep Med 
7(3): 221-227. 
Krol, R. C., S. L. Knuth and D. Bartlett, Jr. (1984). "Selective reduction of genioglossal muscle 
activity by alcohol in normal human subjects." Am Rev Respir Dis 129(2): 247-250. 
Kryger, M., S. Wang-Weigand and T. Roth (2007). "Safety of ramelteon in individuals with mild to 
moderate obstructive sleep apnea." Schlaf & Atmung [Sleep & breathing] 11(3): 159-164. 
Kua, J., L. P. Zhao, T. Kofidis, S. P. Chan, T. C. Yeo, H. C. Tan and C. H. Lee (2016). "Sleep apnoea is a 
risk factor for acute kidney injury after coronary artery bypass grafting." Eur J Cardiothorac 
Surg 49(4): 1188-1194. 
Kuniyoshi, F. H., A. Garcia-Touchard, A. S. Gami, A. Romero-Corral, C. van der Walt, S. 
Pusalavidyasagar, T. Kara, S. M. Caples, G. S. Pressman, E. C. Vasquez, F. Lopez-Jimenez 
and V. K. Somers (2008). "Day-night variation of acute myocardial infarction in obstructive 
sleep apnea." J Am Coll Cardiol 52(5): 343-346. 
Laferriere, A., J. K. Liu and I. R. Moss (2003). "Neurokinin-1 versus mu-opioid receptor binding in 
rat nucleus tractus solitarius after single and recurrent intermittent hypoxia." Brain Res 
Bull 59(4): 307-313. 
Lalley, P. M. (2008). "Opioidergic and dopaminergic modulation of respiration." Respir Physiol 
Neurobiol 164(1-2): 160-167. 
Lamarche, Y., R. Martin, J. Reiher and G. Blaise (1986). "The sleep apnoea syndrome and epidural 
morphine." Can Anaesth Soc J 33(2): 231-233. 
Lander, E. and L. Kruglyak (1995). "Genetic dissection of complex traits: guidelines for interpreting 
and reporting linkage results." Nat Genet 11(3): 241-247. 
Launois, S. H., J. L. Pepin and P. Levy (2007). "Sleep apnea in the elderly: a specific entity?" Sleep 
Med Rev 11(2): 87-97. 
Lecube, A., G. Sampol, P. Lloberes, O. Romero, J. Mesa, F. Morell and R. Simo (2010). 
"Asymptomatic sleep-disordered breathing in premenopausal women awaiting bariatric 
surgery." Obes Surg 20(4): 454-461. 
Leino, K., L. Mildh, K. Lertola, T. Seppala and O. Kirvela (1999). "Time course of changes in 
breathing pattern in morphine- and oxycodone-induced respiratory depression." 
Anaesthesia 54(9): 835-840. 
Leiter, J. C., S. L. Knuth, R. C. Krol and D. Bartlett, Jr. (1985). "The effect of diazepam on 
genioglossal muscle activity in normal human subjects." Am Rev Respir Dis 132(2): 216-
219. 
Liao, P., B. Yegneswaran, S. Vairavanathan, P. Zilberman and F. Chung (2009). "Postoperative 
complications in patients with obstructive sleep apnea: a retrospective matched cohort 
study." Can J Anaesth 56(11): 819-828. 
Lin, E., S. E. Calvano and S. F. Lowry (2000). "Inflammatory cytokines and cell response in surgery." 
Surgery 127(2): 117-126. 
Lindberg, E. and T. Gislason (2000). "Epidemiology of sleep-related obstructive breathing." Sleep 
Med Rev 4(5): 411-433. 
172 
 
Lindberg, E., C. Janson, K. Svardsudd, T. Gislason, J. Hetta and G. Boman (1998). "Increased 
mortality among sleepy snorers: a prospective population based study." Thorax 53(8): 631-
637. 
Lindberg, E., A. Taube, C. Janson, T. Gislason, K. Svardsudd and G. Boman (1998). "A 10-year 
follow-up of snoring in men." Chest 114(4): 1048-1055. 
Lockhart, E. M., M. D. Willingham, A. B. Abdallah, D. L. Helsten, B. A. Bedair, J. Thomas, S. Duntley 
and M. S. Avidan (2013). "Obstructive sleep apnea screening and postoperative mortality 
in a large surgical cohort." Sleep Med 14(5): 407-415. 
Logan, A. G., S. M. Perlikowski, A. Mente, A. Tisler, R. Tkacova, M. Niroumand, R. S. Leung and T. 
D. Bradley (2001). "High prevalence of unrecognized sleep apnoea in drug-resistant 
hypertension." J Hypertens 19(12): 2271-2277. 
Lugaresi, E., G. Coccagna, M. Mantovani and F. Brignani (1970). "[Effects of tracheotomy in 
hypersomnia with periodic respiration]." Rev Neurol (Paris) 123(4): 267-268. 
Lydic, R. and H. A. Baghdoyan (2005). "Sleep, anesthesiology, and the neurobiology of arousal 
state control." Anesthesiology 103(6): 1268-1295. 
Lydic, R., J. C. Keifer, H. A. Baghdoyan and L. Becker (1993). "Microdialysis of the pontine reticular 
formation reveals inhibition of acetylcholine release by morphine." Anesthesiology 79(5): 
1003-1012. 
Macintyre, P. E., J. A. Loadsman and D. A. Scott (2011). "Opioids, ventilation and acute pain 
management." Anaesth Intensive Care 39(4): 545-558. 
Mador, M. J., T. J. Kufel, U. J. Magalang, S. K. Rajesh, V. Watwe and B. J. Grant (2005). "Prevalence 
of positional sleep apnea in patients undergoing polysomnography." Chest 128(4): 2130-
2137. 
Malbois, M., V. Giusti, M. Suter, C. Pellaton, J. F. Vodoz and R. Heinzer (2010). "Oximetry alone 
versus portable polygraphy for sleep apnea screening before bariatric surgery." Obes Surg 
20(3): 326-331. 
Malhotra, A., Y. Huang, R. B. Fogel, G. Pillar, J. K. Edwards, R. Kikinis, S. H. Loring and D. P. White 
(2002). "The male predisposition to pharyngeal collapse: importance of airway length." 
Am J Respir Crit Care Med 166(10): 1388-1395. 
Mant, A., M. King, N. A. Saunders, C. D. Pond, E. Goode and H. Hewitt (1995). "Four-year follow-up 
of mortality and sleep-related respiratory disturbance in non-demented seniors." Sleep 
18(6): 433-438. 
Marin, J. M., S. J. Carrizo, E. Vicente and A. G. Agusti (2005). "Long-term cardiovascular outcomes 
in men with obstructive sleep apnoea-hypopnoea with or without treatment with 
continuous positive airway pressure: an observational study." Lancet 365(9464): 1046-
1053. 
Marshall, N. S., K. K. Wong, P. Y. Liu, S. R. Cullen, M. W. Knuiman and R. R. Grunstein (2008). 
"Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health 
Study." Sleep 31(8): 1079-1085. 
Mason, M., C. J. Cates and I. Smith (2015). "Effects of opioid, hypnotic and sedating medications 
on sleep-disordered breathing in adults with obstructive sleep apnoea." Cochrane 
Database Syst Rev(7): CD011090. 
Mason, M., J. Hernandez Sanchez, A. Vuylsteke and I. Smith (2017). "Association between severity 
of untreated sleep apnoea and postoperative complications following major cardiac 
surgery: a prospective observational cohort study." Sleep Med 37: 141-146. 
Mason, M., E. J. Welsh and I. Smith (2013). "Drug therapy for obstructive sleep apnoea in adults." 
Cochrane Database Syst Rev(5): CD003002. 
McEvoy, R. D., N. A. Antic, E. Heeley, Y. Luo, Q. Ou, X. Zhang, O. Mediano, R. Chen, L. F. Drager, Z. 
Liu, G. Chen, B. Du, N. McArdle, S. Mukherjee, M. Tripathi, L. Billot, Q. Li, G. Lorenzi-Filho, 
F. Barbe, S. Redline, J. Wang, H. Arima, B. Neal, D. P. White, R. R. Grunstein, N. Zhong, C. S. 
173 
 
Anderson, S. Investigators and Coordinators (2016). "CPAP for Prevention of 
Cardiovascular Events in Obstructive Sleep Apnea." N Engl J Med 375(10): 919-931. 
McMillan, A., D. J. Bratton, R. Faria, M. Laskawiec-Szkonter, S. Griffin, R. J. Davies, A. J. Nunn, J. R. 
Stradling, R. L. Riha, M. J. Morrell and P. Investigators (2014). "Continuous positive airway 
pressure in older people with obstructive sleep apnoea syndrome (PREDICT): a 12-month, 
multicentre, randomised trial." Lancet Respir Med 2(10): 804-812. 
McNicholas, W. T. and M. R. Bonsignore (2010). European Respiratory Monograph. Schefield, 
United Kingdom, European Respiratory Society. 
Mehra, R., E. J. Benjamin, E. Shahar, D. J. Gottlieb, R. Nawabit, H. L. Kirchner, J. Sahadevan and S. 
Redline (2006). "Association of nocturnal arrhythmias with sleep-disordered breathing: 
The Sleep Heart Health Study." Am J Respir Crit Care Med 173(8): 910-916. 
Memtsoudis, S., S. S. Liu, Y. Ma, Y. L. Chiu, J. M. Walz, L. K. Gaber-Baylis and M. Mazumdar (2011). 
"Perioperative pulmonary outcomes in patients with sleep apnea after noncardiac 
surgery." Anesth Analg 112(1): 113-121. 
Memtsoudis, S. G., O. Stundner, R. Rasul, Y. L. Chiu, X. Sun, S. K. Ramachandran, R. Kaw, P. 
Fleischut and M. Mazumdar (2014). "The impact of sleep apnea on postoperative 
utilization of resources and adverse outcomes." Anesth Analg 118(2): 407-418. 
Memtsoudis, S. G., O. Stundner, R. Rasul, X. Sun, Y. L. Chiu, P. Fleischut, T. Danninger and M. 
Mazumdar (2013). "Sleep apnea and total joint arthroplasty under various types of 
anesthesia: a population-based study of perioperative outcomes." Reg Anesth Pain Med 
38(4): 274-281. 
Mezzanotte, W. S., D. J. Tangel and D. P. White (1992). "Waking genioglossal electromyogram in 
sleep apnea patients versus normal controls (a neuromuscular compensatory 
mechanism)." J Clin Invest 89(5): 1571-1579. 
Mezzanotte, W. S., D. J. Tangel and D. P. White (1996). "Influence of sleep onset on upper-airway 
muscle activity in apnea patients versus normal controls." Am J Respir Crit Care Med 153(6 
Pt 1): 1880-1887. 
Milleron, O., R. Pilliere, A. Foucher, F. de Roquefeuil, P. Aegerter, G. Jondeau, B. G. Raffestin and 
O. Dubourg (2004). "Benefits of obstructive sleep apnoea treatment in coronary artery 
disease: a long-term follow-up study." Eur Heart J 25(9): 728-734. 
Minoguchi, K., T. Yokoe, T. Tazaki, H. Minoguchi, A. Tanaka, N. Oda, S. Okada, S. Ohta, H. Naito 
and M. Adachi (2005). "Increased carotid intima-media thickness and serum inflammatory 
markers in obstructive sleep apnea." Am J Respir Crit Care Med 172(5): 625-630. 
Mitler, M. M., A. Dawson, S. J. Henriksen, M. Sobers and F. E. Bloom (1988). "Bedtime ethanol 
increases resistance of upper airways and produces sleep apneas in asymptomatic 
snorers." Alcohol Clin Exp Res 12(6): 801-805. 
Mokhlesi, B., M. D. Hovda, B. Vekhter, V. M. Arora, F. Chung and D. O. Meltzer (2013). "Sleep-
disordered breathing and postoperative outcomes after bariatric surgery: analysis of the 
nationwide inpatient sample." Obes Surg 23(11): 1842-1851. 
Mokhlesi, B., M. D. Hovda, B. Vekhter, V. M. Arora, F. Chung and D. O. Meltzer (2013). "Sleep-
disordered breathing and postoperative outcomes after elective surgery: analysis of the 
nationwide inpatient sample." Chest 144(3): 903-914. 
Mokhlesi, B., A. Tulaimat and S. Parthasarathy (2011). "Oxygen for obesity hypoventilation 
syndrome: a double-edged sword?" Chest 139(5): 975-977. 
Mooe, T., S. Gullsby, T. Rabben and P. Eriksson (1996). "Sleep-disordered breathing: a novel 
predictor of atrial fibrillation after coronary artery bypass surgery." Coron Artery Dis 7(6): 
475-478. 
Mooe, T., T. Rabben, U. Wiklund, K. A. Franklin and P. Eriksson (1996). "Sleep-disordered 
breathing in men with coronary artery disease." Chest 109(3): 659-663. 
Moss, I. R., K. A. Brown and A. Laferriere (2006). "Recurrent hypoxia in rats during development 
increases subsequent respiratory sensitivity to fentanyl." Anesthesiology 105(4): 715-718. 
174 
 
Mungan, U., O. Ozeke, L. Mavioglu, C. Ertan, I. O. Karaca, G. Keskin, Z. Kokcu, Y. Selimoglu, A. D. 
Demir and M. A. Ozatik (2013). "The role of the preoperative screening of sleep apnoea by 
Berlin Questionnaire and Epworth Sleepiness Scale for postoperative atrial fibrillation." 
Heart Lung Circ 22(1): 38-42. 
Mutter, T. C., D. Chateau, M. Moffatt, C. Ramsey, L. L. Roos and M. Kryger (2014). "A matched 
cohort study of postoperative outcomes in obstructive sleep apnea: could preoperative 
diagnosis and treatment prevent complications?" Anesthesiology 121(4): 707-718. 
Nagappa, M., G. Ho, J. Patra, J. Wong, M. Singh, R. Kaw, D. Cheng and F. Chung (2017). 
"Postoperative Outcomes in Obstructive Sleep Apnea Patients Undergoing Cardiac 
Surgery: A Systematic Review and Meta-analysis of Comparative Studies." Anesth Analg 
125(6): 2030-2037. 
Nagappa, M., P. Liao, J. Wong, D. Auckley, S. K. Ramachandran, S. Memtsoudis, B. Mokhlesi and F. 
Chung (2015). "Validation of the STOP-Bang Questionnaire as a Screening Tool for 
Obstructive Sleep Apnea among Different Populations: A Systematic Review and Meta-
Analysis." PLoS One 10(12): e0143697. 
Nagappa, M., B. Mokhlesi, J. Wong, D. T. Wong, R. Kaw and F. Chung (2015). "The Effects of 
Continuous Positive Airway Pressure on Postoperative Outcomes in Obstructive Sleep 
Apnea Patients Undergoing Surgery: A Systematic Review and Meta-analysis." Anesth 
Analg 120(5): 1013-1023. 
Nagappa, M., J. Patra, J. Wong, Y. Subramani, M. Singh, G. Ho, D. T. Wong and F. Chung (2017). 
"Association of STOP-Bang Questionnaire as a Screening Tool for Sleep Apnea and 
Postoperative Complications: A Systematic Review and Bayesian Meta-analysis of 
Prospective and Retrospective Cohort Studies." Anesth Analg 125(4): 1301-1308. 
Narkiewicz, K., M. Kato, B. G. Phillips, C. A. Pesek, D. E. Davison and V. K. Somers (1999). 
"Nocturnal continuous positive airway pressure decreases daytime sympathetic traffic in 
obstructive sleep apnea." Circulation 100(23): 2332-2335. 
Narkiewicz, K. and V. K. Somers (2003). "Sympathetic nerve activity in obstructive sleep apnoea." 
Acta Physiol Scand 177(3): 385-390. 
Nashef, S. A., F. Roques, P. Michel, E. Gauducheau, S. Lemeshow and R. Salamon (1999). 
"European system for cardiac operative risk evaluation (EuroSCORE)." Eur J Cardiothorac 
Surg 16(1): 9-13. 
Naughton, M. T., M. A. Rahman, K. Hara, J. S. Floras and T. D. Bradley (1995). "Effect of continuous 
positive airway pressure on intrathoracic and left ventricular transmural pressures in 
patients with congestive heart failure." Circulation 91(6): 1725-1731. 
Nelson, A. M., A. S. Battersby, H. A. Baghdoyan and R. Lydic (2009). "Opioid-induced decreases in 
rat brain adenosine levels are reversed by inhibiting adenosine deaminase." 
Anesthesiology 111(6): 1327-1333. 
Network, S. I. G. (2003). "Management of Obstructive Sleep Apnoea/Hypopnoea Syndrome in 
Adults." (gideline number 73). 
Netzer, N., A. H. Eliasson, C. Netzer and D. A. Kristo (2001). "Overnight pulse oximetry for sleep-
disordered breathing in adults: a review." Chest 120(2): 625-633. 
Netzer, N. C., R. A. Stoohs, C. M. Netzer, K. Clark and K. P. Strohl (1999). "Using the Berlin 
Questionnaire to identify patients at risk for the sleep apnea syndrome." Ann Intern Med 
131(7): 485-491. 
Newman, A. B., F. J. Nieto, U. Guidry, B. K. Lind, S. Redline, T. G. Pickering, S. F. Quan and G. Sleep 
Heart Health Study Research (2001). "Relation of sleep-disordered breathing to 
cardiovascular disease risk factors: the Sleep Heart Health Study." Am J Epidemiol 154(1): 
50-59. 
Ngiam, J., R. Balasubramaniam, M. A. Darendeliler, A. T. Cheng, K. Waters and C. E. Sullivan (2013). 
"Clinical guidelines for oral appliance therapy in the treatment of snoring and obstructive 
sleep apnoea." Aust Dent J 58(4): 408-419. 
175 
 
Nguyen, A. T., V. Jobin, R. Payne, J. Beauregard, N. Naor and R. J. Kimoff (2005). "Laryngeal and 
velopharyngeal sensory impairment in obstructive sleep apnea." Sleep 28(5): 585-593. 
Nguyen, N. T., H. Masoomi, K. Laugenour, Y. Sanaiha, K. M. Reavis, S. D. Mills and M. J. Stamos 
(2011). "Predictive factors of mortality in bariatric surgery: data from the Nationwide 
Inpatient Sample." Surgery 150(2): 347-351. 
Nieto, F. J., T. B. Young, B. K. Lind, E. Shahar, J. M. Samet, S. Redline, R. B. D'Agostino, A. B. 
Newman, M. D. Lebowitz and T. G. Pickering (2000). "Association of sleep-disordered 
breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart 
Health Study." JAMA 283(14): 1829-1836. 
Nuber, R., J. Vavrina and W. Karrer (2000). "[Predictive value of nocturnal pulse oximetry in sleep 
apnea screening]." Schweiz Med Wochenschr Suppl 116: 120S-122S. 
Oksenberg, A., I. Khamaysi, D. S. Silverberg and A. Tarasiuk (2000). "Association of body position 
with severity of apneic events in patients with severe nonpositional obstructive sleep 
apnea." Chest 118(4): 1018-1024. 
Opp, M. R., L. Kapas and L. A. Toth (1992). "Cytokine involvement in the regulation of sleep." Proc 
Soc Exp Biol Med 201(1): 16-27. 
Opperer, M., C. Cozowicz, D. Bugada, B. Mokhlesi, R. Kaw, D. Auckley, F. Chung and S. G. 
Memtsoudis (2016). "Does Obstructive Sleep Apnea Influence Perioperative Outcome? A 
Qualitative Systematic Review for the Society of Anesthesia and Sleep Medicine Task Force 
on Preoperative Preparation of Patients with Sleep-Disordered Breathing." Anesth Analg 
122(5): 1321-1334. 
Ostermeier, A. M., M. F. Roizen, M. Hautkappe, P. A. Klock and J. M. Klafta (1997). "Three sudden 
postoperative respiratory arrests associated with epidural opioids in patients with sleep 
apnea." Anesth Analg 85(2): 452-460. 
Palmer, L. J., S. G. Buxbaum, E. Larkin, S. R. Patel, R. C. Elston, P. V. Tishler and S. Redline (2003). 
"A whole-genome scan for obstructive sleep apnea and obesity." Am J Hum Genet 72(2): 
340-350. 
Palmer, L. J., S. G. Buxbaum, E. K. Larkin, S. R. Patel, R. C. Elston, P. V. Tishler and S. Redline (2004). 
"Whole genome scan for obstructive sleep apnea and obesity in African-American 
families." Am J Respir Crit Care Med 169(12): 1314-1321. 
Partinen, M. and C. Guilleminault (1990). "Daytime sleepiness and vascular morbidity at seven-
year follow-up in obstructive sleep apnea patients." Chest 97(1): 27-32. 
Partinen, M., A. Jamieson and C. Guilleminault (1988). "Long-term outcome for obstructive sleep 
apnea syndrome patients. Mortality." Chest 94(6): 1200-1204. 
Patel, S. R. (2015). "The complex relationship between weight and sleep apnoea." Thorax 70(3): 
205-206. 
Patel, S. R., D. P. White, A. Malhotra, M. L. Stanchina and N. T. Ayas (2003). "Continuous positive 
airway pressure therapy for treating sleepiness in a diverse population with obstructive 
sleep apnea: results of a meta-analysis." Arch Intern Med 163(5): 565-571. 
Pattinson, K. T. (2008). "Opioids and the control of respiration." Br J Anaesth 100(6): 747-758. 
Peker, Y., H. Kraiczi, J. Hedner, S. Loth, A. Johansson and M. Bende (1999). "An independent 
association between obstructive sleep apnoea and coronary artery disease." Eur Respir J 
14(1): 179-184. 
Peppard, P. E., T. Young, J. H. Barnet, M. Palta, E. W. Hagen and K. M. Hla (2013). "Increased 
prevalence of sleep-disordered breathing in adults." Am J Epidemiol 177(9): 1006-1014. 
Peppard, P. E., T. Young, M. Palta, J. Dempsey and J. Skatrud (2000). "Longitudinal study of 
moderate weight change and sleep-disordered breathing." JAMA 284(23): 3015-3021. 
Peppard, P. E., T. Young, M. Palta and J. Skatrud (2000). "Prospective study of the association 
between sleep-disordered breathing and hypertension." N Engl J Med 342(19): 1378-1384. 
Pillar, G. and P. Lavie (1995). "Assessment of the role of inheritance in sleep apnea syndrome." Am 
J Respir Crit Care Med 151(3 Pt 1): 688-691. 
176 
 
Pillar, G., R. P. Schnall, N. Peled, A. Oliven and P. Lavie (1997). "Impaired respiratory response to 
resistive loading during sleep in healthy offspring of patients with obstructive sleep 
apnea." Am J Respir Crit Care Med 155(5): 1602-1608. 
Punjabi, N. M., B. S. Caffo, J. L. Goodwin, D. J. Gottlieb, A. B. Newman, G. T. O'Connor, D. M. 
Rapoport, S. Redline, H. E. Resnick, J. A. Robbins, E. Shahar, M. L. Unruh and J. M. Samet 
(2009). "Sleep-disordered breathing and mortality: a prospective cohort study." PLoS Med 
6(8): e1000132. 
Quan, S. F., R. Budhiraja, D. P. Clarke, J. L. Goodwin, D. J. Gottlieb, D. A. Nichols, R. D. Simon, T. W. 
Smith, J. K. Walsh and C. A. Kushida (2013). "Impact of treatment with continuous positive 
airway pressure (CPAP) on weight in obstructive sleep apnea." J Clin Sleep Med 9(10): 989-
993. 
Rabbitts, J. A., C. B. Groenewald, N. M. Dietz, C. Morales and J. Rasanen (2010). "Perioperative 
opioid requirements are decreased in hypoxic children living at altitude." Paediatr Anaesth 
20(12): 1078-1083. 
Ramachandran, S. K., N. Haider, K. A. Saran, M. Mathis, J. Kim, M. Morris and M. O'Reilly (2011). 
"Life-threatening critical respiratory events: a retrospective study of postoperative 
patients found unresponsive during analgesic therapy." J Clin Anesth 23(3): 207-213. 
Ramachandran, S. K. and L. A. Josephs (2009). "A meta-analysis of clinical screening tests for 
obstructive sleep apnea." Anesthesiology 110(4): 928-939. 
Ramachandran, S. K., S. Kheterpal, F. Consens, A. Shanks, T. M. Doherty, M. Morris and K. K. 
Tremper (2010). "Derivation and validation of a simple perioperative sleep apnea 
prediction score." Anesth Analg 110(4): 1007-1015. 
Redline, S., P. V. Tishler, M. G. Hans, T. D. Tosteson, K. P. Strohl and K. Spry (1997). "Racial 
differences in sleep-disordered breathing in African-Americans and Caucasians." Am J 
Respir Crit Care Med 155(1): 186-192. 
Redline, S., P. V. Tishler, T. D. Tosteson, J. Williamson, K. Kump, I. Browner, V. Ferrette and P. 
Krejci (1995). "The familial aggregation of obstructive sleep apnea." Am J Respir Crit Care 
Med 151(3 Pt 1): 682-687. 
Redolfi, S., D. Yumino, P. Ruttanaumpawan, B. Yau, M. C. Su, J. Lam and T. D. Bradley (2009). 
"Relationship between overnight rostral fluid shift and Obstructive Sleep Apnea in 
nonobese men." Am J Respir Crit Care Med 179(3): 241-246. 
Reichmuth, K. J., D. Austin, J. B. Skatrud and T. Young (2005). "Association of sleep apnea and type 
II diabetes: a population-based study." Am J Respir Crit Care Med 172(12): 1590-1595. 
Reyner, L. A. and J. A. Horne (1998). "Falling asleep whilst driving: are drivers aware of prior 
sleepiness?" Int J Legal Med 111(3): 120-123. 
Robinson, R. W., C. W. Zwillich, E. O. Bixler, R. J. Cadieux, A. Kales and D. P. White (1987). "Effects 
of oral narcotics on sleep-disordered breathing in healthy adults." Chest 91(2): 197-203. 
Roggenbach, J., M. Klamann, R. von Haken, T. Bruckner, M. Karck and S. Hofer (2014). "Sleep-
disordered breathing is a risk factor for delirium after cardiac surgery: a prospective cohort 
study." Crit Care 18(5): 477. 
Rosenberg, J., G. Wildschiodtz, M. H. Pedersen, F. von Jessen and H. Kehlet (1994). "Late 
postoperative nocturnal episodic hypoxaemia and associated sleep pattern." Br J Anaesth 
72(2): 145-150. 
Rosenberg, R., J. M. Roach, M. Scharf and D. A. Amato (2007). "A pilot study evaluating acute use 
of eszopiclone in patients with mild to moderate obstructive sleep apnea syndrome." 
Sleep Med 8(5): 464-470. 
Rosenberg, R., J. M. Roach, M. Scharf and D. A. Amato (2007). "A pilot study evaluating acute use 
of eszopiclone in patients with mild to moderate obstructive sleep apnea syndrome." 
Sleep medicine 8(5): 464-470. 
Roure, N., S. Gomez, O. Mediano, J. Duran, L. Pena Mde, F. Capote, J. Teran, J. F. Masa, M. L. 
Alonso, J. Corral, A. Sanchez-Armengod, C. Martinez, A. Barcelo, D. Gozal, J. M. Marin and 
177 
 
F. Barbe (2008). "Daytime sleepiness and polysomnography in obstructive sleep apnea 
patients." Sleep Med 9(7): 727-731. 
Rowley, J. A., L. S. Aboussouan and M. S. Badr (2000). "The use of clinical prediction formulas in 
the evaluation of obstructive sleep apnea." Sleep 23(7): 929-938. 
Rowsell, L., K. K. H. Wong, B. J. Yee, D. J. Eckert, A. A. Somogyi, J. Duffin, R. R. Grunstein and D. 
Wang (2019). "The effect of acute morphine on obstructive sleep apnoea: a randomised 
double-blind placebo-controlled crossover trial." Thorax 74(2): 177-184. 
Sanner, B. M., M. Konermann, C. Doberauer, T. Weiss and W. Zidek (2001). "Sleep-Disordered 
breathing in patients referred for angina evaluation--association with left ventricular 
dysfunction." Clin Cardiol 24(2): 146-150. 
Santiago, T. V. and N. H. Edelman (1985). "Opioids and breathing." J Appl Physiol (1985) 59(6): 
1675-1685. 
Schmidt-Nowara, W. W., D. B. Coultas, C. Wiggins, B. E. Skipper and J. M. Samet (1990). "Snoring in 
a Hispanic-American population. Risk factors and association with hypertension and other 
morbidity." Arch Intern Med 150(3): 597-601. 
Schulz, R., M. Grebe, H. J. Eisele, K. Mayer, N. Weissmann and W. Seeger (2006). "[Obstructive 
sleep apnea-related cardiovascular disease]." Med Klin (Munich) 101(4): 321-327. 
Schulz, R., W. Seeger, C. Fegbeutel, H. Husken, R. H. Bodeker, H. Tillmanns and M. Grebe (2005). 
"Changes in extracranial arteries in obstructive sleep apnoea." Eur Respir J 25(1): 69-74. 
Schwab, R. J., K. B. Gupta, W. B. Gefter, L. J. Metzger, E. A. Hoffman and A. I. Pack (1995). "Upper 
airway and soft tissue anatomy in normal subjects and patients with sleep-disordered 
breathing. Significance of the lateral pharyngeal walls." Am J Respir Crit Care Med 152(5 Pt 
1): 1673-1689. 
Schwartz, A. R., A. R. Gold, N. Schubert, A. Stryzak, R. A. Wise, S. Permutt and P. L. Smith (1991). 
"Effect of weight loss on upper airway collapsibility in obstructive sleep apnea." Am Rev 
Respir Dis 144(3 Pt 1): 494-498. 
Schwartz, A. R., P. L. Smith, R. A. Wise, A. R. Gold and S. Permutt (1988). "Induction of upper 
airway occlusion in sleeping individuals with subatmospheric nasal pressure." J Appl 
Physiol (1985) 64(2): 535-542. 
Sforza, E., V. Capecchi and E. Lugaresi (1992). "Haemodynamic effects of short-term nasal 
continuous positive airway pressure therapy in sleep apnoea syndrome: monitoring by a 
finger arterial pressure device." Eur Respir J 5(7): 858-863. 
Shah, N., S. Redline, H. K. Yaggi, R. Wu, C. G. Zhao, R. Ostfeld, M. Menegus, D. Tracy, E. Brush, W. 
D. Appel and R. C. Kaplan (2013). "Obstructive sleep apnea and acute myocardial 
infarction severity: ischemic preconditioning?" Sleep Breath 17(2): 819-826. 
Shah, Z. A., S. A. Jortani, R. Tauman, R. Valdes, Jr. and D. Gozal (2006). "Serum proteomic patterns 
associated with sleep-disordered breathing in children." Pediatr Res 59(3): 466-470. 
Shahar, E., C. W. Whitney, S. Redline, E. T. Lee, A. B. Newman, F. Javier Nieto, G. T. O'Connor, L. L. 
Boland, J. E. Schwartz and J. M. Samet (2001). "Sleep-disordered breathing and 
cardiovascular disease: cross-sectional results of the Sleep Heart Health Study." Am J 
Respir Crit Care Med 163(1): 19-25. 
Shaw, I. R., G. Lavigne, P. Mayer and M. Choiniere (2005). "Acute intravenous administration of 
morphine perturbs sleep architecture in healthy pain-free young adults: a preliminary 
study." Sleep 28(6): 677-682. 
Shneerson, J. and J. Wright (2001). "Lifestyle modification for obstructive sleep apnoea." Cochrane 
Database Syst Rev(1): CD002875. 
Shneerson, J. M. (2005). Sleep Medicine, A Guide to Sleep and Its Disorders, Blackwell. 
Sin, D. D., F. Fitzgerald, J. D. Parker, G. Newton, J. S. Floras and T. D. Bradley (1999). "Risk factors 
for central and obstructive sleep apnea in 450 men and women with congestive heart 
failure." Am J Respir Crit Care Med 160(4): 1101-1106. 
178 
 
Singh, M., P. Liao, S. Kobah, D. N. Wijeysundera, C. Shapiro and F. Chung (2013). "Proportion of 
surgical patients with undiagnosed obstructive sleep apnoea." Br J Anaesth 110(4): 629-
636. 
Smith, P. L., R. A. Wise, A. R. Gold, A. R. Schwartz and S. Permutt (1988). "Upper airway pressure-
flow relationships in obstructive sleep apnea." J Appl Physiol (1985) 64(2): 789-795. 
Somers, V. K., M. E. Dyken, M. P. Clary and F. M. Abboud (1995). "Sympathetic neural mechanisms 
in obstructive sleep apnea." J Clin Invest 96(4): 1897-1904. 
Somers, V. K., A. L. Mark, D. C. Zavala and F. M. Abboud (1989). "Contrasting effects of hypoxia 
and hypercapnia on ventilation and sympathetic activity in humans." J Appl Physiol (1985) 
67(5): 2101-2106. 
Somers, V. K., D. P. White, R. Amin, W. T. Abraham, F. Costa, A. Culebras, S. Daniels, J. S. Floras, C. 
E. Hunt, L. J. Olson, T. G. Pickering, R. Russell, M. Woo and T. Young (2008). "Sleep apnea 
and cardiovascular disease: an American Heart Association/american College Of 
Cardiology Foundation Scientific Statement from the American Heart Association Council 
for High Blood Pressure Research Professional Education Committee, Council on Clinical 
Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with 
the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research 
(National Institutes of Health)." Circulation 118(10): 1080-1111. 
Spicuzza, L., D. Caruso and G. Di Maria (2015). "Obstructive sleep apnoea syndrome and its 
management." Ther Adv Chronic Dis 6(5): 273-285. 
Stoohs, R. and C. Guilleminault (1992). "Cardiovascular changes associated with obstructive sleep 
apnea syndrome." J Appl Physiol (1985) 72(2): 583-589. 
Stradling, J., D. Smith, M. Radulovacki and D. Carley (2003). "Effect of ondansetron on moderate 
obstructive sleep apnoea, a single night, placebo-controlled trial." J Sleep Res 12(2): 169-
170. 
Stradling, J. R., C. Barbour, J. Glennon, B. A. Langford and J. H. Crosby (2000). "Prevalence of 
sleepiness and its relation to autonomic evidence of arousals and increased inspiratory 
effort in a community based population of men and women." J Sleep Res 9(4): 381-388. 
Stradling, J. R., C. Barbour, J. Glennon, B. A. Langford and J. H. Crosby (2000). "Which aspects of 
breathing during sleep influence the overnight fall of blood pressure in a community 
population?" Thorax 55(5): 393-398. 
Stradling, J. R., J. H. Crosby and C. D. Payne (1991). "Self reported snoring and daytime sleepiness 
in men aged 35-65 years." Thorax 46(11): 807-810. 
Su, M. C., K. L. Chiu, P. Ruttanaumpawan, S. Shiota, D. Yumino, S. Redolfi, J. S. Haight and T. D. 
Bradley (2008). "Lower body positive pressure increases upper airway collapsibility in 
healthy subjects." Respir Physiol Neurobiol 161(3): 306-312. 
Sullivan, C. E., F. G. Issa, M. Berthon-Jones and L. Eves (1981). "Reversal of obstructive sleep 
apnoea by continuous positive airway pressure applied through the nares." Lancet 
1(8225): 862-865. 
Svanborg, E. (2005). "Impact of obstructive apnea syndrome on upper airway respiratory 
muscles." Respir Physiol Neurobiol 147(2-3): 263-272. 
Tarhan, S., E. A. Moffitt, W. F. Taylor and E. R. Giuliani (1972). "Myocardial infarction after general 
anesthesia." JAMA 220(11): 1451-1454. 
Teschler, H., M. Berthon-Jones, T. Wessendorf, H. J. Meyer and N. Konietzko (1996). "Influence of 
moderate alcohol consumption on obstructive sleep apnoea with and without AutoSet 
nasal CPAP therapy." Eur Respir J 9(11): 2371-2377. 
Thakre, T. P., M. R. Mamtani and H. Kulkarni (2009). "Lack of association of the APOE epsilon 4 
allele with the risk of obstructive sleep apnea: meta-analysis and meta-regression." Sleep 
32(11): 1507-1511. 
179 
 
Thomas, R. J., C. Guilleminault, I. Ayappa and D. M. Rapoport (2014). "Scoring respiratory events in 
sleep medicine: who is the driver--biology or medical insurance?" J Clin Sleep Med 10(11): 
1245-1247. 
Thurnheer, R., K. E. Bloch, I. Laube, M. Gugger, M. Heitz and R. Swiss Respiratory Polygraphy 
(2007). "Respiratory polygraphy in sleep apnoea diagnosis. Report of the Swiss respiratory 
polygraphy registry and systematic review of the literature." Swiss Med Wkly 137(5-6): 97-
102. 
Tishler, P. V., E. K. Larkin, M. D. Schluchter and S. Redline (2003). "Incidence of sleep-disordered 
breathing in an urban adult population: the relative importance of risk factors in the 
development of sleep-disordered breathing." JAMA 289(17): 2230-2237. 
Trinder, J., F. Whitworth, A. Kay and P. Wilkin (1992). "Respiratory instability during sleep onset." J 
Appl Physiol (1985) 73(6): 2462-2469. 
Turan, A., J. You, C. Egan, A. Fu, I. Gazmuri, A. Khanna, Y. Eshraghi, R. Ghosh, S. Bose, S. Qavi, L. 
Arora, D. I. Sessler and A. G. Doufas (2015). "Relationship between chronic intermittent 
hypoxia and intraoperative mean arterial pressure in obstructive sleep apnea patients 
having laparoscopic bariatric surgery." Anesthesiology 122(1): 64-71. 
Uchoa, C. H., J. Danzi-Soares Nde, F. S. Nunes, A. A. de Souza, F. B. Nerbass, R. P. Pedrosa, L. A. 
Cesar, G. Lorenzi-Filho and L. F. Drager (2015). "Impact of OSA on cardiovascular events 
after coronary artery bypass surgery." Chest 147(5): 1352-1360. 
Unosawa, S., A. Sezai, T. Akahoshi, T. Niino, K. Shimura, M. Shiono, H. Sekino and T. Akashiba 
(2012). "Arrhythmia and sleep-disordered breathing in patients undergoing cardiac 
surgery." J Cardiol 60(1): 61-65. 
Utriainen, K. T., J. K. Airaksinen, O. Polo, O. T. Raitakari, M. J. Pietila, H. Scheinin, H. Y. Helenius, K. 
A. Leino, E. S. Kentala, J. R. Jalonen, H. Hakovirta, T. M. Salo and T. T. Laitio (2013). 
"Unrecognised obstructive sleep apnoea is common in severe peripheral arterial disease." 
Eur Respir J 41(3): 616-620. 
van Oosten, E. M., A. Hamilton, D. Petsikas, D. Payne, D. P. Redfearn, S. Zhang, W. M. Hopman and 
A. Baranchuk (2014). "Effect of preoperative obstructive sleep apnea on the frequency of 
atrial fibrillation after coronary artery bypass grafting." Am J Cardiol 113(6): 919-923. 
Van Ryswyk, E. and N. A. Antic (2016). "Opioids and Sleep-Disordered Breathing." Chest 150(4): 
934-944. 
Vasu, T. S., K. Doghramji, R. Cavallazzi, R. Grewal, A. Hirani, B. Leiby, D. Markov, D. Reiter, W. K. 
Kraft and T. Witkowski (2010). "Obstructive sleep apnea syndrome and postoperative 
complications: clinical use of the STOP-BANG questionnaire." Arch Otolaryngol Head Neck 
Surg 136(10): 1020-1024. 
Vasu, T. S., R. Grewal and K. Doghramji (2012). "Obstructive sleep apnea syndrome and 
perioperative complications: a systematic review of the literature." J Clin Sleep Med 8(2): 
199-207. 
Vazir, A., P. C. Hastings, M. Dayer, H. F. McIntyre, M. Y. Henein, P. A. Poole-Wilson, M. R. Cowie, 
M. J. Morrell and A. K. Simonds (2007). "A high prevalence of sleep disordered breathing in 
men with mild symptomatic chronic heart failure due to left ventricular systolic 
dysfunction." Eur J Heart Fail 9(3): 243-250. 
Vgontzas, A. N., D. A. Papanicolaou, E. O. Bixler, K. Hopper, A. Lotsikas, H. M. Lin, A. Kales and G. 
P. Chrousos (2000). "Sleep apnea and daytime sleepiness and fatigue: relation to visceral 
obesity, insulin resistance, and hypercytokinemia." J Clin Endocrinol Metab 85(3): 1151-
1158. 
Vgontzas, A. N., E. Zoumakis, H. M. Lin, E. O. Bixler, G. Trakada and G. P. Chrousos (2004). "Marked 
decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-
alpha antagonist." J Clin Endocrinol Metab 89(9): 4409-4413. 
180 
 
Vincken, W., C. Guilleminault, L. Silvestri, M. Cosio and A. Grassino (1987). "Inspiratory muscle 
activity as a trigger causing the airways to open in obstructive sleep apnea." Am Rev 
Respir Dis 135(2): 372-377. 
Walker, J. M., R. J. Farney, S. M. Rhondeau, K. M. Boyle, K. Valentine, T. V. Cloward and K. C. 
Shilling (2007). "Chronic opioid use is a risk factor for the development of central sleep 
apnea and ataxic breathing." J Clin Sleep Med 3(5): 455-461. 
Wang, D., S. Marshall Nathaniel, J. Duffin, J. Yee Brendon, K. Wong Keith, N. Noori, S. W. Ng 
Susanna and R. Grunstein Ronald (2011). "Phenotyping interindividual variability in 
obstructive sleep apnoea response to temazepam using ventilatory chemoreflexes during 
wakefulness." Journal of sleep research 20(4): 526-532. 
Wang, D., A. A. Somogyi, B. J. Yee, K. K. Wong, J. Kaur, P. J. Wrigley and R. R. Grunstein (2013). 
"The effects of a single mild dose of morphine on chemoreflexes and breathing in 
obstructive sleep apnea." Respir Physiol Neurobiol 185(3): 526-532. 
Wang, D. and H. Teichtahl (2007). "Opioids, sleep architecture and sleep-disordered breathing." 
Sleep Med Rev 11(1): 35-46. 
Wellman, A., A. S. Jordan, A. Malhotra, R. B. Fogel, E. S. Katz, K. Schory, J. K. Edwards and D. P. 
White (2004). "Ventilatory control and airway anatomy in obstructive sleep apnea." Am J 
Respir Crit Care Med 170(11): 1225-1232. 
Wetter, D. W., T. B. Young, T. R. Bidwell, M. S. Badr and M. Palta (1994). "Smoking as a risk factor 
for sleep-disordered breathing." Arch Intern Med 154(19): 2219-2224. 
Whitelaw, W. A., R. F. Brant and W. W. Flemons (2005). "Clinical usefulness of home oximetry 
compared with polysomnography for assessment of sleep apnea." Am J Respir Crit Care 
Med 171(2): 188-193. 
Whittle, A. T., I. Marshall, I. L. Mortimore, P. K. Wraith, R. J. Sellar and N. J. Douglas (1999). "Neck 
soft tissue and fat distribution: comparison between normal men and women by magnetic 
resonance imaging." Thorax 54(4): 323-328. 
Widyastuti, Y., R. Stenseth, A. Wahba, H. Pleym and V. Videm (2012). "Length of intensive care 
unit stay following cardiac surgery: is it impossible to find a universal prediction model?" 
Interact Cardiovasc Thorac Surg 15(5): 825-832. 
Wu, H. and F. Yan-Go (1996). "Self-reported automobile accidents involving patients with 
obstructive sleep apnea." Neurology 46(5): 1254-1257. 
Yarmush, J., R. D'Angelo, B. Kirkhart, C. O'Leary, M. C. Pitts, 2nd, G. Graf, P. Sebel, W. D. Watkins, 
R. Miguel, J. Streisand, L. K. Maysick and D. Vujic (1997). "A comparison of remifentanil 
and morphine sulfate for acute postoperative analgesia after total intravenous anesthesia 
with remifentanil and propofol." Anesthesiology 87(2): 235-243. 
Ye, L., G. W. Pien and T. E. Weaver (2009). "Gender differences in the clinical manifestation of 
obstructive sleep apnea." Sleep Med 10(10): 1075-1084. 
Younes, M. (2004). "Role of arousals in the pathogenesis of obstructive sleep apnea." Am J Respir 
Crit Care Med 169(5): 623-633. 
Young, T., J. Blustein, L. Finn and M. Palta (1997). "Sleep-disordered breathing and motor vehicle 
accidents in a population-based sample of employed adults." Sleep 20(8): 608-613. 
Young, T., L. Evans, L. Finn and M. Palta (1997). "Estimation of the clinically diagnosed proportion 
of sleep apnea syndrome in middle-aged men and women." Sleep 20(9): 705-706. 
Young, T., L. Finn, P. E. Peppard, M. Szklo-Coxe, D. Austin, F. J. Nieto, R. Stubbs and K. M. Hla 
(2008). "Sleep disordered breathing and mortality: eighteen-year follow-up of the 
Wisconsin sleep cohort." Sleep 31(8): 1071-1078. 
Young, T., M. Palta, J. Dempsey, J. Skatrud, S. Weber and S. Badr (1993). "The occurrence of sleep-
disordered breathing among middle-aged adults." N Engl J Med 328(17): 1230-1235. 
Young, T., P. E. Peppard and D. J. Gottlieb (2002). "Epidemiology of obstructive sleep apnea: a 
population health perspective." Am J Respir Crit Care Med 165(9): 1217-1239. 
181 
 
Young, T., E. Shahar, F. J. Nieto, S. Redline, A. B. Newman, D. J. Gottlieb, J. A. Walsleben, L. Finn, P. 
Enright and J. M. Samet (2002). "Predictors of sleep-disordered breathing in community-
dwelling adults: the Sleep Heart Health Study." Arch Intern Med 162(8): 893-900. 
Yue, H. J. and C. Guilleminault (2010). "Opioid medication and sleep-disordered breathing." Med 
Clin North Am 94(3): 435-446. 
Yumino, D., H. Wang, J. S. Floras, G. E. Newton, S. Mak, P. Ruttanaumpawan, J. D. Parker and T. D. 
Bradley (2009). "Prevalence and physiological predictors of sleep apnea in patients with 
heart failure and systolic dysfunction." J Card Fail 15(4): 279-285. 
Zarbock, A., E. Mueller, S. Netzer, A. Gabriel, P. Feindt and D. Kindgen-Milles (2009). "Prophylactic 
nasal continuous positive airway pressure following cardiac surgery protects from 
postoperative pulmonary complications: a prospective, randomized, controlled trial in 500 
patients." Chest 135(5): 1252-1259. 
Zhao, L. P., T. Kofidis, T. W. Lim, S. P. Chan, T. H. Ong, H. C. Tan and C. H. Lee (2015). "Sleep apnea 
is associated with new-onset atrial fibrillation after coronary artery bypass grafting." J Crit 
Care 30(6): 1418 e1411-1415. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
182 
 
Appendix 1 
Systematic Cochrane Review (Chapter 4). Figure 4.2. A summary of the risk of bias of 
included studies 
 
 
 
 
 
Cochrane Database of Systematic Reviews 
14 JUL 2015 DOI: 10.1002/14651858.CD011090.pub2 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011090.pub2/full#CD011090-fig-0002 
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Appendix 2 
MIMOSA study, Chapter 5.  
Screening questionnaire employed to check for eligibility to participate in the study 
and for safety to stop the CPAP treatment. 
 
MIMOSA 
Morphine In Moderate Obstructive Sleep Apnoea 
      Telephone Screening Proforma to check 
eligibility and 
      ensure suitability to withdraw from CPAP  
 
Date of telephone call:  __________________ Time of telephone call:  __________ 
 
Is the patient interested in participating in the MIMOSA study   Yes   No 
and happy to proceed with the telephone screening call?   
 
SECTION 1: 
Check Inclusion Criteria        Yes                 No 
1. Age ≥ 18 years  
2. Currently using CPAP for a previous diagnosis of moderate OSA 
diagnosed by nocturnal oximetry, respiratory PSG or PSG 
(defined as AHI or ODI of 15-29 events/hour)  
 
              (diagnosis to be confirmed by baseline respiratory polygraphy after CPAP 
withdrawal 
              for 6 nights) 
 
 
If answered yes to all inclusion criteria, please complete exclusion criteria below 
Check Exclusion Criteria        Yes                 No 
16. Inability to give informed consent or comply with the protocol  
17. Current, clinically significant acute respiratory tract infection (at 
screening and at study visit)  
 
18. Chronic respiratory disease (other than OSA), symptomatic 
ischemic heart disease 
 
19. Pregnancy or suspected pregnancy/breast feeding  
20. Current or recent (within last week of entering the trial and for the 
duration of the trial) use of gabapentin, pregabalin, melatonin, 
mirtazapine, benzodiazepines, barbiturates, sodium oxybate, 
 
Patient Addressograph Label 
Name: 
Date of Birth: 
Hospital No: 
NHS No:  
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ramelteon, Z-drugs and opiates/opioids 
21. Monoamine oxidase inhibitors (MAOIs) linezolid, taken within 2 
weeks of participation in the trial 
 
22. A known allergy to the IMP or NIMP(s)  
23. Patients with an inadequate command of English and requiring an 
interpreter overnight 
 
24. CPAP intolerant/poor responder   
25. History of drug abuse including alcohol, amphetamines, 
barbiturates, benzodiazepines, cocaine, methaqualone, cannabis 
and opioids 
 
26. Professional Driver  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 1 completed by: 
Signature: ___________________________ 
Print name: __________________________ 
Date: ______________ Designation: ______ 
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MIMOSA 
Morphine In Moderate Obstructive Sleep Apnoea 
      Telephone Screening Proforma to check 
eligibility and 
      suitability to withdraw from CPAP  
 
 
If answered no to all exclusion criteria, please complete section 2 below 
SECTION 2: Further questions to the patient:        Yes                 No 
1. Are you too sleepy to withdraw from CPAP for six consecutive 
nights? 
 
2. Prior to starting CPAP, have you ever fallen asleep whilst driving?  
3. Prior to starting CPAP, have you ever had a road traffic accident 
due to falling asleep? 
 
 
The patient will be deemed unsafe to participate in the trial if they answer yes to any one of the 
above questions in Section 2. 
Decision:        Eligible                                   Not Eligible 
 
I have confirmed with the patient that they are eligible to participate in the MIMOSA study. I am happy 
for the patient to stop using CPAP for 6 nights prior to undergoing a baseline respiratory polygraphy 
study at home. I have emphasized to the patient that if they feel concerned, unsafe or wish to start 
using their CPAP machine again during these 6 nights they can do so and should let research team 
know as soon as it is convenient. 
 
____________________________  ___________________________ ___________________ 
Print Name    Signature            Delegation 
 
___________________________ 
Date  
 
 
Baseline rPSG visit 
Date: __ __ / __ __ / __ __ __ __           Time: __ __ : __ __ 
Last night of CPAP: __ __ / __ __ / __ __ __ __ 
 
 
 
 
Page 2 completed by: 
Signature: ___________________________ 
Print name: __________________________ 
Date: ______________ Designation: ______ 
Patient Addressograph Label 
Name: 
Date of Birth: 
Hospital No: 
NHS No:  
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